0001144204-14-049404.txt : 20140813 0001144204-14-049404.hdr.sgml : 20140813 20140813170114 ACCESSION NUMBER: 0001144204-14-049404 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140813 DATE AS OF CHANGE: 20140813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harvard Apparatus Regenerative Technology, Inc. CENTRAL INDEX KEY: 0001563665 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455210462 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35853 FILM NUMBER: 141038289 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL ROAD CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: (508) 893-8999 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD CITY: HOLLISTON STATE: MA ZIP: 01746 10-Q 1 v386033_10q.htm 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 10-Q

 

 

 

x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2014

 

¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

 

Commission file number 001-35853

 

 

 

HARVARD APPARATUS

REGENERATIVE TECHNOLOGY,

INC.

 

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   45-5210462

(State or Other Jurisdiction of

Incorporation or Organization)

  

(IRS Employer

Identification No.)

 

84 October Hill Road, Holliston, MA   01746
(Address of Principal Executive Offices)   (Zip Code)

 

(774) 233-7300

(Registrant’s telephone number, including area code)

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   x YES ¨ NO

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x YES ¨ NO

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
   
Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ YES x NO

 

As of August 8, 2014, there were 7,846,959 shares of common stock, par value $0.01 per share, outstanding.

 

 

 

 
 

  

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

 

Form 10-Q

For the Quarter Ended June 30, 2014

 

INDEX

 

    Page
PART I-FINANCIAL INFORMATION 3
     
Item 1. Financial Statements 3
     
  Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013 (unaudited) 3
     
  Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2014 and 2013 (unaudited) 4
     
  Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2014 and 2013 (unaudited) 5
     
  Notes to Unaudited Consolidated Financial Statements 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 15
     
Item 4. Controls and Procedures 15
     
PART II-OTHER INFORMATION 15
     
Item 1A. Risk Factors 15
     
Item 6. Exhibits 16
     
SIGNATURES  17

 

2
 

  

PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements.

 

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited, in thousands, except par value and per share data)

 

   June 30,   December 31, 
   2014   2013 
         
ASSETS          
Current assets:          
Cash  $10,065   $14,008 
Related party receivables   82    22 
Inventories, net   146    38 
Prepaid expenses   356    421 
Total current assets   10,649    14,489 
          
Property, plant and equipment, net of accumulated depreciation of $400 and $248 at June 30, 2014 and December 31, 2013, respectively   1,038    575 
Total non-current assets   1,038    575 
Total assets  $11,687   $15,064 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable  $434   $244 
Related party payable   41    90 
Accrued and other current liabilities   350    161 
Total current liabilities   825    495 
Total non-current liabilities   -    - 
Total liabilities   825    495 
           
Commitments and contingencies (note 8)          
           
Stockholders' equity:          
Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2014 and December 31, 2013   -    - 
Common stock, par value $0.01 per share, 30,000,000 shares authorized; 7,843,362 and 7,742,080 shares issued and outstanding at June 30, 2014 and December 31 2013, respectively   78    77 
Additional paid-in capital   18,294    16,466 
Accumulated deficit   (7,513)   (1,974)
Accumulated other comprehensive income   3    - 
Total stockholders' equity   10,862    14,569 
Total liabilities and stockholders' equity  $11,687   $15,064 

 

See accompanying notes to unaudited consolidated financial statements.

 

3
 

  

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except per share data)

 

   Three months ended
June 30,		   Six months ended
June 30,		 
   2014   2013   2014   2013 
                 
Revenues  $23   $-   $46   $- 
Cost of revenues   12    -    24    - 
Gross profit   11    -    22    - 
                     
Operating expenses:                    
Research and development   1,214    1,265    2,431    2,425 
Sales and marketing   88    34    164    54 
General and administrative   1,242    790    2,966    1,630 
Total operating expenses   2,544    2,089    5,561    4,109 
                     
Operating loss   (2,533)   (2,089)   (5,539)   (4,109)
                     
Loss before income taxes   (2,533)   (2,089)   (5,539)   (4,109)
Income taxes   -    -    -    - 
                     
Net loss  $(2,533)  $(2,089)  $(5,539)  $(4,109)
                     
Basic and diluted net loss per share  $(0.32)  $(0.27)  $(0.71)  $(0.53)
Weighted average common shares, basic and diluted   7,816    7,740    7,788    7,740 
                     
Comprehensive loss:                    
Net loss  $(2,533)  $(2,089)  $(5,539)  $(4,109)
Foreign currency translation adjustments   6    -    3    - 
Total comprehensive loss  $(2,527)  $(2,089)  $(5,536)  $(4,109)

 

See accompanying notes to unaudited consolidated financial statements.

 

4
 

  

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

 

   Six Months ended
June 30,		 
   2014   2013 
         
Cash flows used in operating activities:          
Net loss:  $(5,539)  $(4,109)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation expense   1,471    294 
Depreciation   151    83 
Changes in operating assets and liabilities:          
(Increase) in related party receivables   (60)   - 
(Increase) in inventories   (108)   - 
Decrease in prepaid expenses   65    - 
Increase (decrease) in accounts payable   71    (35)
(Decrease) in related party payable   (49)   - 
Increase (decrease) in accrued and other current liabilities   189    (66)
Net cash used in operating activities   (3,809)   (3,833)
           
Cash flows used in investing activities:          
Additions to property, plant and equipment   (495)   (51)
Net cash used in investing activities   (495)   (51)
           
Cash flows from financing activities:          
Proceeds from funding provided by Harvard Bioscience, Inc.   -    3,884 
Proceeds from issuance of common stock   358    - 
Net cash provided by financing activities   358    3,884 
Effect of exchange rate changes on cash   3    - 
Net decrease in cash   (3,943)   - 
Cash at the beginning of the period   14,008    - 
Cash at the end of the period  $10,065   $- 

 

See accompanying notes to unaudited consolidated financial statements.

 

5
 

  

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

A BUSINESS SEGMENT OF HARVARD BIOSCIENCE, INC.

 

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

 

1.Overview and Basis of Presentation

 

Overview

 

Prior to November 1, 2013, Harvard Apparatus Regenerative Technology, Inc. (“HART” or the “Company”) was a business segment of Harvard Bioscience, Inc. (“Harvard Bioscience”). The Company is engaged in the development and commercialization of regenerated organs for human transplant.

 

Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets.

 

HART was incorporated in Delaware on May 3, 2012 by Harvard Bioscience, as a wholly-owned subsidiary, to provide a means for separating Harvard Bioscience’s regenerative medicine business from its other businesses. Harvard Bioscience has been designing and manufacturing devices for life science researchers for over 100 years. Harvard Bioscience first focused on providing devices to scientists involved in regenerative medicine research in 2008. Since early 2009, Harvard Bioscience’s regenerative medicine business initiative was operated as a segment of Harvard Bioscience.

 

On October 31, 2013, Harvard Bioscience contributed its regenerative medicine business assets, plus $15 million of cash, into HART (the “Separation”). On November 1, 2013, the previously announced spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience stockholders of all the shares of common stock of HART (the “Distribution”).

 

Basis of Presentation

 

The Company historically operated as part of Harvard Bioscience, and not as a stand-alone company. For periods prior to the Separation on October 31, 2013, the consolidated financial statements presented herein, which include periods prior to the Separation, and are discussed below, have been prepared on a stand-alone basis and are derived from the financial statements and accounting records of Harvard Bioscience using the historical basis of assets and liabilities of HART. The Company’s financial statements from that period include expenses of Harvard Bioscience allocated to HART for certain functions provided by Harvard Bioscience, including, but not limited to, general corporate expenses related to executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. These expenses were allocated to HART on the basis of headcount, time devoted to HART activities, percentage of operating expenses or other relevant measures. The Company believes the assumptions and allocations underlying the financial statements are reasonable and appropriate under the circumstances. Both HART and Harvard Bioscience consider the basis on which the expenses have been allocated to be a reasonable reflection of the utilization of services provided to or the benefits received by the Company during the periods presented. However, the amounts recorded for these transactions and allocations are not necessarily representative of the amounts that would have been reflected in the financial statements had HART operated independently of Harvard Bioscience. Accordingly, the financial statements for these periods are not necessarily indicative of HART’s future results of operations, financial position and cash flows.

 

Prior to the Separation on October 31, 2013, Harvard Bioscience used a centralized approach to manage substantially all of its liquid resources and to finance its operations and, as a result, no separate cash accounts for HART were historically maintained, and debt and liquid resources maintained at the Harvard Bioscience group level are not included in the accompanying consolidated financial statements prior to the Separation. Harvard Bioscience funded all of HART’s operating and capital resource requirements prior to the Distribution. After October 31, 2013, the accompanying consolidated financial statements reflect the consolidated financial position and results of operations of the Company as an independent publicly traded company.

 

Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred.

 

The financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”).

 

6
 

  

Unaudited Interim Financial Information

 

 The accompanying interim balance sheet as of June 30, 2014 and consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2014 and 2013 are unaudited. The accompanying interim consolidated statements of cash flows for the six months ended June 30, 2014 and 2013 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of June 30, 2014, its results of operations for the three and six months ended June 30, 2014 and 2013, and the Company’s consolidated statements of cash flows for the six months ended June 30, 2014 and 2013.  The financial data and other information disclosed in these notes related to the three and six month periods ended June 30, 2014 and 2013 are unaudited. The results for the three and six months ended June 30, 2014 and 2013 are not necessarily indicative of results to be expected for the year ending December 31, 2014, any other interim periods or any future year or period.

 

2.Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

 

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-10, Development Stage Entities (Topic 915): “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”, which removes the definition of a development stage entity from the Accounting Standards Codification, eliminated the requirement that development stage entities present inception-to-date information in the company’s financial statements, label those financial statements as those of a development stage entity, disclose a description of the development stage activities in which they engage and disclose in the first year the entity is no longer a development stage entity that in prior years it had been. The ASU is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 14, 2014. The Company has elected the permissible early application of the changes in the accompanying interim unaudited consolidated financial statements, and for all future periods.

 

The accounting policies, other than the change noted above, underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K.

 

There are no other recently issued accounting standards which are not yet effective which the Company believes would materially impact the financial statements.

 

3.Liquidity

 

The Company has incurred net losses since inception through June 30, 2014. Since inception, through the Separation, the Company received funding for operating losses from Harvard Bioscience and a $15.0 million cash contribution at the Separation. During the six month period ended June 30, 2014 the Company received an additional $0.36 million from the exercise of stock options. The Company is currently investing significant resources in development and commercialization of products for use in the field of regenerative medicine. The Company expects to continue to incur operating losses and negative cash flows from operations.

 

4.Inventories

 

Inventories consisted of the following:

 

   June
30, 2014		   December
31, 2013		 
   (in thousands) 
Finished goods  $16   $7 
Raw materials   130    31 
Total  $146   $38 

 

7
 

  

5.Related Party Transactions

 

Harvard Bioscience is considered to be a related party to the Company because David Green, the Company’s Chairman and CEO, is also a director of Harvard Bioscience.

 

Cost Allocations

 

For periods presented prior to the Separation, HART’s operations were fully integrated with Harvard Bioscience, including executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. The accompanying financial statements for periods prior to the Separation reflect the application of certain estimates and allocations of operating expenses and the Company believes the methods used to allocate these operating expenses were reasonable. The allocation methods included time devoted to HART activities, headcount, percentage of operating expenses or other relevant measures. Allocations of expenses for these services were $0.7 million for the three month period ended June 30, 2013 and $1.2 million for the six month period ended June 30, 2013. These allocated expenses are reflected in the total operating expenses in the consolidated statements of operations, in addition to direct expenses.

 

Agreements with Harvard Bioscience

 

In connection with the Separation of the Company from Harvard Bioscience, on October 31, 2013 the Company entered into a series of agreements with Harvard Bioscience, including a separation and distribution agreement, a transition services agreement, a tax sharing agreement, a sublicense agreement, a product distribution agreement, an intellectual property matters agreement and a sublease agreement. Some of these agreements require us to pay fees to Harvard Bioscience for services provided subsequent to the Separation, and will remain in place through at least October 31, 2014. Expenses recorded under these agreements were $0.1 million and $0.2 million for the three and six months ended June 30, 2014, respectively.

 

6.Concentrations

 

At the time of the Separation, the Company entered into a 10-year product distribution agreement with Harvard Bioscience under which each company will become the exclusive distributor for the other party for products such other party develops for sale in the markets served by the other. In addition, Harvard Bioscience has agreed that except for certain existing activities of its German subsidiary, to the extent that any Harvard Bioscience businesses desire to resell or distribute any bioreactor that is then manufactured by HART, HART will be the exclusive manufacturer of such bioreactors and Harvard Bioscience will purchase such bioreactors from the Company. Sales to Harvard Bioscience accounted for 100% of the revenues and receivables as of and for the six months end June 30, 2014.

 

7.Stock-Based Compensation

 

Harvard Bioscience maintains the Third Amended and Restated 2000 Stock Option and Incentive Plan, (as amended, the “Harvard Bioscience Plan”) for the benefit of certain of its officers, directors and employees. The disclosure of stock based compensation for the periods prior to the Separation represent the Company’s portion of such plan maintained by Harvard Bioscience in which the Company’s employees and directors participated. The securities underlying all options and awards granted under the Harvard Bioscience Plan consist of shares of Harvard Bioscience common stock.

 

HART maintains the 2013 Equity Incentive Plan (the “2013 Plan”) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the 2013 Plan consist of shares of HART common stock. Additionally, equity awards related to shares of the Company’s common stock were issued from the 2013 Plan at the time of the Distribution to the holders of Harvard Bioscience equity awards as part of an adjustment (the “Adjustment”) to those equity awards to prevent a loss of value to the holders due to the Distribution.

 

Prior to the Separation, HART stock-based compensation expense represented an allocation from Harvard Bioscience’s stock-based compensation expense for employees whose time had been allocated to HART. After the Separation, HART continues to record the expense on stock-based awards of Harvard Bioscience stock options and restricted stock units, issued by Harvard Bioscience, to former Harvard Bioscience employees now employed by HART.

 

As noted above relating to the Adjustment, Harvard Bioscience award holders were also issued stock-based compensation awards in HART stock options and restricted stock units. HART recognizes compensation expense on those awards to former Harvard Bioscience employees who now are employed by HART, and does not recognize expense on the Adjustment awards given to individuals not now employed by HART. Additionally, HART records expense on grants made under the 2013 Plan to HART officers, directors and employees granted subsequent to the Adjustment.

 

8
 

  

Harvard Bioscience Plan Award Information

 

During the six months ended June 30, 2013, all awards were granted to employees and directors at exercise prices equal to or greater than fair market value of the Harvard Bioscience’s common stock on the date of grant.

 

The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:

 

   Stock Options   Restricted Stock Units 
   Stock Options
Outstanding		   Weighted
Average Exercise
Price		   Restricted Stock
Units Outstanding		   Grant Date
Fair Value		 
Balance at December 31, 2013   2,500,339   $3.20    326,185   $5.46 
Granted   -    -    -    - 
Exercised   (23,057)   3.36    -    - 
Vested (RSUs)   -    -    (154,628)   4.70 
Cancelled/forfeited   (311,635)   5.58    -    - 
Balance at June 30, 2014   2,165,647   $2.85    171,557   $6.14 

 

Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2014   2013   2014   2013 
   (in thousands)   (in thousands) 
                 
Research and development  $11   $21   $31   $37 
Sales and marketing   4    -    7    - 
General and administrative   165    137    324    257 
Total stock-based compensation  $180   $158   $362   $294 

 

The Company did not capitalize any stock-based compensation related to the Harvard Bioscience Plan.

 

 Harvard Apparatus Regenerative Technology, Inc. 2013 Equity Incentive Plan

 

The 2013 Plan was adopted by the Board of Directors on October 11, 2013. The aggregate number of shares authorized for issuance under the Plan is 3,000,000 shares of common stock.

 

The Company currently has 3,000,000 shares of its common stock reserved for the issuance, exercise or vesting of awards under the 2013 Plan. During the six months ended June 30, 2014, 150,000 options were granted under the 2013 Plan to HART employees at exercise prices equal to or greater than fair market value of the Company’s common stock on the date of grant.

 

The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:

 

   Stock Options   Restricted Stock Units 
   Stock Options
Outstanding		   Weighted
Average Exercise
Price		   Restricted Stock
Units Outstanding		   Grant Date
Fair Value		 
Balance at December 31, 2013   2,075,707   $4.34    19,492   $6.00 
Granted   150,000    8.40    -    - 
Exercised   (102,705)   4.94    -    - 
Vested (RSUs)   -    -    (9,796)   6.00 
Cancelled/forfeited   (147,301)   4.46    (1,716)   6.00 
Balance at June 30, 2014   1,975,701   $4.61    7,980   $6.00 

 

9
 

  

The following assumptions were used to estimate the fair value of stock options granted during the three and six months ended June 30, 2014:

 

   Three Months Ended   Six Months Ended 
   June 30, 2014   June 30, 2014 
Volatility   74%   74%
Risk-free interest rate   1.68%   1.66%
Expected holding period   6.22 years    6.22 years 
Dividend Yield   -%   -%

 

The weighted average fair values of the options granted under the 2013 Plan during the six months ended June 30, 2014 was $5.55, using the Black-Scholes option-pricing model.

 

Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2014   2013   2014   2013 
   (in thousands)   (in thousands) 
                 
Research and development  $26   $-   $313   $- 
Sales and marketing   -    -    65    - 
General and administrative   89    -    731    - 
Total stock-based compensation  $115   $-   $1,109   $- 

 

The Company did not capitalize any stock-based compensation related to the 2013 Plan.

 

8.Commitments and Contingencies

 

From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that we expect to be material in relation to our business, financial condition, results of operations or cash flows.

 

10
 

  

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward Looking Statements

 

This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in “Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations, and our plans, objectives, expectations and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “goals,” “sees,” “estimates,” “projects,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that may cause our actual results to differ materially from those in the forward-looking statements include our ability to obtain and maintain regulatory approval for the bioreactors, scaffolds and other devices and product candidates we pursue; the success of our clinical trials and device and product development programs and the number of patients who can be treated with our products; the amount and timing of costs associated with our development of bioreactors, scaffolds and other devices and products; our failure to comply with regulations and any changes in regulations; our ability to access debt and equity markets; unpredictable difficulties or delays in the development of new technology; our collaborators not devoting sufficient time and resources to successfully carry out their duties or meet expected deadlines; our ability to attract and retain qualified personnel and key employees and retain senior management; our inability to operate effectively as a stand-alone, publicly traded company; the actual costs of separation may be higher than expected; the availability and price of acceptable raw materials and components from third-party suppliers; difficulties in obtaining or retaining the management and other human resource competencies that we need to achieve our business objectives; increased competition in the field of regenerative medicine and the financial resources of our competitors; our ability to obtain and maintain intellectual property protection for our device and product candidates; our inability to implement our growth strategy; plus factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 31, 2014 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

 

Overview

 

Our Business

 

We are a clinical-stage regenerative medicine company developing life-saving regenerated organs for transplant. Our first product, the HART-Trachea, is intended to be used by surgeons to restore the structure and/or function of a severely damaged airway in patients who need an airway transplant. The HART-Trachea is comprised of the patient’s own bone marrow cells seeded on our proprietary porous plastic scaffolding in our proprietary InBreathTM organ bioreactor.  Our HART-Trachea has been used in six successful human airway transplant surgeries to date, each approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. In addition to pursuing our HART-Trachea product, we are also working with a number of leading researchers in their efforts to regenerate other organs. We use our depth of knowledge, our existing technologies and products and continued research and development to develop and provide devices to be used for growing organs outside the body for transplant.

 

Business Drivers/Factors Affecting Results of Operations

 

Our business efforts focus on developing and providing new synthetic scaffolds and organ bioreactor products to regenerative medicine researchers and practitioners. Going forward, we intend to generate revenues from the sale of regenerated organs and related bioreactors and scaffolds. Until we are able to commercialize our HART-Trachea product upon receipt of regulatory agency approvals to market that product for clinical use we expect our costs to exceed our revenues.

 

Once we receive regulatory agency approvals to market the HART-Trachea product for surgeons to use in human trachea transplants, we expect to generate meaningful revenues. At that time, we anticipate that we will be paid on a per-procedure basis for the use of the HART-Trachea. Although we hope to eventually receive regulatory approvals to market additional regenerated organs, we expect that approval for the HART-Trachea and successful commercialization thereof could lead to sufficient sales for us to achieve profitability.

 

11
 

  

We began the first quarter 2014 with our pre-IND meeting with the FDA. Based on the feedback from that meeting, we expect to submit our IND request to the FDA in 2015. Between now and then we will be completing the required preclinical large animal model testing, the ex-vivo accelerated lifetime testing and protocol standardization required by the FDA. We expect similar requirements to apply for us to get approval to begin a clinical trial in Europe too. In the pre-IND meeting we did not discuss the design of our proposed clinical trial in any detail but we do expect to have several conversations with the FDA throughout this year as we develop both the pre-clinical testing protocols and proposed clinical trial design. At this point we expect the trial to be open-label and the trial design to be a single-arm trial. With single arm trials, it is important for the trial to be well enough controlled to show that the treatment caused the effect. We intend to propose the patient’s lung function before the surgery as the control and the patient’s lung function after the surgery as the endpoint. We intend to measure lung function using the FEV1, or forced expiratory volume in one second. This is a common endpoint used for approval in clinical trials for other therapies such as for cystic fibrosis. It was also the endpoint studied in the published 5-year follow up on the very first patient ever treated with a regenerated trachea. In that case the patient’s FEV1 improved by approximately 85% from before the surgery to 3 months after the surgery. According to the American Thoracic Society, the change in FEV1 should be greater than 20% to be clinically significant in evaluations in this time frame.

 

We also applied to the FDA for an orphan drug designation for the HART-Trachea. During the first quarter, the FDA informed us that they accepted our statistics on the number of patients that might require a trachea transplant, but they requested some follow up data on the patients treated so far with the HART-Trachea in order to complete their review of our application. We sent the requested follow up data to the FDA during the second quarter. We expect this submission to be sufficient for the FDA to determine whether or not it will grant orphan drug designation to the HART-Trachea, and we expect that the FDA will notify us of their decision in the next several weeks.

 

During the second quarter, the European Medicines Agency (EMA), through its Committee for Advanced Therapies (CAT), informed us of CAT’s conclusion that our HART-Trachea product is classified as a tissue-engineered, advanced therapy medicinal product, or Combined ATMP. This classification grants our HART-Trachea product a pathway to approval on a European Union-wide basis, although clinical trials are managed through individual countries’ regulatory agencies there.

 

We met with the Medicines and Healthcare Products Regulatory Agency of the U.K. (MHRA) in June to discuss the HART-Trachea product and the MHRA’s views on certain preclinical studies, as well as our planned approach to clinical studies. We chose the U.K. to approach first in Europe due to the MHRA’s familiarity with cell therapies, and the availability of surgeons and hospitals there that are already familiar with early progress in tissue-engineered products. Based on that meeting we continue to see a path to clinical trials and approval in Europe prior to the United States.

 

Clinical Update

 

During the second quarter, a sixth human tracheal transplant was performed using our HART-Trachea product, at Krasnodar Regional Hospital in Russia. The patient was a 24-year-old male suffering from extensive tracheal damage following an automobile accident. The surgery was a success and the patient was recovering well in the days following the procedure.

 

Basis of Presentation

 

Historically, we operated as part of Harvard Bioscience, and not as a stand-alone company. On October 31, 2013, Harvard Bioscience contributed the assets of its regenerative medicine business and $15 million of cash to HART, and on November 1, 2013 distributed all of the outstanding common shares of HART to Harvard Bioscience’s shareholders on a pro-rata basis. The contribution and related separation is referred to herein as the “Separation” and the distribution is referred to herein as the “Distribution” and the “spin-off”. The consolidated HART financial statements for periods prior to the Separation, were prepared on a stand-alone basis and were derived from the financial statements and accounting records of Harvard Bioscience using the historical basis of assets and liabilities of HART. Our financial statements from the periods prior to the Separation include expenses of Harvard Bioscience allocated to HART for certain functions provided by Harvard Bioscience, including, but not limited to, general corporate expenses related to executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. These expenses were allocated to HART on the basis of headcount, time devoted to HART activities, percentage of operating expenses or other relevant measures. Prior to the Separation, Harvard Bioscience used a centralized approach to manage substantially all of its liquid resources and to finance its operations and, as a result, no separate cash accounts for HART were historically maintained, and debt and liquid resources maintained at the Harvard Bioscience group level are not included in the accompanying consolidated financial statements prior to the Separation. Harvard Bioscience funded all of HART’s operating and capital resource requirements prior to the Distribution. After October 31, 2013, the financial statements reflect the consolidated financial position and results of operations of the Company as an independent publicly traded company.

 

12
 

  

Relationship with Harvard Bioscience

 

Prior to November 1, 2013, HART was a wholly-owned subsidiary of Harvard Bioscience, Inc. HART was incorporated on May 3, 2012 by Harvard Bioscience to provide a means for separating its regenerative medicine device business from its other businesses. Harvard Bioscience first focused on providing devices to scientists involved in regenerative medicine research in 2008. From early 2009 to the Separation, Harvard Bioscience’s regenerative medicine device business initiative operated as a division of Harvard Bioscience. Harvard Bioscience decided to separate its regenerative medicine business into our company, a separate corporate entity, and then to spin off its interest in our business to its stockholders. On October 31, 2013, Harvard Bioscience contributed the assets of its regenerative medicine business and approximately $15 million in cash to us. On November 1, 2013, Harvard Bioscience spun off its interest in HART via a pro-rata distribution of its HART common shares to Harvard Bioscience’s stockholders. As a result of that distribution, Harvard Bioscience is no longer a stockholder of our common stock and no longer controls our operations.   We had no material assets or activities as a separate corporate entity until the contribution to us by Harvard Bioscience of those assets and that business.

 

On October 31, 2013, we entered into agreements with Harvard Bioscience that will govern the Separation and various interim and ongoing relationships. They provide for, among other things, the transfer from Harvard Bioscience to us of assets and the assumption by us of liabilities comprising our businesses. In accordance with such agreements, we will pay Harvard Bioscience to provide continued services in the areas of accounting, payroll, facilities usage, benefits administration, human resources, information services and various other corporate services, operations, and engineering for periods ranging from six months to one year following the Distribution. All of the agreements relating to the Separation were made in the context of a parent-subsidiary relationship and were entered into in the overall context of the Separation. The terms of these agreements may be more or less favorable to us than if they had been negotiated with unaffiliated third parties.

 

Harvard Bioscience is considered to be a related party to HART because David Green, our Chairman and CEO, is also a director of Harvard Bioscience.

 

Results of Operations

 

Components of Operating Loss

 

Research and development expense. Research and development expense consists of salaries and related expenses, including stock-based compensation, for personnel and contracted consultants and various materials and other costs to develop our new products, primarily: synthetic organ scaffolds, including investigation and development of materials and investigation and optimization of cellularization; 3D organ bioreactors; and for periods prior to 2014, development costs of a stem cell injector, a product that we are not currently pursuing. Other research and development expenses include the costs of outside service providers and material costs for prototype and test units and outside testing facilities performing cell growth and materials experiments, as well as the costs of all other preclinical research and testing and expenses related to writing, issuing and defending our patents. We expense research and development costs as incurred.

 

Sales and marketing expense. Sales and marketing expense consists primarily of salaries and related expenses, including stock-based compensation, for personnel performing sales, marketing, and business development roles, and costs associated with their travel and participation in trade shows and conferences. It also includes the costs of catalogs, marketing communications and web site development and maintenance.

 

General and administrative expense. General and administrative expense consists primarily of salaries and other related expenses, including stock-based compensation, for personnel in executive, accounting, information technology and human resources roles. Other costs include professional fees for general legal and accounting services, insurance, investor relations and facility costs.

 

Comparison of the three months ended June 30, 2014 to the three months ended June 30, 2013:

 

Research and Development Expense

 

Research and development expense was flat, at $1.2 million for the three months ended June 30, 2014 compared with $1.2 million for the three months ended June 30, 2013. An increase in fees related to patents and depreciation for lab and test equipment was offset by a year to year reduction of costs related to our stem cell injector development project which we terminated during 2013.

 

 Sales and Marketing Expense

 

Sales and marketing expense increased approximately $54,000, or 155%, to $88,000 for the three months ended June 30, 2014 compared with $34,000 for the three months ended June 30, 2013. The increase was primarily due to additional salary-related costs of $60,000.

 

13
 

  

General and Administrative Expense

 

General and administrative expense increased $0.5 million, or 57%, to $1.2 million for the three months ended June 30, 2014 compared with $0.8 million for the three months ended June 30, 2013. Of the $0.5 million increase, direct salary costs increased by $0.1 million over those allocated to HART by Harvard Bioscience for the three months ended June 30, 2013. General and administrative costs also increased by $0.3 million due to costs associated with being a stand-alone public company, such as external and internal accountants, information technology, legal fees, investor relations, director fees and insurance.

 

Comparison of the six months ended June 30, 2014 to the six months ended June 30, 2013:

 

Research and Development Expense

 

Research and development expense was flat, at $2.4 million for the six months ended June 30, 2014 compared with $2.4 million for the six months ended June 30, 2013. A $0.4 million year to year increase in non-cash stock-based compensation expense related to the initial stock option grants made to employees at the time of the spin-off was offset by a year to year reduction of costs related to our stem cell injector development project which we terminated during 2013.

 

 Sales and Marketing Expense

 

Sales and marketing expense increased approximately $110,000, or 201%, to $164,000 for the six months ended June 30, 2014 compared with $54,000 for the six months ended June 30, 2013. The increase was primarily due to additional salary-related costs of $127,000.

 

General and Administrative Expense

 

General and administrative expense increased $1.4 million, or 82%, to $3.0 million for the six months ended June 30, 2014 compared with $1.6 million for the six months ended June 30, 2013. Of the $1.4 million increase, $0.8 million was related to an increase in non-cash stock-based compensation expense related to the initial stock option grants made to employees at the time of the spin-off. Additionally, direct salary costs increased by $0.2 million over those allocated to HART by Harvard Bioscience for the six months ended June 30, 2013. General and administrative expense also increased by $0.5 million due to costs associated with being a stand-alone public company, such as external and internal accountants, information technology, legal fees, investor relations, director fees and insurance.

 

Financial Condition, Liquidity and Capital Resources

 

Sources of liquidity.

 

We have incurred net losses since inception. Since inception, through the Separation, we received funding for operating losses from Harvard Bioscience and a $15.0 million cash contribution at the Separation.

 

During the six month period ended June 30, 2014 we received $0.4 million of cash proceeds from exercise of stock options.

 

We are currently investing significant resources in development and commercialization of products for use by clinicians and researchers in the field of regenerative medicine and have incurred operating losses to date. We expect to continue to incur operating losses and negative cash flows from operations at least until we receive regulatory approval to market a clinical product, as revenues from research bioreactors sales will not generate sufficient gross profits to offset our operating expenses.

 

Operating activities.   Net cash used in operating activities of $3.8 million for the six months ended June 30, 2014 reflected our $5.5 million net loss, offset by a $1.5 million add-back of non-cash stock-based compensation expense, a $0.1 million add-back for depreciation and $0.1 million of changes in working capital items.

  

Net cash used in operating activities of $3.8 million for the six months ended June 30, 2013 reflected our $4.1 million net loss, offset by a $0.3 million add-back of non-cash stock-based compensation expense.

 

Investing activities.   Net cash used in investing activities during the six month periods ended June 30, 2014 and 2013 reflected additions to property, plant and equipment.

 

14
 

  

Financing activities. Cash generated from financing activities during the six months ended June 30, 2014 was primarily a result of employees’ exercises of stock options.

 

Cash generated from financing activities during the six months ended June 30, 2013 represented Harvard Bioscience’s funding of our business activities.

 

Recent Authoritative Accounting Guidance

 

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-10, Development Stage Entities (Topic 915): “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”, which removes the definition of a development stage entity from the Accounting Standards Codification, eliminated the requirement that development stage entities present inception-to-date information in the company’s financial statements, label those financial statements as those of a development stage entity, disclose a description of the development stage activities in which they engage and disclose in the first year the entity is no longer a development stage entity that in prior years it had been. The ASU is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 14, 2014. We have elected the permissible early application of the changes in the accompanying interim unaudited consolidated financial statements, and for all future periods.

 

Critical Accounting Policies and Estimates

 

The critical accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Part II, Item 7 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 31, 2014.

 

Item 3.Quantitative and Qualitative Disclosures About Market Risk.

 

We do not have any material foreign currency exchange risks, we do not enter into derivative agreements, we do not have any off balance-sheet arrangements, and we do not have any interest rate risks. Also, we have no debt outstanding.

 

Item 4.Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

As required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2014.   Based upon the evaluation described above, our Chief Executive Officer and Chief Financial Officer have concluded that they believe that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

 

Changes in Internal Control over Financial Reporting

 

During the period covered by this report, we have concluded that there were no changes during the fiscal quarter in our internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II. OTHER INFORMATION

 

Item 1A.Risk Factors

 

To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form-10Q relates to such risk factors, there have been no material changes in the risk factors described in “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 31, 2014.

  

15
 

  

Item 6. Exhibits
   

Exhibit
Index

  
   
31.1+ Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
31.2+ Certification of Chief Executive Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
32.1* Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
32.2* Certification of Chief Executive Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS** XBRL Instance Document
   
101.SCH** XBRL Taxonomy Extension Schema Document
   
101.CAL** XBRL Taxonomy Extension Calculation Linkbase Document
   
101.LAB** XBRL Taxonomy Extension Labels Linkbase Document
   
101.PRE** XBRL Taxonomy Extension Presentation Linkbase Document
   
101.DEF** XBRL Taxonomy Extension Definition Linkbase Document

 

+ Filed herewith.
* This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
   
** XBRL (Extensive Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

  

16
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.

 

Date: August 13, 2014

 

  HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.
     
  By: /S/ David Green
    David Green
    President and Chief Executive Officer  
     
  By: /S/ Thomas McNaughton
    Thomas McNaughton
    Chief Financial Officer

 

17
 

  

INDEX TO EXHIBITS

 

31.1+ Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
31.2+ Certification of Chief Executive Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
32.1* Certification of Chief Financial Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
32.2* Certification of Chief Executive Officer of Harvard Apparatus Regenerative Technology, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS** XBRL Instance Document
   
101.SCH** XBRL Taxonomy Extension Schema Document
   
101.CAL** XBRL Taxonomy Extension Calculation Linkbase Document
   
101.LAB** XBRL Taxonomy Extension Labels Linkbase Document
   
101.PRE** XBRL Taxonomy Extension Presentation Linkbase Document
   
101.DEF** XBRL Taxonomy Extension Definition Linkbase Document

 

+ Filed herewith.
* This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
   
** XBRL (Extensive Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

 

18

  

 

 EX-31.1 2 v386033_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

Certification

I, Thomas McNaughton, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Harvard Apparatus Regenerative Technology, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 13, 2014

 

  /s/ Thomas McNaughton 
  Thomas McNaughton
  Chief Financial Officer

 

 

  

 EX-31.2 3 v386033_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

Certification

I, David Green, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Harvard Apparatus Regenerative Technology, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 13, 2014

 

  /s/ David Green  
  David Green
  President and Chief Executive Officer

 

 

  

 EX-32.1 4 v386033_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

CERTIFICATION OF PERIODIC FINANCIAL REPORT

PURSUANT TO 18 U.S.C. SECTION 1350

 

The undersigned officer of Harvard Apparatus Regenerative Technology, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014 (the “Report”) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

Date: August 13, 2014

 

    /s/ Thomas McNaughton 
  Name: Thomas McNaughton
  Title: Chief Financial Officer

 

 

  

 EX-32.2 5 v386033_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

CERTIFICATION OF PERIODIC FINANCIAL REPORT

PURSUANT TO 18 U.S.C. SECTION 1350

 

The undersigned officer of Harvard Apparatus Regenerative Technology, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2014 (the “Report”) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

Date: August 13, 2014   /s/ David Green 
  Name: David Green
  Title: President and Chief Executive Officer

 

 

 

 EX-101.INS 6 hart-20140630.xml XBRL INSTANCE DOCUMENT 0001563665 2013-01-01 2013-06-30 0001563665 2014-01-01 2014-06-30 0001563665 2013-04-01 2013-06-30 0001563665 2014-04-01 2014-06-30 0001563665 2012-05-03 2013-10-31 0001563665 2014-06-30 0001563665 2014-08-08 0001563665 2013-12-31 0001563665 2012-12-31 0001563665 2013-06-30 0001563665 hart:HarvardBiosciencePlanMember 2014-01-01 2014-06-30 0001563665 hart:EquityIncentivePlan2013Member 2014-01-01 2014-06-30 0001563665 hart:HarvardBioscienceIncMember 2013-01-01 2013-06-30 0001563665 hart:HarvardBioscienceIncMember 2014-01-01 2014-06-30 0001563665 hart:HarvardBioscienceIncMember 2013-04-01 2013-06-30 0001563665 hart:HarvardBioscienceIncMember 2014-04-01 2014-06-30 0001563665 us-gaap:AccountsReceivableMember 2014-01-01 2014-06-30 0001563665 hart:HarvardBiosciencePlanMember 2013-12-31 0001563665 hart:EquityIncentivePlan2013Member 2013-12-31 0001563665 hart:HarvardBiosciencePlanMember 2014-06-30 0001563665 hart:EquityIncentivePlan2013Member 2014-06-30 0001563665 us-gaap:RestrictedStockUnitsRSUMember hart:HarvardBiosciencePlanMember 2013-12-31 0001563665 us-gaap:RestrictedStockUnitsRSUMember hart:EquityIncentivePlan2013Member 2013-12-31 0001563665 us-gaap:RestrictedStockUnitsRSUMember hart:HarvardBiosciencePlanMember 2014-01-01 2014-06-30 0001563665 us-gaap:RestrictedStockUnitsRSUMember hart:EquityIncentivePlan2013Member 2014-01-01 2014-06-30 0001563665 us-gaap:RestrictedStockUnitsRSUMember hart:HarvardBiosciencePlanMember 2014-06-30 0001563665 us-gaap:RestrictedStockUnitsRSUMember hart:EquityIncentivePlan2013Member 2014-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:HarvardBiosciencePlanMember 2013-01-01 2013-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:HarvardBiosciencePlanMember 2013-01-01 2013-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:HarvardBiosciencePlanMember 2013-01-01 2013-06-30 0001563665 hart:HarvardBiosciencePlanMember 2013-01-01 2013-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:EquityIncentivePlan2013Member 2013-01-01 2013-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:EquityIncentivePlan2013Member 2013-01-01 2013-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:EquityIncentivePlan2013Member 2013-01-01 2013-06-30 0001563665 hart:EquityIncentivePlan2013Member 2013-01-01 2013-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:HarvardBiosciencePlanMember 2014-01-01 2014-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:HarvardBiosciencePlanMember 2014-01-01 2014-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:HarvardBiosciencePlanMember 2014-01-01 2014-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:EquityIncentivePlan2013Member 2014-01-01 2014-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:EquityIncentivePlan2013Member 2014-01-01 2014-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:EquityIncentivePlan2013Member 2014-01-01 2014-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:HarvardBiosciencePlanMember 2013-04-01 2013-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:HarvardBiosciencePlanMember 2013-04-01 2013-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:HarvardBiosciencePlanMember 2013-04-01 2013-06-30 0001563665 hart:HarvardBiosciencePlanMember 2013-04-01 2013-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:EquityIncentivePlan2013Member 2013-04-01 2013-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:EquityIncentivePlan2013Member 2013-04-01 2013-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:EquityIncentivePlan2013Member 2013-04-01 2013-06-30 0001563665 hart:EquityIncentivePlan2013Member 2013-04-01 2013-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:HarvardBiosciencePlanMember 2014-04-01 2014-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:HarvardBiosciencePlanMember 2014-04-01 2014-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:HarvardBiosciencePlanMember 2014-04-01 2014-06-30 0001563665 hart:HarvardBiosciencePlanMember 2014-04-01 2014-06-30 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember hart:EquityIncentivePlan2013Member 2014-04-01 2014-06-30 0001563665 us-gaap:SellingAndMarketingExpenseMember hart:EquityIncentivePlan2013Member 2014-04-01 2014-06-30 0001563665 us-gaap:GeneralAndAdministrativeExpenseMember hart:EquityIncentivePlan2013Member 2014-04-01 2014-06-30 0001563665 hart:EquityIncentivePlan2013Member 2014-04-01 2014-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"> <strong>4.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Inventories</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventories consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June<br/> 30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December<br/> 31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>146</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>5.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Related Party Transactions</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 9pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Harvard Bioscience is considered to be a related party to the Company because David Green, the Company&#8217;s Chairman and CEO, is also a director of Harvard Bioscience.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <i>Cost Allocations</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.65pt; MARGIN: 0pt 0px 0pt 9.35pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.65pt; MARGIN: 0pt 0px 0pt 9.35pt; FONT: 10pt Times New Roman, Times, Serif"> For periods presented prior to the Separation, HART&#8217;s operations were fully integrated with Harvard Bioscience, including executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. The accompanying financial statements for periods prior to the Separation reflect the application of certain estimates and allocations of operating expenses and the Company believes the methods used to allocate these operating expenses were reasonable. The allocation methods included time devoted to HART activities, headcount, percentage of operating expenses or other relevant measures. Allocations of expenses for these services were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.7</font> million for the three month period ended June 30, 2013 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.2</font> million for the six month period ended June 30, 2013. These allocated expenses are reflected in the total operating expenses in the consolidated statements of operations, in addition to direct expenses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.65pt; MARGIN: 0pt 0px 0pt 9.35pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <i>Agreements with Harvard Bioscience</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.65pt; MARGIN: 0pt 0px 0pt 9pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 26.65pt; MARGIN: 0pt 0px 0pt 9pt; FONT: 10pt Times New Roman, Times, Serif"> In connection with the Separation of the Company&#160;from Harvard Bioscience, on October 31, 2013 the Company&#160;entered into a series of agreements with Harvard Bioscience, including a separation and distribution agreement, a transition services agreement, a tax sharing agreement, a sublicense agreement, a product distribution&#160;agreement, an intellectual property matters agreement and a sublease agreement. Some of these agreements require us to pay fees to Harvard Bioscience for services provided subsequent to the Separation, and will remain in place through at least October 31, 2014. Expenses recorded under these agreements were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million for the three and six months ended June 30, 2014, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> 6.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Concentrations</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the time of the Separation, the Company entered into a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>-year product distribution agreement with Harvard Bioscience under which each company will become the exclusive distributor for the other party for products such other party develops for sale in the markets served by the other. In addition, Harvard Bioscience has agreed that except for certain existing activities of its German subsidiary, to the extent that any Harvard Bioscience businesses desire to resell or distribute any bioreactor that is then manufactured by HART, HART will be the exclusive manufacturer of such bioreactors and Harvard Bioscience will purchase such bioreactors from the Company. Sales to Harvard Bioscience accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of the revenues and receivables as of and for the six months end June 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"> <strong>7.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Stock-Based Compensation</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&#160;</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Harvard Bioscience maintains the Third Amended and Restated 2000 Stock Option and Incentive Plan, (as amended, the &#8220;Harvard Bioscience Plan&#8221;) for the benefit of certain of its officers, directors and employees. The disclosure of stock based compensation for the periods prior to the Separation represent the Company&#8217;s portion of&#160;such plan maintained by Harvard Bioscience in which the Company&#8217;s employees and directors participated. The securities underlying all options and awards granted under the Harvard Bioscience Plan consist of shares of Harvard Bioscience common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> HART maintains the 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the 2013 Plan consist of shares of HART common stock. Additionally, equity awards related to shares of the Company&#8217;s common stock were issued from the 2013 Plan at the time of the Distribution to the holders of Harvard Bioscience equity awards as part of an adjustment (the &#8220;Adjustment&#8221;) to those equity awards to prevent a loss of value to the holders due to the Distribution.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Prior to the Separation, HART stock-based compensation expense represented an allocation from Harvard Bioscience&#8217;s stock-based compensation expense for employees whose time had been allocated to HART. After the Separation, HART continues to record the expense on stock-based awards of Harvard Bioscience stock options and restricted stock units, issued by Harvard Bioscience, to former Harvard Bioscience employees now employed by HART.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As noted above relating to the Adjustment, Harvard Bioscience award holders were also issued stock-based compensation awards in HART stock options and restricted stock units. HART recognizes compensation expense on those awards to former Harvard Bioscience employees who now are employed by HART, and does not recognize expense on the Adjustment awards given to individuals not now employed by HART. Additionally, HART records expense on grants made under the 2013 Plan to HART officers, directors and employees granted subsequent to the Adjustment.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 26.9pt; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> <i>Harvard Bioscience Plan Award Information</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the six months ended June 30, 2013, all awards were granted to employees and directors at exercise prices equal to or greater than fair market value of the Harvard Bioscience&#8217;s common stock on the date of grant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Stock&#160;Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Restricted&#160;Stock&#160;Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Stock&#160;Options<br/> Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Restricted&#160;Stock<br/> Units&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date<br/> Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,500,339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>326,185</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(23,057)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (RSUs)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(154,628)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cancelled/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(311,635)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,165,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>171,557</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>165</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>180</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>158</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>362</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company did not capitalize any stock-based compensation related to the Harvard Bioscience Plan.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;<i>Harvard Apparatus Regenerative Technology, Inc. 2013 Equity Incentive Plan</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The 2013 Plan was adopted by the Board of Directors on October 11, 2013. The aggregate number of shares authorized for issuance under the Plan is <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company currently has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,000,000</font> shares of its common stock reserved for the issuance, exercise or vesting of awards under the 2013 Plan. During the six months ended June 30, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> options were granted under the 2013 Plan to HART employees at exercise prices equal to or greater than fair market value of the Company&#8217;s common stock on the date of grant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Stock&#160;Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Restricted&#160;Stock&#160;Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Stock&#160;Options<br/> Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Restricted&#160;Stock<br/> Units&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date<br/> Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,075,707</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(102,705)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (RSUs)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(9,796)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cancelled/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(147,301)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,975,701</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,980</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following assumptions were used to estimate the fair value of stock options granted during the three and six months ended June 30, 2014:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Expected holding period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.22 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.22 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Dividend Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The weighted average fair values of the options granted under the 2013 Plan during the six months ended June 30, 2014 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.55</font>, using the Black-Scholes option-pricing model.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>731</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company did not capitalize any stock-based compensation related to the 2013 Plan.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>8.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Commitments and Contingencies</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 28.05pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that we expect to be material in relation to our business, financial condition, results of operations or cash flows.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Inventories consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June<br/> 30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December<br/> 31,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="55%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>146</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>38</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Stock&#160;Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Restricted&#160;Stock&#160;Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Stock&#160;Options<br/> Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Restricted&#160;Stock<br/> Units&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date<br/> Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,500,339</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.20</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>326,185</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(23,057)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (RSUs)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(154,628)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.70</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cancelled/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(311,635)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.58</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,165,647</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.85</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>171,557</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Stock&#160;Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Restricted&#160;Stock&#160;Units</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Stock&#160;Options<br/> Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted<br/> Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Restricted&#160;Stock<br/> Units&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Grant&#160;Date<br/> Fair&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,075,707</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>19,492</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>150,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.40</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(102,705)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (RSUs)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(9,796)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Cancelled/forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(147,301)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.46</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,716)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Balance at June 30, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,975,701</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,980</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>21</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>165</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>257</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="36%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>180</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>158</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>362</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%" colspan="5"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>26</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>313</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>731</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Total stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>115</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following assumptions were used to estimate the fair value of stock options granted during the three and six months ended June 30, 2014:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 70%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.66</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Expected holding period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.22 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.22 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="44%"> <div>Dividend Yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 15000000 10065000 14008000 82000 22000 146000 38000 356000 421000 10649000 14489000 1038000 575000 1038000 575000 11687000 15064000 434000 244000 41000 90000 350000 161000 825000 495000 0 0 825000 495000 0 0 78000 77000 18294000 16466000 -7513000 -1974000 3000 0 10862000 14569000 11687000 15064000 360000 16000 7000 130000 31000 1200000 200000 700000 100000 1 P10Y 2500339 2075707 0 150000 23057 102705 311635 147301 2165647 1975701 3.20 4.34 0 8.40 3.36 4.94 -5.58 -4.46 2.85 4.61 326185 19492 0 0 154628 9796 0 1716 171557 7980 5.46 6.00 0 0 4.70 6.00 0 6.00 6.14 6.00 37000 0 257000 294000 0 0 0 0 31000 7000 324000 362000 313000 65000 731000 1109000 21000 0 137000 158000 0 0 0 0 11000 4000 165000 180000 26000 0 89000 115000 0.74 0.74 0.0166 0.0168 P6Y2M19D P6Y2M19D 0 0 5.55 3000000 3000000 0.01 0.01 2000000 2000000 0 0 0 0 0.01 0.01 30000000 30000000 7843362 7742080 7843362 7742080 400000 248000 0 46000 0 23000 0 24000 0 12000 0 22000 0 11000 2425000 2431000 1265000 1214000 54000 164000 34000 88000 1630000 2966000 790000 1242000 4109000 5561000 2089000 2544000 -4109000 -5539000 -2089000 -2533000 -4109000 -5539000 -2089000 -2533000 0 0 0 0 -4109000 -5539000 -2089000 -2533000 -0.53 -0.71 -0.27 -0.32 7740000 7788000 7740000 7816000 0 3000 0 6000 -4109000 -5536000 -2089000 -2527000 294000 1471000 83000 151000 0 60000 0 108000 0 -65000 -35000 71000 0 -49000 -66000 189000 -3833000 -3809000 51000 495000 -51000 -495000 3884000 0 0 358000 3884000 358000 0 3000 0 -3943000 0 14008000 0 10065000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><b>1.</b></div> </td> <td style="TEXT-ALIGN: justify"> <div style="CLEAR:both;CLEAR: both"><b>Overview and Basis of Presentation</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Overview</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Prior to November 1, 2013, Harvard Apparatus Regenerative Technology, Inc. (&#8220;HART&#8221; or the &#8220;Company&#8221;) was a business segment of Harvard Bioscience, Inc. (&#8220;Harvard Bioscience&#8221;). The Company is engaged in the development and commercialization of regenerated organs for human transplant.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> HART was incorporated in Delaware on May 3, 2012 by Harvard Bioscience, as a wholly-owned subsidiary, to provide a means for separating Harvard Bioscience&#8217;s regenerative medicine business from its other businesses. Harvard Bioscience has been designing and manufacturing devices for life science researchers for over 100 years. Harvard Bioscience first focused on providing devices to scientists involved in regenerative medicine research in 2008. Since early 2009, Harvard Bioscience&#8217;s regenerative medicine business initiative was operated as a segment of Harvard Bioscience.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 18.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On October 31, 2013, Harvard Bioscience contributed its regenerative medicine business assets, plus $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million of cash, into HART (the &#8220;Separation&#8221;). On November 1, 2013, the previously announced spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience stockholders of all the shares of common stock of HART (the &#8220;Distribution&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 18.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 18.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company historically operated as part of Harvard Bioscience, and not as a stand-alone company. For periods prior to the Separation on October 31, 2013, the consolidated financial statements presented herein, which include periods prior to the Separation, and are discussed below, have been prepared on a stand-alone basis and are derived from the financial statements and accounting records of Harvard Bioscience using the historical basis of assets and liabilities of HART. The Company&#8217;s financial statements from that period include expenses of Harvard Bioscience allocated to HART for certain functions provided by Harvard Bioscience, including, but not limited to, general corporate expenses related to executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. These expenses were allocated to HART on the basis of headcount, time devoted to HART activities, percentage of operating expenses or other relevant measures. The Company believes the assumptions and allocations underlying the financial statements are reasonable and appropriate under the circumstances. Both HART and Harvard Bioscience consider the basis on which the expenses have been allocated to be a reasonable reflection of the utilization of services provided to or the benefits received by the Company during the periods presented. However, the amounts recorded for these transactions and allocations are not necessarily representative of the amounts that would have been reflected in the financial statements had HART operated independently of Harvard Bioscience. Accordingly, the financial statements for these periods are not necessarily indicative of HART&#8217;s future results of operations, financial position and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Prior to the Separation on October 31, 2013, Harvard Bioscience used a centralized approach to manage substantially all of its liquid resources and to finance its operations and, as a result, no separate cash accounts for HART were historically maintained, and debt and liquid resources maintained at the Harvard Bioscience group level are not included in the accompanying consolidated financial statements prior to the Separation. Harvard Bioscience funded all of HART&#8217;s operating and capital resource requirements prior to the Distribution. After October 31, 2013, the accompanying consolidated financial statements reflect the consolidated financial position and results of operations of the Company as an independent publicly traded company.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses&#160;incurred.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The financial statements reflect the Company&#8217;s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Unaudited Interim Financial Information</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;The accompanying interim balance sheet as of June 30, 2014 and consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2014 and 2013 are unaudited. The accompanying interim consolidated statements of cash flows for the six months ended June 30, 2014 and 2013 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company&#8217;s&#160;financial position as of June 30, 2014, its results of operations for the three and six months ended June 30, 2014 and 2013, and the Company&#8217;s&#160;consolidated statements of cash flows for the six months ended June 30, 2014 and 2013. &#160;The financial data and other information disclosed in these notes related to the three and six month periods ended June 30, 2014 and 2013 are unaudited. The results for the three and six months ended June 30, 2014 and 2013&#160;are not necessarily indicative of results to be expected for the year ending December 31, 2014, any other interim periods or any future year or period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>2.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 45.35pt; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In June 2014, &#160;the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-10, Development Stage Entities (Topic 915): &#8220;Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&#8221;, which removes the definition of a development stage entity from the Accounting Standards Codification, eliminated the requirement that development stage entities present inception-to-date information in the company&#8217;s financial statements, label those financial statements as those of a development stage entity, disclose a description of the development stage activities in which they engage and disclose in the first year the entity is no longer a development stage entity that in prior years it had been. The ASU is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 14, 2014. The Company has elected the permissible early application of the changes in the accompanying interim unaudited consolidated financial statements, and for all future periods.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accounting policies, other than the change noted above, underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the financial statements for the year ended December 31, 2013 included in the Company&#8217;s Annual Report on Form 10-K.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> There are no other recently issued accounting standards which are not yet effective which the Company believes would materially impact the financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0in"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> 3.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Liquidity</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 30.6pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has incurred net losses since inception through June 30, 2014. Since inception, through the Separation, the Company received funding for operating losses from Harvard Bioscience and a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.0</font> million cash contribution at the Separation. During the six month period ended June 30, 2014 the Company received an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.36</font> million from the exercise of&#160;stock options. The Company is currently investing significant resources in development and commercialization of products for use in the field of regenerative medicine. The Company expects to continue to incur operating losses and negative cash flows from operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 10-Q false 2014-06-30 2014 Q2 Harvard Apparatus Regenerative Technology, Inc. 0001563665 --12-31 Smaller Reporting Company HART 7846959 EX-101.SCH 7 hart-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Overview and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Liquidity link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Concentrations link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Overview and Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Liquidity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Concentrations (Details Textual) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 hart-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 hart-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 hart-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 hart-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#ZP-;3N@$``-<0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-?+6T M*2FFYL[?FBG5/)OQ*=`DCGLT4]*!=*%K>I#AX`ER M/J]<\+STC]2KA1B'QEN\86I;97'H/0 M3H5FYG>!3=V;WQI3"@C&W+A77GL,NJSHES*S3Z5FT>$F'90JS\L,A,KFM=^! MR&H#7-@"P-55U(Y1S4NYY3Z@WRZVM!W8F4&:]VL;G\B1(.&X1L)Q@X3C%@E' M#PG''1*./A*.>R0<+,8"@L51&19+95@\E6$Q58;%51D66V58?)5A,5:&Q5D3 M+,Z:8''6!(NS)EB<-?DO9W4^-@)MKW__.MHV1W*+=:L*[)G_-=9-CRD7W(!X M=\8'[+,#_.Q]B,/'S[%1VOH@;N#T7=@F[:8ZU+X1&%?"+FMW9=:=H@_QIPON MA69HC@D$B`YMVAY+#+\!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P" M```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````````C)+/ M3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?/ M/UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBD ME)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\ MU<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5 M\YS3$$ MX4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`$ MM^X'F$1-0E,[V-Y'__U,UZ4M=-HEZ!*P0^271Z\4>;'ZVC?)!SI?6Y,)&*0B M09/;HC9E)MXVSP\SD?B@3:$;:S`3!_1BM;R_6[Q@HT/\R%=UZY,8Q?A,5"&T MCU+ZO,*]]@/;HHEOMM;M=8A+5\I6YSM=HE1I.I'N,H987L5,UD4FW+J(YV\. M;3SY_]AVNZUS?++Y^QY-N'&$_+1NYRO$$(-J5V+(1+?EY?'-;!`5"WE;#`R9 MU<"0E,,-!T@Z:M(G'1\.331;EZB?-86#.SED;A3T":-SZ9E'MW4RK@**S919 MS902`XI9#2A2#C<<(.FH<9]T0FS%>';-<2F/3](OW!FB$]1K8^D*YTREVSK5 M$DPHOZCXDV3])ZF4DL/=:$C?<&>*3!2PHR'9J!&W;T:4;WIM,UT%_5U48TH, M<*L!4H[BGB44.4P`=\?D-``#__P,`4$L#!!0`!@`(````(0!: MJ!")W@(``#@(```/````>&PO=V]R:V)O;VLN>&ULE)7;;N(P$(;O5]IWB'*_ MS8&>5:@HI"I2"VB3;2\M-S%@-;&SME/@[7<2EC!)EFJY"A,SGV=^_^/.[[J63 M42[L'>%6_0]#+A8\9F,9%QD39@=1+*4&RM MI+:54FV"A!N6].T+".6:-5ZH(G\H>`JK-SVW9SN#NLFYLA*VH$5J(FAO3P>] M_'/?ORS_64KQRME:'Y+*T-J\<9'(=?E7D'9;1STH8%TMO?'$K&#===WZW1/C MRY79OP2\@_B5@K!/];1$U=Y>$3(4"0F$X69+)F*G/I=PA*7J$^C,LRUUR^&' MFB1>63BFC&;3AL_#Z2@@X5,01"%"^%!FS?!/8)`YQ9A+A*G4 M/EI*&$%%+\$T"LGLD:": M:R(79*Z8!@\V6KI"Q52VP"V%1991M2US0[X4')Q,A2'#.):%,*@E'V:N%OBJ M7QX:AD?$'Z`S;CV0&%XFN"!C0PX"N M!V66<5/>$+HZ,RC$P(4&%UM+`FP>K^-!I!N)Z'O:E`];QNLX[T@/_^#@,?!. M]![H?YCL!JCCOMHV9,P,Y:DF$=N8@L*]>$!@_WH=YV$]_D)0NA^`D$.36 MQ^1C]T-P$@AR#R#L?[_RL%,MPM:E5:KG=EG@MLV"M`6 MD#CY^ZVFL.DJ>XCSDMB<4T6?KNJJ=JV^O!6Y]2JK.E/EVA:CL6W),E7;K-RO M[1__/C[,;:MNDG*;Y*J4:_M=UO:7S>^_K4ZJ>JX/4C86>"CKM7UHFN/2<>KT M((ND'JFC+`'9J:I(&OA:[9WZ6,EDVQH5N>..QU.G2++21@_+ZAX?:K?+4AFI M]*6098-.*IDG#:R_/F3'^NRM2.]Q5R35\\OQ(57%$5P\97G6O+=.;:M(E]_V MI:J2IQQTOXE)DIY]MU^NW!=96JE:[9H1N'-PH=>:%\["`4^;U38#!7K;K4KN MUO97L8S=L>UL5NT&_R3K%'84W(Q<7WM*50X+ M@+]6D>G4@!U)WMK_IVS;'-:V-QWYL[$G@&X]R;IYS+1+VTI?ZD85_R%)=*[0 MB=LY`8O.B8!'P\8.+J35%25-LEE5ZF1!LL"KZF.B4T\LP>%9$+[^(O%7"D&: M=O)5>VE]P>)K",OK9CI=.:^PDVE'"9`RLZV>,J>4\$S1^Z;=1N<'O8V@)O&9 MH8,&BBZR8$.X+`^B?3M.9Q7:B*F8T?<%UQ27,L)KQG1!*=$UA3F)KQF&$R+4 MHT*'!6KRV@;GEQC,QG1M`5+F;0Q=CX*A"3+#R,0F+/BQ"?:&1,CD,T(TF0EA MF1$@9=(*$6Q_0Q/LUX-)9V+NA.Y`;(*](1$"I\A,O>&(:#(3PM8:(*43PE2& M)MBO!X68F,N\QB;8&Q(AT\\(T62H9F9JL>P)D`([>,D^G^YN^"$C^I`1#S&( M/"A%]\=)DUF<6&H$2/&[A!,,#BD\9=(C$W8G'HMS3&&WMR:2]#7#*.;#J:?) M3%+OMLV@`"F8>G->K4W08VHC$Q13AL8FZO<@T;+XC!9-9EI8"0J0<@[/A)V' M$&&4.EOT)P*/DFGL+GAOBTU83+W>FB@2T(#N#T_+9IIX-^HX*,KU)_U6MLL. M*3Z>\T9$<-^?\JPC^$2,>WLJ3'?AN_-.8,\F78CE5M!Q4-B#ZWNLEH2,<$,: MOJ7SX/M>O_9V;V+J84"<[L7WB\/.3<2Q-P?ZM@;9.B".$FZ((X1;X@AA0)QN MS/>+PS8.OB\5?-[G.I8,@1P\2`P,A\!H"(Q_`=(TU,WY?C'8RHD8EO^!0,Y` MI"CA1J0(X5:D"&$@4KIA&^+T1?WC&ZW^;<(*XYQ5OJ#C+-K&]3`>>8P0)E@$2/Y4\@D#-P#BGAQCDDA%OGD!`&SJ'N]8:X.\\AWA"(2!:F0"`'*^=5 M?IK@57*:(,O\F+CM+4G$8&1"1`VG9(#QG83IQG@$Y)U2S?F+GF%&ULE)G?;Z,X M$,??3[K_`?&^(3@-::(DJP6[=ROM2:?3_7BFQ$E0`XZ`-NU_?V,,P6-2._NR MVS"?F?CK&8;!67]]+T[>&Z_J7)0;/YQ,?8^7F=CEY6'C__/WTY='WZN;M-RE M)U'RC?_!:__K]M=?UA=1O=1'SAL/(I3UQC\VS7D5!'5VY$5:3\29EV#9BZI( M&_A8'8+Z7/%TUSH5IX!,IU%0I'GIJPBKZIX88K_/,TY%]EKPLE%!*GY*&UA_ M?]^Y"6'W88\R0P\"_$BT>\[>0F<@Y'W4YN!/RMOQ_?I MZZGY2UQ^Y_GAV$"ZYZ!("EOM/BBO,]A1"#,AN(*`O2#U]5>)GRD$:3+(-QFEC06+KR$M M;UL2S=;!&VQEUC&Q8A:^=V6B1XPD/2(W3L:E_87!)\0NK"=DUD#251?LB*EK M!NF^G:A>AG0R9"SP]\4W$$PD8R):8H2.$8()-B:T($CH#`NU"Y3PQH?@UQR0 MT$A"K)@'C9GCQ25.@CH)9B.0/EB(FXM30.)'K"*6#$VG4Z" M.@EF(Y!.T*3KM.=1PCB/X=(HH5@QC^W=&#Y.L?H$6>=#=.HN,R$RWDN6P MKTA/]#-Z)(SU$&+[+J63JRX58]/I)*B3 M8#8"Z92CB_:`L->EA'$>QW6IF`=5EZ'96W2K4;-4V>:=Y]3HJNRV*Q*SQ&)D MTMQ/!>F$19'(6':L&%O2G`1U$LQ&()TA/.KTK-U7G:V7JSP[R";5C5`WPJP( M5BN'@+MK-%0C@_X0'!=I!_55:C1/9#4;%476F='&&+8.XP56))__FJ+["E6. M@:-*C?#:XPZRYD_%L2#4'859$:Q6#@.&6GXHS(I@M7)",-3>4:QJKG`4JVWX:#>Z6VM*NM=M#-QIG8C!09S6&1(>LGI4J,F>:^4FV] ML"RB'1RTF8D[R-(Q$S="W0BS(CAY6!7LGZ[JSHJ5 M7E@=60SW1%>Q"K(D*"%.A+H19D6PVAM#C[NYRE->4.NH6.=$DW1Q+!M"W0BS M(EBM,?0X*E8-*?H#\T;%*DB=3ST:[_()'.++C5)6HQPH,BY&;UC(//@J0>IH M7QV!%[PZ\(2?3K67B5=Y;$_@;.%Z5?VD$(&XV7C.H6?&MKKP=4`)_WG M],#_2*M#7M;>B>\AY'2R@'Q6ZK<"]:$1Y_:4^5DT<,;?_GF$WW0XG'A/)P#O MA6CZ#_)<^_HKT?9_````__\#`%!+`P04``8`"````"$`_]PD"_\%``!)'``` M&0```'AL+W=OZ^=KNA>@\L'!LU_Z^ZTZ/8=@6>U'E;5"?Q!%^V=9-E7?PL=F%[:D1 M^48-J@YA'$596.7ET4<+C\T<&_5V6Q;B4UV\5>+8H9%&'/(.XF_WY:GMK57% M''-5WGQ].ST4=74"$Z_EH>Q^**.^5Q6/7W;'NLE?#Y#W=\;SHK>M/IR9K\JB MJ=MZVP5@+L1`SW->A:L0+#T_;4K(0);=:\1V[;^PQX]IY(?/3ZI`_Y;BO1V] M]]I]_?YK4VY^+X\"J@WS)&?@M:Z_2NF7C?P*!H=GHS^K&?BS\39BF[\=NK_J M]]]$N=MW,-TI9"03>]S\^"3:`BH*9H(XE9:*^@`!P*M7E;(UH"+Y=_7_O=QT M^[6?9$&ZB!(&*M[>KJ/Q0Q;0J-Q-H(_-=&6!KP.%TL9U@) M,2*5X*>\RY^?FOK=@ZX!G^TIESW('L%RGQG&,>1Z*57(41IYD5;6_L+W((L6 MYN?;<\SY4_@-:EIHS4?4P.N@88,BA&B&D"",<4CN(O>>I5AZED67H7S$+\9N M8K>;Y!8W4KSVP?80?,R6@UWTC!H^TJ2#PDH0).,$9J8YHX8K MSY';)_3E_&REF/I<#'8Q6]1@M@]Q$J5&8"4K^4\65P+PF2ZW'$0#H*V&&AU` MPEB6F`FQ(EC9$4Q[EF+JV=C%U%&C)YIE:<8OY,X@T=N35Z-H#*:5,`8M6JDY M3X(+ZYM)X-Q;6SL?L8[#51&9UVE-_$_N8"WXF*^U[3+\'%L6+R-3&(13-('1,(#EOFU"CKFT36C0G M"$++F95P4#,UW:CJO#T8V'GF@48=Y9P$P3 MVHG?1;O$0;N,WAIIT0SD<@?N9CP'DJ.N<5^9AJ=*HZ=%AHA6)?A=T%.CZ*(S MM<:YT*+^6I&O3*GL$.Y"'I>C:`@F21T"BB:1Q^]"GAI%W1NL:/?(18W]U6)E M!'8%"/'F[3P2(Z;J$%#4[SR+T3-#.P2"OIDAN!!XU@T4"+$$*7:D\8.`TA[F!?2IFO19/LXS>Q3ZE)MYTQ7XNFL[T+ M?-P%/DI\+9IT#XUC!X M?C=\.YPDO<3J+&CX`0YR3OE._)$WN_+8>@>QA:%1L("N;O`H"#]T]4D=I[S6 M'1SAJ+=[.+(3<"@1!2#>UG77?Y"'3<,AX//_````__\#`%!+`P04``8`"``` M`"$`Y]-$P(,"``"B!@``&0```'AL+W=O7=Q28EUO"UXHUO( MZ1-8>KWZ^&&YUV9K:P!'D*&U.:V=ZQ:,65 2';3XI=1&<8=#4S';&>!% M/TDU+(WC&5-E1(G%?=5JPS<-^GY,,BZ>N?O!&;V2PFBK2Q?S:R^"I;P+!QF?P" M;+3>>NA]X5_A9'8V^ZY?@.^&%%#R7>-^Z/T7D%7M<+6G:,C[6A1/MV`%!HHT M43KU3$(W6`!>B9)^9V`@_+&_[V7AZIQ.IE&2Q3-$DPU8=R<](R5B9YU6?P(F M.3`%CO3`@?<#1S*-LG0ZOTS>9F&AH-[?+7=\M31Z3W#/H*;MN-^!R0*97S:$ M3CSVQH-S.J<$B[6X"`^K='*Y9`^8G#A@U@&#UP&3#`B&HH,RJHU7]F"O[*/U MI:S#BV.9]&69R7MD/!C7YJCX='(U\`;E@,F.,-,!\9]!A(PWZ,$Y15=#;&D6 M#[Q!.6".E=/LE7!Q6XW7]N!3[7]I!NV`.=9^Q?7L/_%;>`3-"&??E>,\> M?.IY?!AUZ13A+"DP%GZ!I+!%ZY_M`@G.&MT.+NDG[+C-\P!;1 M\0J^<5/)UI(&2IP:1W,,VX0F$P9.=_U)W6B'W:%_K/%?`'@0X@C!I=;N>>#; MV/!W6?T%``#__P,`4$L#!!0`!@`(````(0#Z'AZFN`(``+P'```9````>&PO M=V]R:W-H965TPX^+&Y?JA(],ZFXJ&/L M.QY&K*8BY74>XU\_[Z]N,%*:U"DI1)?$]IIMX,C^8I3*93(M`-RK@WTV///O*:0;*A3*8`6R&>#/J0FBG8[![MOF\+\%VB ME&5D5^H?8O^5\;S04.T)&#*^HO0U88I"0D'&"=HPJ"@A`/A%%3=O!B2$O+3_ M>Y[J(L;AU)G,O-`''&V9TO?<2&)$=TJ+ZH^%?!-4+Q*\B<".-Q$?IDYO=FT@ MK:^$:+)<2+%'\*[`4:HAYLWS(Q#L#-GC>XO_<@A1&9$[H])J0?`*JO*\#,)P MX3Y#*ND;L[+,#*.>F=X,D76'&+=&-^DFWO?XPRV;CC!5`TN]+\C(H:^/"]2% M;^!Q^-?#@U8?,$-B?4Q,YT,D.4:"(;$Y)@Y$!@[#_W%HX!B#>)_\()P,CUY9 MYOJ`&1'KLT1REMB<(@;^()#+*VA@N$P'L0?A=.3/,J?\G262L\3F%#'P![?M MLX, M(I*V_=J!%DU[@;="0]ML'POX2C)H(IX#<":$[@:F5?3?W>5?````__\#`%!+ M`P04``8`"````"$`_7P(2N,"``!8"```&0```'AL+W=O; M)49*DRHAA:A8C%^9PK?;CQ\V)R&?5,Z81N!0J1CG6M=KUU4T9R51CJA9!3.I MD"71,)29JVK)2-(L*@LW\+S0+0FOL'58RVL\1)IRRNX%/9:LTM9$LH)HX%"7L:\))SJ/\2QT%I$W\T&. M#DSI!VXL,:)'I47YQXK\LY4U"+:'F%BVN)F@#OB2;;C10G M!$T#[U0U,2WHK\&YC=X&D;]QGR&G]*S9 M60U<.TVX'$KVEY(W$Q>`.VK(19_ZWW5HX8S8P)FZ&-J=?=`G"48@4XH!"*3L M>A`CCC%X=QD(@K<`+9O5S'N:Q8AM2C%@`Y,^FRGM_-VF;9-E%D%[]MX?^.&0 M8&>/\64TX;YK0<\V& M[]U9S9G+=\)H-?A\NAFWX'A!V)<,6.%G=WT.C7C,.LK1SFKZ]0VB,=ZT9L!G M#L'>%C-=8R,>\XW[SVK:&@\3#<>`,;B8M$1VA[<;8,EDQO:L*!2BXFAV;Q^: MIGO:'2QW07,V=!.PL=&PO=V]R:W-H965TGDWB$*M)'-FFM'^_,S:X$-I">0"2G#ES MSLS@87[UU#;DD2LM9)?3.(@HX5TA2]&MR1G8\I\]QY!T\JJ5IFX%*M0MTKSDH;U#9A M$D63L&6BHXYAIL[AD%4E"GXKBW7+.^-(%&^8`?VZ%KW>L;7%.70M4P_K_J*0 M;0\42]$(\VQ)*6F+V?VJDXHM&_#]%(]9L>.V%T?TK2B4U+(R`="%3NBQY\OP M,@2FQ;P4X`#+3A2ON\[T;7>)-F2P.>6)$Z#<9)FTS-80J?(&KQEABWF2FX(3`WDU#W#&8QGP+QSYG1X MKV]9!8](>Q)//+]3X#!G*(!L'U>`08,:9..!`H<9VQ&(_+,#]Y/# MW.^W%\&#G,G+V#C7#G.&:YC/C[O&H%-U=Y@S%.!"&/S:LI.=QZ!!#;*7R7(U M;')?>--H M4L@U+I`82NCO^N5VG=CUY!_`;NG9BO]@:B4Z31I>06@4X"@IMYW&7 MTL!6L5]K^!?!X9R,`@!74IK=!>X__[]D\1\``/__`P!02P,$%``&``@````A M`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/ MV'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^ M-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=; M5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`&9/'-)7S_ M2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP M?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.] M*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T M._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_ M7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM? MH5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^ MRIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-" MG9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP;<#N+DXKL MZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U, M8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU M)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$ MXR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA M;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD. MVF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2 MU.#9DRD*0Y/L(&,<8[Z4%3]F\=%]$P``&````'AL+W=O MY.] MR6:S'\^(K9(!V@`SSOS[K:9:^P-U\&4SEMX^J=-Y9TQ:\7KED MXKL.JW.^+>K]ROWG[Y>GV'7:+JNW6M^6__ZR_+$F]?VP%CG0(:Z M7;F'KCLN/*_-#ZS*V@D_LAHB.]Y460=?F[W7'AN6;?M%5>D%OA]Y55;4+F98 M-&-R\-VNR-DSS]\J5G>8I&%EU@'_]E`RNXO?OJ=%?M#!^4.84=B8XOMYS-K0D$X*]3%:(U0)'LH_\\%=ONL'*GT22<^5,"<&?#VNZE$"E=)W]K M.U[]AR`B4V&20":!3YF$P+\C%T_E8OB\+)X$<4C"Z&L*'FZG5^E18I%%S^KE!"%G>EJ=T`TPC(*&,[78X$:` MR'C->K3%RJI4(C$W:G1N5IKDGK(Y\7[EO5, MVK=-).9L8^J^DI7N]212I$U:#[D]&=H]M>U>8I!6'`RZ2S=\.E=AD]9#ED^& MGD]MSY<8I#702O=\%30I/63Y9.CY6KO*9D?,3:7T\&VEKEC^B-?2H>=350I) M[^SJRBH&TYO)N=YY-X(F-6L*"&HS>+KO#ZH`IX'A:[;=2@Q2FUG$4S.JU#?)/30#@N$, M"-7S)O5"C)R><3!7-M\#4IE$`B(:J?<"DYKPY=%S($`7U_4*E6E*:HC!.S_- M0F*Y3"J32`"9SQ1WDYHU#<;]F!0_7JVI$-KV*S%8T@$]?28HW4UJ#TV$8#@1 M0NNNB<3(>OEQ9'%.30`-(]6G)C5K*HQ4;3@=0E4665C$R!]S5][8X,!%2"\! M5][8\#@%#PPJUNQ9RLJR=7+^)HY*`GBQOUS%8YR$+))`G'E8UU-QO-,?T%P" M<+IRS/;L9];LB[IU2K:#E/Y$>$"#YS/XI>/'_G?\AG=PKM+_>X!S-`8'$?X$ MP#O.N_,7<0)T.9E;_P\``/__`P!02P,$%``&``@````A`'1,3QTU`P``1PH` M`!@```!X;"]W;W)KWSUWK M/&'&">V7;N@%KH/[DE:DWRS=7S\?;J:NPP7J*]32'B_=%\S=V]7'#XL=98^\ MP5@XP-#SI=L(,L0>]P.-R7M!J!8DY:( M%T7J.ETY_[+I*4/K%O)^#A-4OG*KCR/ZCI2,_,J7"-MJWX07>?,=DT`I8[A8QD8O/JY1[S$AP%&B]*)5-) M6Q``_YV.R*T!CJ!G]=R12C1+-\Z\=!+$(<"=->;B@4A*URFW7-#NCP:IC$:2 M:$\"SSU)"*\7!L?[8'B.P5XT3<,T^[<$7Z>CW+E'`JT6C.X0B>N,D,A$%"<0TQ'B M@[Q1(WATO4899&G,1GJ51JXA$[7:,J_B8,`0`,9<+T`&+5V@'!U()Y8`#9DI M!P,O",WIXMUI0UQBBCN_"33F9Y4.N(:?EG)XSY,#A.'3GLJ,G@RQ9 MUK;)->3=7?7NM"%.]KV#NG!^Z238$F6=]EQ#]*Z*]:ZR["S.0@QQLVO$2;`E M+C;W3JXA6MQDFL1Q9LDO#,0DB8+IFWI#6@C%\W+C%-H2EUCB]IASZDS(67G_ M5^]UK3ZL9=E1P=>8J3JW$@```!;```%````'AL+W-H87)E9%-T&UL MQ%WI;MQ6FOT_P+S#A>"&%:`D:[$==\9QHZS%T;1MJ55R&HU@?E!5+(F3*K*: M9$FN8'[D-0:8`?0L>I1^DCGGNPLO[V4M=M(8H#N)BW?]EO.MI%__Z?-THN[2 MLLJ*_/NM_=V]+97FPV*4Y3??;WVZ.MUYM:6J.LE'R:3(T^^W%FFU]:CIY=K"W]_+9-,GR+34LYGG]_=:K@Q=;:IYG?Y^G1_J7@V]?;;UY765O7M=O MCHOA?)KFM>KG(W62UUF]4&>Y7A_'?OVL?O/Z&8?JX2_5AR*O;RL,':6C\.F_ MS_-==;C74P=[^\_#A_WYS:[:>]7]T!W#VUO]]#[+4W56I]/J/\+5GH8_F+-? MIC=959<);O0QF:;AJ*<_).5=4HY4?S9+RJ2>5PHSTCS%?V=WJ;I*A[=Y,2EN M%CV08;@;SC>['(%B93+!D%'Z6?TY783CGN[M[>V_>'GX\N6+\-'1O"PQ79UF MU1!+_"U-2E)3'2=U?-R=G?V#GEU,PLV>_M"_O`I_M(0HIM,B5X.Z&/[<4X/; MI$PK=3ZO1:RQ9#C-\?EJ,8MON[^W\Y=P1A_2.1()/9TDT7I/Q\FDBA9RNURD M9590KKO)Z\897ICAI]")*CS'T[\WQ;P"9E0]*/4DK2I5U+=I>9]5 MJ:IFZ3`;9[%B'J=#*.:^Z-YAN*@5R*2JTKKZ+GJ<5+?A;Y?I!$(W4M`AX$69 M#M/L+KG&:<*!9_D=9+THLQ3GS=,Z?'Y1IK,D&ZGT,X"MBN=?%35T9&A41I\P M7@.HB'/TU&Q"O0=Q5/KW>3:CU,BNJABK9`B@F^MCCU)@YC"#RD-V\>S)\[T] MF?;DX/DKE=0*0)8Z(),GH&`ZO88R62KV<&W2F[`QB35*SIT7^<[JL^O[==_+ M\F62)=?9)*M!PX@Y_:&@?`5.+,B`D#9M1BT9A$7*.;A)PHDP.8)[6XPU()Q$'EUETSFJ7JRM[NWKR!ZJB+N0;EZ0'W^ M7_^``\[K6\C^+^GHWY3[,:LJ1^P&*#>4NO`.)`=D>/W98)57'.[;WJOGA[W# MEP="TV][WS['75[]UB/3#3A10/=5.H>NN,=%^5N,6405W\48 M7,'3^'#R$>[%^:DZOSBY[%^=88#J?SQ61^+AQ1!$Y+IDYL4H:PV`_I(.V`/SDFRP/!J(AIE"@ES M[#GBX;.CVP1^717<5V(4D3+/#D=7W(8`(RM2I=]P>KEIM-*>EC6Q2W@V1`.R M/%<'[U>&,/8H:GMD9LFADC6>^[;=H^,*2_SXY3M]N7M/Z5G+_Y`L':)*(E:" MIRM$U7J!%>41N`R46Q+.A3M&Q^S:+YSD'7-<%E,USO($&@#,7W%&&.9AFHXJ MI:?,\Q$GX+!W&3)AZGJA;&KI;594B$;R(4("L"3*(;57HMN`W5,:+`MSU*+P MT.ZF_I9=)P\GGHS'B%*Y/&RUZ)2"#0&F&OT"Q)'1X33N9P668MXU1@B)F]Z#OM"Y(=8W6!P!L.LP!+ MN#Q"`.8X>8R+8H(@`0#R4_^:&<%A'241W\XK9!AA$H_3:EAF,XWW.%7G7NJG MJ_1SK=Y.P)UH*7O4\$`7($))L?Y8W.D$@LG"])R\;)B*5-O_^/5_F(K[QZ__ MJ[@F:(Q?:-Z0TL./WZC[!/Z&NK:WJM(;29R!9LMD4R]JYR/\H?"F);(JD^P7#?K8M[3)5^F4[G1'%>E#$H*B\S$T<2X4`P^S M(124$C')QLA?:MC$4;2'C<2,/(3JE&H?>94%F-:]X3@KX?2/F;FEJ-$L$YFY ML=T&E)$-:CC9="ONBLD=QHJ#X)4`W-7M*3@"9957NTI+)= M];2$GP^!E8(#55:[-D@T,")6Y!H^<+08]#AVAL`L M0Q:;"IOGP.LA97B6Y3O%>&PM@E5VD;N."Y%P@)S9)`4,["IL5M_"%"$7`K/+ M7>P"U^D0A2#LA",C\0NC`^,A4P&;>I)A`,`"\]90QCN\5KY.RZ_!T]VI=5CL M4A;SFUO9;<2(CWPA<4G1"(MU%E.4#VCRZAP3(OD)VGB9+RT(Z4/2TG=A6B M,.,T,#@W9I,7;02+BAV+.\=`OBL8?+)_9!TZC=0H'X+A7%+!81><2]J=GJ$_<8%0WIQEM%J&UUKD0<%K\%@A2,2]EYB2](<_,2D)?'8'@ M@K(I+R;D17G.D>D>`MA!%2(`9$&+"M3X%G5]<6=QL`Q'L#Z/I6(3K0"HX7K1 M*4:R!#.U4E(@W)XXD+;<.%9ZQSH9G`/N8G!6TB6; MT$]=MGAS84NKKKMA0Q@@T6/NAL-HW)K#MZ3,5?,)J(A'1A5`,ZOG"!74K*BD M[B1TI$.C,VR1>^7"-QYWG1WJD%/Q1A-@G?2+L!*H$BI``L,#`=(1QO(@9H*N M'53''>#(<3%/^90UA`F\'$M8R0S$ MT"%D:&""X`@.X;[P/A;J/H.U,HI%^85U0SH1D4EE?1)0&\^1RVB`]1-B0/QI M@#P6QC&W\Z[?O^ATT#_ER1QEY!!V*AC1S8,B$S-[96U<])YB17'\UAES(GZ#;M;JKE#;8!0C4D%86:P M8`)UO$3X'BRWS.T4;X,587%8H9D@L:`^F25U1 MHL6W$0WTBEG.55@(KQ(U3C*TLE@V!T!"?7E\:(Y@%:9+>'`@\6`Z;/#7BX4V M1224I\&/#_\4(=A56G>:ZX[08B&2KGWHK.F0E7`0T*09C//!4X.%@TY[00>/ MW:$(SAO\4GVPT&^%NV/MU4KV^+#>J;*;`(*!S/2HA\0@NR=S<51D(AYJ5:WN MN.?D%OQ`W+N$=&K0L>X@Z4"T M=P*+R=9`M7T%_1^J/^Z_^.8[%@9.&!OGXAE2EX],N-T<[-*U!5]ZSH[4K)`0 M(5OA.33MMQ"#'Q%72"`G=@AUO6;W=_!3!=>`1?H@KWC>(_C=.BT#8()QLTD7 M>%9(ZFJ8&R%X8D)4(U?",->V5!".<$>PE';694LZ27J$QGI*!Q?JJ=3<'@)+ M=GCN'/[,/&'W)B0D`)OU)<@M+396VZF+'6&&K_8&P1+VD#K53':PC(1DBJ,;;`H*F4,F,J0J=Y$>L!E_9Z1`'V;*I(5CB!R[V MC%_@*.C+$5/I(!M,-$@9@2')QPWGT`?ZF:;"V3-`"_)K+NHSBAE"X',-36-[ MX,A/U[3._07G-1X_B8YN^4\]!P0#4=@VQ7-9:2;*QX M2R2W9^SQBHKX0QJWZ#:=P@%'76CGSUV40AI`VSB7]S*FP:"N1T@HH\%EK276 M-BYP0]01F1B"G#H-LH=B_E?GRG3\@E=RX%V#CPN5(9@=ZHBXBQ;1>=]+H`^0 M"^W2.8NFIJ`:P*DH\(4&*R>BIRXR&#@,6E$!=_O*^S_O"HH5,'N8EBA+:FQ@ M/F65]:-0&BY)V<^&9U[,!N>;T88#5`"%KH"T8@Y;7W/#F"1J*B5-]D4GC^R> M+NG&0)_GIYPUT;V.&K7MZ$A.T&E(6.':W7,U+HD>X%@VA1F3W&B.L*N.FYR> M"RULX-OESGG"#,0S>4+H:])T0*.A_/"E.X6S=LA8HZP.A2O&CP_2;8SK21:P M#6=`:=W`1O^GZ8.1^JMQFR`L.G--E?4M!LD`4Q87\)&K&LV'<.=)562S.)%7 MP5LF2!S"]G26R]H'TZXCK%S!P`G0I>-Z$9284SQ*CK2ZZ)P?R+%6TB2[(A4Z M6]ZN91\M6C*]M"VD>_B*Y@\[@=X#;HA*#QUE8YC'*-07]Q#,J$N-TA_J._KT M'Q]HJL('%BK#WX&<,B'JCD5+)%U1\[90U!8)H,@0_H_435&,HD;1)^$VE\D] M\H(:WZ+1T@<9S.`+C-]50$&\V#@C2)5WZ=:;QP<5C'MS:6HS%_(NT14[+TV2 M>_.1*Q!N^?(M85C!W0[4H*J1SS"I=#`E0&+2=0(*V;>B\*NO\]'HW757-#K8#'NC@4HRQ^.YV#O,OM$-+9+8B&G&+`5- M.Q'Z_ZL&UTZ&=1EF@3D;J"XA!OBL$RKD7N`APG!*49,]CU07<(\&IF$#N=<8 M)U>FXBA/&!K/@C].4Z@Q@D:(CPB;68XI!>A5UW+"F::\I>&X.85;4;.$JZZK M+WJU2)"'GM37E1H]B20I'`%H7O1UB!32%B27@$W\MC&)>A`&,J) M1!#UR?[N031_`X-]*#0#=2VQFW<4Q:TT,@#2&8-8RQM_':PUSXD7KD'!B_X: M><``2>59CX"XHI7>D2DR>OT;4$+W-RS1NU#OSR1UC3*A!-PRB3+6N#;6;AG_ M"DD_&MXNA88''A8^?"%^?("4"$`B+B*"@;.TD+AQLO;8/EQPYDRZU[`CF8JH MU?/-[%H(I72-5.<2G!RYS61`\ED:9PA#K0=H)$2HQY=0V[\;!ZBU)[)GWJ8L MK]0IWK1&7QM+BZ9_F>82UP<"V+$:"UCMF[`WO7D`SYJG)J#0L4*%TI[%1OW^ M4T4`\+HC9.HN*E@N!NKJIY284A0"5HKY)?/&&8]B6(>?<&[1:$;J.AT*4K,* M\0XY'?A3U`&O0Y8,02^WJ`37)%4Z*-@TN2)8JN!_48'HRT)=L+V#(:@R%KA& MD1ATIHNF$V',ZZ$%%ON;IE?Y0)*@^Q`'7E#K1M+3'H$1R:ET7S[!VL8[&MU`F?0?/ON MORD%4;.M[#A#*]6(=L$O4MF!O#R$LC/VY!'MRT.A\@YND9\Q+QGYXU8$`5XJ M`W+1FF3C`_K+L+_^XA?)0IO65>F/#C[8K@CA/W*>&;\W@I4(D*3.);Q#"130 M0[RGOYVASB6BE\=G@EQ4QPM4:7MJF]5S/5W#!=\#B#HL93#+QX[XU[HMB6RS MBF*4`FVV,'4EKFN#"BU3*=IIBP7LBW88(=],#C,!A(DZ\X`")6XQ]-CC]EOO M-L^H.S1#4#\R`5HC80]ZX<4;D00'Q9:-^EX;2GNX>0L_FCH0I MM+7/2'Q]Q0K-@*4&#(%+W<\&GP]>M5@.68'=^?"_$>``H#TCUX49Y)E-`@C9 M**WB]'3P#'1T#1&1/DAW3EN6D!@X5"?P"(#%;3%1M@M;AO`0OZ\L_$9"N5,M M(0T@D4+5$$/9=\+`"W2+T0O"G0TC;*`-Y*H<>4.A\I?3H:I)_#H<;`X%$\#I MOHT&9#0^IO&;O";L#F:VSPBEI;A1!"`03=W=,:IY#5,X)5LPK=Y>!C]#:_@1 M%7BWS&5R0?W]B>!07K>,?_9(K"Y6A?A:RU>\P0GS9[18P,R&1RS>+8D31",% M/%8M2XO1J"W>;@$EA!VV>&1WPK:X.'7#-E^1A@)ZWPE`-B-QCU4+%!# MZ]BDN7Q>W%M2.'\AXF*?)3F"D91WP)4)/%W$-$8H&N'J]*GDNLJ*LWCGDF4R MYU_*+4,F`*^`TZ:$05\>%9QL0`G_%\`AE-/9=WABCB>Z$&JVV9!>$!;0`B\) MPDX9*CJZZ?AF5&!+D*LY07M/%"7=.]$68VY@@)'J+F!E1O`I1PCM]!J=[`G@ MREV79L.[GEB0"I8-[QNX4(F5R4,QWU:RH>-K#+2S17%PUUPE$IH.L1-SU:=] M@T&A=$K`%+I<7<6.K@:30]`;MM/P3^3*&DU0LA%Q'<1#'N`LP_6@4V]J',BY MH8&9()A,2`[``L)G&&QQJ@$R;%+2\82!0>@L$2"^FP!/RPI`Z3E4:OF8)D>+ MB'2%$2YG+_E7N-*N"<47>?$-.J$`B48)1'3$Q#W;GC#TME7ZBDH#`_K"CP_: M*XSR[9<.?AX?S$BV$T;C5GR(S7YB(>1T7W]QX?'AQ'`D'`#S,8RJ%M&!PEER M/-RG:1T-1[RC<_7X<`Q6AX].P?/'AQ_YT:7PT5O3R`@1L@42]X6N<*SL$'\; M;2<<9V\>O;O\(\@.SFU?#CY543WEB-TO2`*-GD&+QBG;-<.%O<.VN!^.$Y:N M,Y84JDUS)2*H1)EVT@3-.`PM='*:IH21.XM5\1\S'Y9(,#GTW&"MRH79@7^\$P6KM_8@VWZ9K@8D).N ML$!3#Z?UON%)"C8F1T1@!.<&`F!>6]'-:0#(8U-R@M/9I'KWS0OL.H!*;@#/ M*-:BZ7$NW\?#-..3-U\_DQ"1OH5TB#6&3XP/*ER'X;?)L(@/W`%'ZC>^$#0U M;_;S="W%/)"_'-P`DXFBUTE)L&=#H&$-$9[8+U?@-,:B-4=W!.SN!.@RCNA! MVG^AOP]G?Q8W#D$GNG\/8RE4:#?Q4+Z[XC)?>:F3`6TE!J84%CLMHY; M*"$T;R[$MBZ"]YK4IL@6&O\(5R) MF>*=,ORY,7NBQ?H/G-OI[Y%<>'G MG<$0%P4>Z@UWZ/7QUM-BE$Y6:OMOA/Q&;4,2025:'Y9$PI\!%3[C@IK5%PUN M%0:6-IFLW*^UQ(K6A%-Y?YBU6[C*#)=ATE$8197HF@)WY[YP@&\>\XU[-9PD MV50G^_2KJ\CF\[,VN"E^+3-A$\([$0:^J\?>:S0&2MT9&]9,=;T,VX.D1BF^A6_1).L/GB"&QQ1RY:Z5!MU9>Q_?LL70&) M;H'@S*7T$_UO7=^UU_>NBIOW4>/="3[TP=Y(2#Z3LZRT_ETZ*$C MWH1/ZP_@+WAB\M=(!TD/08N"P0ZN)8-\O[29B9&Z@'SBD]%2#D#?H[2[KV!^ MI]>EW:ME)#A?^U4CM7VM#V(1+NUW+!!&$)JS5>5^W7R`V;76E]G3"KOFO?N$(M.=SAZ;[Y*E'XH*_[]/GW M"]@*J6-6.#8^9H\XQ*NBRRH&-18*K5M3?"2,3WH/TI&<6)GQ8PEZ905 M,Y:JWHHY+JVBGC&*[$ZLV&26,MDKI^3X5ARR54MOMW;>DCNNG;?TIFMG;G3? M)MUFS+BDUTQBRDF9^J]E&0XW)!2M)0MO(BF;3%U"SDVFKLR];;+`1H25`S(% MJ9AS%*=HN?1T#UYRQ^[!*V_5/66C>RPAB,Y<.NY#0+["?1%EW>ER=ZW3LK\4 M@'Y_!VW%7Q$#(N`M+D0F-##'WOM^UF9^G8*L7?-K:(K,,>-?GO2#_5BTSZ?8 M'J]QL]LHYQ^`L:"D(;\,_= M,C*`$@'Z[Z/0L23=.2]W M?*K?83\SJ>UFH6?X*[S>_)\`````__\#`%!+`P04``8`"````"$`3*K[IK@+ M``!/;0``#0```'AL+W-T>6QE`DF\T!5S?(N6B!IBAHB;(9\Z%0U)V=HM^],\O7K"B12W/%5=H(.4N4=N8W MSYT=+LFK;U\\5_MLAQLG\*=Z[[RK:[:_"):._SC5_WIOGHUU;1-9_M)R`]^> MZJ_V1O_V^K>_N=I$KZ[]Z7!< M)WIEM'3-6UQ^>/2#T'IP`>I+S[`6*6WVH4#>??'=^^Z__KZFW_\8"__^>-7Q>]^_%KOI&P(3;!!.2S.!IYIJ<-*-!QW:PH'`RQ M;((CUU=0GT9VZ)OP04O>W[^NH6CRH91&S7?BWU7\^C&T7GM]5CJ(#=@$KK-$ M%(]S5JHE4^7\XM:I&_`_RP['Q^!;)T. M==56)0@4694@4&155MUW)&3^)%*@T:$X5@D"158E"!19=20Y`X^46Y4@4&15 M@D"155E/2F*L0@-1<:P2!(JL2A`HLJJTXC/)P!/E5B4(%%F5(&C;JLFR"@MK MDW4HBI69M/HX7<+-;V_K\V*K1EBG/@3A$L[TI*@:L$>-CUU>NO8I@11HZ MCT_X-PK6\.]#$$5P7N3Z:NE8CX%ON?"VDXY(_Y:,A#-'<))HJD=/SN(9F'&- MB5@W,8MC<0RV,))RUT#F^:XVXU[S1:.::N MK)!?"K$QZ^.+5<=[)*T8492S8L`>*2M&B,K(^TUJ78YXUKK`]+P'R8Z^N9^_ M#08PB@>F>':28)*?\%Q!?+9`.-WM%[>2?+74IP"I4HRW64/8"$1+H.=]DWHR MNT.QL+!=]Q-.WW]?914#-.&NKUY69&<";!?!4_>X\0'?0J<[>1M7!_$'X'5H M$&P\.#!(L]9K]_5NZSW8H1&R/"SO!<`C/X`">7D)(!$\3_L8!_J`G87TTX0]MJKWV`+THY0_.)Q:!H!J;>H&@*IA"X.;C%F*"6 MX&9(11@`CY*HR.N$'C=CM*@&`D%5AB3>T%>5(BD&53DR-T5?58HD$%1E2&H) M52F28E"5(XDI5*5(`@$THB1#4DNH2I$4@ZHHI7CF`+MI8B2VF\ MWLM*>Z?:4Q`ZO\`B$Z_[6D`SU0YUO$XP=J6#5&)@C075(%#7"0;I M+B`I1#!R5:L))DGE&*BI$$_2[(]I3+O$LEQ82S53>LPQ^:$.N:RU4Z3?1R@5!<: M7I&"'?EXEWU9&435,MA=+I7YZ8W6;M%O&Q756 MG.FJE8MDJK<%N$V=M?7,E$U!U2MQ;@KB@,(=7D[<#]J&V]0/N#"K%66U6C/_ M4S/\P0JDA;AO.HF"B>4N5XMYLT:DPR7#GJN-[B:#2L2>0MD1I>=TVW*;J/?+,6M1FC;S+>3,'M'?R?M`VW!/W M`U%XH+;JL"H4@/53F5!9V!0TYP.G!EHL@1502Y\?BAFBP217@%O?,TY@DBM( M(5WIHIY]R$DXSSZ=Y>ZA[%$!]U?B))P4M7Q$*-O%@?A_5M^C@R>G2/DV_9Y% MRY+JW MV:<5ME$1MB:2"[WYR[RSC8P:WCP6;G;?_;UVIKU?H&3920+$QH@:GKT@+V<8`/ M0%I""ZZ!KTT+-H,GM'!;>([+@*U?=7'!D(06K_NAH.Z-?79D%U#DN%!D$5R4 M5FY'[",16B!R75JY'<%PE!:(7)=6;D=`2&@9P*0NK=R.8`5*"]RM+JW,C@;& M>JZOH:#N+_;:D?=5W.TL@HO2RNW(^^I`T%8?!>48$ M!CP69;%UX7$U`3[LANWFQQ*="(37;@E1>K(7S]H<;LZ2$>+C`:=1$4*W+VO7 M\JTH"%\UW,&?D>.-/A0D]Z<@R'3$4^C#1Q%`W\&C@>"I0QKH)=80[\.X>[L. MF2P6>/7@Y;QUR,#H&`WO?]C?KT,&1L=D^*2*]9,(F0_^>IM9B,^E.'6+D/CH M^,_VDO<<7L-]`"E"Z<[>1J&5^1\?4GU!Q=SA+7TR&GR*B!\!D-Y_**D_[^`. M/JD2\Q&S]EZP%0U-)>65LW MNL^^G.KY^S^S.R"",R6_^M[Y'$2,Q%3/WW_$6TM"%$./'-+-QPWK_OIV-)C>W9O]LW)V-SXR!/3R;#&!)7NR)8W"54L^XW+CPO*\P$38!_RD_-M7)AQ@^NY\+"EL484SYD!_?HD*GVS5J1#S!5,O9ZK+ZDL*C"Q%[DP'[51$A3I^MNQ ME(KMK-=7_3,%R)54LN#&8&YT`KMQ[P*5R%8VFXR`1%@V@/%#S%Y MHNN$3DFXW=0)^E?PB^[\#O1)7GY1(OM-E!RR#>=DV/XOGO/4\`Q.C@1X(GLI M7_'1;W!K#$YT#:`3_?_-S5.$7L+&3??WS>5+?6Q_J"#C!W;.S9_R\BL7QY,! M3S-(`V9CG7T\H(TLO>81*!.9.84D\E\-%N, M)Q3P8,^U>1%HD@3I61M9_&C5EC4RN1N#[:H1&HVDT6RP'6`FMHCK89V;8 M=J/D)8!2`Y^Z8EBX=`V6[T<$H2#[A'!,%I#SF&A(Z]MVO`G?(''IE=A9`CX; M@KI$%#=>4U)S)W_>\LT56X<(FD3[0Q M.`JAFKL*/U>&L*MLZ?K=6:*K;.4229]XH&S^(\H0=I51O]`MTI5&_4KO(P^T M04,-SQK"GC:OU'<6<;2UM5Y79=)''FC#]][@^8"PI\UO!XLXVEK/5EL?:0FG MVE:NMF']@`]Y&OV&L$A78RO`2K3$K!Z!B^5TOIJUA>E(I-"?P_-7TYXXKQ=W M5Z:KCGI]D]QAV@A0>+L[.>4>*+_.Z%S0R9;FZBUKGMC3M,B]CBLTN7W4,*KHX\X7FN@U2><8FB M<#3-W68KO*YKS1^P7U7LR']GZBA*'>3\`(^.1PMX(RB[H=D+(ZMZR]E+`YM5 M_?,$ZS>'K6$\`O@@I;E=X$[2+/3;[P```/__`P!02P,$%``&``@````A`&0) MLBBW`@``*0<``!D```!X;"]W;W)K&ULE%5=;]L@ M%'V?M/^`>*\_\U4K3M6DZC9IDZ9I'\\$8QO5&`M(T_[[72!U;+?JLA?;P+F' M<\^%Z_7-DVC0(U.:RS;'<1!AQ%HJ"]Y6.?[U\_YJA9$VI"U((UN6XV>F\U,5T6AIK63!`=R(ZUL%)*)8B!H:I"W2E&"A!&N-)U&L(0;TZYIW^H5-T$OH!%$/A^Z*2M$! MQ9XWW#P[4HP$S;Y4K51DWT#>3_&,T!=N-WA%+SA54LO2!$`7>J&O<[X.KT-@ MVJP+#AE8VY%B98YOXVRWP.%F[?SYS=E1#[Z1KN7QD^+%5]XR,!O*9`NPE_+! M0K\4=@J"PU?1]ZX`WQ4J6$D.C?DACY\9KVH#U9Y#0C:OK'B^8YJ"H4`3)'/+ M1&4#`N")!+/F0TP\S%B]QYBI`U(+M=FP3F&-/NJQ+/)SEN/6;FZQHN)K.'BVVX]9N8%30_:;K@Z\'DD:?$_DBQX+"F>G0^F/SD><_)H-C5I MN)J>0[TDWYK\Y1-,56S'FD8C*@^V[22093_K.^(VSN"D0BN:S.^@4[KYL%^` M3M61BGTCJN*M1@TK@3(*EN"1\KW.#XSLW-782P,]RGW6\$MB<`>B`,"EE.9E M8+MI_Y/;_`4``/__`P!02P,$%``&``@````A`.>5%W*@`@``L08``!D```!X M;"]W;W)K&ULE%7);MLP$+T7Z#\0O$<+O0N6@\1" MV@`M4!1=SC1%241$42#I./G[#D5+\=;6N5@B^>9QWIOQ:'G[(FOTS+41JDEQ M'$08\8:I7#1EBG_^>+B98V0L;7):JX:G^)4;?+OZ^&&Y4_K)5)Q;!`R-27%E M;9N$H6$5E]0$JN4-G!1*2VIAJNYN<48O!=/*J,(&0!?Z1,\U+\)%"$RK92Y`@;,=:5ZD^"Y.LC$. M5\O.GU^"[\S!.S*5VGW2(O\B&@YF0YE<`39*/3GH8^ZV(#@\BW[H"O!-HYP7 M=%O;[VKWF8NRLE#M"0ARNI+\->.&@:%`$Y")8V*JA@3@%TGA.@,,H2_=Y(19+\_AZTK@\?[8'CV MP=-@3":S^14IA%Y.YTY&+5TMM=HAZ#A(V+34]6^<`'-OBQMSQ'1Q#,G.(82,!\R1#FB-]^MP0="0 M!]82,AGXO1"/@1(/]I\@UO]%9/]"'*F`:]ZOP@6E&+P:,B1D>J+"8^9=BT7' M9^O#L]%\_F:P;Z;#XW@216_A/G4_.OR?0W)=\C6O:X.8VKJQ$,.5PZZ?6/=Q M`BWKALYP`!.CI27_2G4I&H-J7D!H%,Q@1&@_<_S"JK;KNXVR,"NZUPH^#1R: M/@H`7"AE^X6[8/C8K/X```#__P,`4$L#!!0`!@`(````(0#;1'NW*0,``#\) M```8````>&PO=V]R:W-H965T&ULK%;;CMHP$'VOU'^P_+X) M">$6`2L@VG:E5JJJ7IY-XA!KDSBRS;+[]QT[%^+`HEVI+X0,9X[/G!G;+.]? MBAP]4R$9+U?8 M9$:I0L!0RA7.E*I"UY5Q1@LB'5[1$GY)N2B(@E=Q<&4E*$E,4I&[_F@T=0O" M2EPSA.(]'#Q-64PC'A\+6JJ:1-"<*-`O,U;)EJV(WT-7$/%TK.YB7E1`L68ULN$ M007:=B1HNL(;+XSFV%TOC3]_&#W)WG(RA@,!1K'GVBFF.<@ M`#Y1P?1D@"'DQ3Q/+%'9"H^GSF0V&GL`1WLJU0/3E!C%1ZEX\;<&>0U53>(W M)/"\0G(C<=PDPK-)7#B!/YG-S>HW$H,F$9[O6M&MRS8N1D21]5+P$X+)A,)D M1?2<>R&0M?;52W>&ON4G&*E)-IIEA6<8@5429N!Y[8W]I?L,C8L;S/8*QD;L M6H3NDJ:->@$7]':BP>?_(%JS:-'M03G@_8@D'D7WAUW=[ZZL&&WTM[[:)F*/%C-JNB7AF>`>F1\V/T.Q> M@>?9L)1-/Z),@VUE3>0\E;N+2-2/6&O#!NR[HC?S?*'/O8]V5!/9NIJ(O<6' MD]>!6J.C?L22JJ_?WKESNX$:;,NI(X&Y&LS)4%\0]=%64'&@.YKG$L7\J`__ M.;2UBW;WTL;7^8/X%NXK<[H/XWX(N_T*?AQ&XROQ31!NS+TWY`G"R.@>QJH'NK\_Z'P```/__`P!02P,$%``&``@````A`/)E M>W6Y`P``(@P``!@```!X;"]W;W)K'AV>&HUE]>:G*X)E)Q46]#LEH'`:LSD7!Z^,Z_.?OA\^+,%":U@4M1LFC2*5GUA%U4@TK(9?#D)65,.K/$:J MD8P69E%51O%X/(LJRNNP94CE>SC$X MNHK*IW/S.1=5`Q2/O.3ZU9"&096GWXZUD/2QA'._D`G-+;=YN:*O>"Z%$@<] M`KJH%7I]YF6TC(!ILRHXG`!M#R0[K,,M23,2A]%F90SZE[.+\ M^,YK!FY#GC`#CT(\8>BW`B%8'%VM?C`9^%,&!3O0OC!]/&M(]A1/A MP=+B-6,J!T>!9A1/D2D7)0B`OT'%L33`$?IBGA=>Z-,Z3&:CZ7R<$`@/'IG2 M#QPIPR`_*RVJ_]H@TE&U)'%'`L^.A$Q&DW@Z7QB6.RN3;B4\[?9W=YIT\?"T M\>^6&[5'-TYF5-/-2HI+`.4)AU,-Q6(G*1"CA0DDHI7=F_HS3\%,)-DBRSJ< MAP$L5U`(SQL2SU?1,R0O[V)V-V+\B+V-P$PA;>8`$>CM18/70]&8]P^*1A84 M;;?;6>#M%/%`H8VP2S('\!1"3G^!0F2!?+BVDL27M&MCB!LT]4/V?4@OVT4\ MW5`"OT`WLD!!P<.IAX6O:M<%W1/>A_3"7<03#ND?"D\6>.U_T@ULY>(Z(]5N ML>L0TWI,&>X[A)C"'I1$UOT(A>"<]:WV/9$S7^3M/F658;"OK$,6?<7NKY#, M1;R]X7(.#8K);#0'_1^\-\CD"^L0__XO_7SO^R#K=.8BGE;\0#M-Z;Y/&.S+ MZ9"WF[V_0C(7\?9>^GMC0YPE_\V-0']3:YB">50*-^OT\F MVA=D(<>I:RCS(%\`-F@G4>;KT=ZZ#]84:5L]M`Q[[)V%?+O(P*ZW*+LP\R!? M+[9K1^_]PH+199C!#C(J6^9V.&D_J1631[9G9:F"7)QQ\(#XS:J'VZEH1\8P M%IGV]1O`A-;0(_N#RB.O55"R`Q@Y M-C=0MC->^Z)%`P;#G"8TS&;FWQ/,X@P&A_$(NMI!"&U?<(-^NM_\````__\# M`%!+`P04``8`"````"$`B]-=QL0%``!.&```&````'AL+W=OR_'QY>#\2Z_ON5'[X6755:<5CX;#'V/G])B MFYWV*__OOQZ^W/E>52>G;7(L3GSE?^>5_W7]\T_+UZ)\J@Z4RY/RZ?G\)2WR,TH\9L>L_BZ+ M^EZ>+K[M3T69/!XQ[S+>+1T`_62RG0/QE_K:R_O>I0O/Y29MO?LA.'VE@GL0*/1?$D M0K]M!83DP,E^D"OP1^EM^2YY/M9_%J^_\FQ_J+'<$\Q(3&RQ_1[S*H6B*#,( M)Z)26AQ!`/]Z>29:`XHD;_+ZFFWKP\H?30>3V7#$$.X]\JI^R$1)WTN?J[K( M_VV"F"K5%`E5$5Q5$389S-AP/IJAR(7$D4K$5=]],`XGLSMY]PN)8Y6(JTZT M:+N)03-MJ6*RL$Y:UI M=KNK#=)BQC9"Z(B7KF4VEQ=)!%,Z"C%/;.0@L8V0>\_IO87134<#X\]7>YTH M1'DI!-.V9)K2EHG:H%8F&R%4&=Z"U^LDHRDA#5E*N5!,($I`&*^U4$*LT9UX M@:J7V=5BL<;"805ZVAL-4;EF';E,E$Z,"43Y"ANV^%YN+-:8-N&D(%LP!XIU MHHRB!(2A6@3D:Y2-/])>PLD[_:4AJMA=5S&5:.80FT2(2`D+([4(_T`Q9;OV M*BK(W"T2?B^8&R@F$"4@+-0B\'\44VYLLU,056S>5:R-,CUF0Y2P,%F+\`\4 M4Y9L).URVBZB!JRNLB%8@)1`CW6SL;RX^A6Q4+7VS6$AK%:S&R,FJV5B6H5(Q`E M?).WAZZW:\A6S/5V$D4)]'C[QUZ&H6OM&J*"=?;XD8DR@MEN3_G>9.VA:^T: ML@5SK9U$40+"0[O/Y(=V#V+#T3$Q#5'!.M\6D8DR@KWK[*%P88OO96>7T9UG MTK'Q2$<9#6,"4<&$OUY/0$1W""B(.GMWHQZV4484&Z*<;G+VT'5V#1D%(A>* M"40)"`^U1!'.'H;S#SA[J-S8<1/QXK+RV>Q8$6XM?+%FY.VS;AW4)H"K[.R!PC\]Z1 M$"-A[\@((Z/>D3%&)%7G/A.,R*]59V2*$?FB=T9F&)&-TAUAR,&6J&<^##G- M5M/)@0;8,?3E0`/6K\$0#.37?[=:B`-,O)WZJB$'WU!](\C!UTK?"+3&9T3? M"+3&?KUO!%HW'RM=;@Q:X[#3S<&IZWW_79#0$[\1+="'@U0?I_OQXA[]Y]YX M`ZZ];8%U[%U&K&+OPF,->Y<0*R@7,&BUP&GN.=GSWY-RGYTJ[\AW>#B&\M.K M;,Z#FQ]U<<8#AS/=HL8YKOSS@'-[CB.5H7"575'4^@T3A>G3G6?DEY^^T@3ZUWF1:RRE2V&KFW)+%*[.#NL M['_^?AW,;*LHPVP7)BJ3*_M3%O:W]:^_+"\J?RN.4I869,B*E7TLR]/"<8KH M*-.P&*J3S""R5WD:EO`Q/SC%*9?AKEJ4)H[GNA,G#>/,Q@R+_)$<:K^/(_FB MHG,JLQ*3Y#()2^!?'.-3<.0 MJ3S<)E#WAQB%T35W]:&3/HVC7!5J7PXAG8-$NS7/G;D#F=;+70P5:-FM7.Y7 M]G>Q"+R)[:R7E4#_QO)2M/ZVBJ.Z_);'NS_B3(+:T"?=@:U2;QKZ8Z>_@L5. M9_5KU8$_IZ">F(!":\%X>/K$F]5"*7I M)-]UEBH7D"^@+>_KV73IO(.2D8%L$#*UK1HB*"*X(G0#@%U-$8KC%'WHW->: M7QGI1921QQE]`6&,NHC)O(80CB!=FV,_-PV&SK>DF,WJM)6@&X2,6I`Q101] M"$(-DCQ.38-7-M1==VG65(S4$#*KNCP8CWT6#TA\)-PF3FC!?F_3TAOO?E?U M(JKF,PAI-PF:$$)'Z+%1L&=UBA7[>]8CZIMP@*)1"#K":,PET M;L*-V[_!(+?.8231@=]0IWW4+MQB=T"3(2#AP:39#%0SYOQW-$.W;M,2;E.XV68( M0F<=^+/6S#&R,8#?F`WE]I3E"W1LZ%@]:X3++'1C0'T^U@NA_)C]/]C:[AP0 M+A\$HNWUL/&:'6\D)/'6I*`$V32XTUQT<-K;-R>B0XS$;Q)[:@8( M]'#:63X%#*BWL]=9T.R0ACX1SF,3X;'.5JOH9!!N\P04T(#PU+*C$Y@@'AU_ M-FN*I/38:'B07G=$"+>Q!4.O/2/\,3/$P&N'&_:4'>R@YQW/TZNX>'Q*&!"* M]P4[S'%7/NWJ3UNRA[.`'@^FS\:`#$$Z?P,2O"4>&Q?]1];KCHGV3WS34@1= M_7@^8F`&+F=7TDF2S^OIV8$W$9T>?$9 M84#X3@7CK?-+B0":JE`OO*W`M_I4Y@<9R"0IK$B=]4V$@/>)^EN\)=G`+4EU MI>#4`;BD.(4'^3/,#W%66(G<1KJ,D M7`*X0P#OE2JO'_1[?'W!M?X?``#__P,`4$L#!!0`!@`(````(0`(LA!:TP(` M`&H'```9````>&PO=V]R:W-H965TS`P:L8HQLIVG__:YQL"#INKP`ML\]/O?<:[.^ M>^4->J%2,=&F./0"C&B;BX*U58I__7RX66&D-&D+THB6IOB-*GRW^?QI?13R M6=64:@0,K4IQK767^+[*:\J)\D1'6U@IA>1$PU!6ONHD)44?Q!L_"H*%SPEK ML65(Y#4`<6>-4R_ M]:08\3QYK%HAR;Z!O%_#&OE%6UAFK/(2&35U*\953E8"C0>%$O(Q<-"(`G MXLQT!AA"7OOWD16Z3G&\\.;+(`X!CO94Z0=F*#'*#TH+_L>"0B/*D40GDAC4 MG]9AZLK@V2D8WD/PPIM%\^7J"@F^3:=W)R.:;-92'!%T'`A6'3']&R;`/-AB MDW!&_9 MJ(4&N%ZM`4.[35Q8.=Y>WM9BH(#.J?D4L?LO(OL(,5$/VXS5FYZ)X4!^[+D) M2C%XY!1&T6*J<6LQJ[Z!@NG:;KP6KU:S(#A#9&-$.(?U,622`)S8<0(?"S?@ M<^%GI=]:C!4>+R8;V_:Q`%#HLC^K#]Q]9IOW$5:\O=OLZ>545G1'FT:A7!S, MO16!:V[67:GWD6GRL_EMF,!9@WG?+$SRV48S'`A(G;]\US`S, MP=MRVMR$^&/-[UG_G)9G_?V]/AEOJ&DK?-Z8]F1J&NA5><\!EMS`_4FM^WO_ZRON+FI3TBU!F@<&XWYK'K+KYEM>41U44[P1=T MAC=[W-1%!Q^;@]5>&E3L^D;UR9I-IPNK+JJS217\YA$-O-]7)8IP^5JCZPN+5>KRT?DZJ)Y>;U\*W%]`8GGZE1U'[VH:=2EGQ_.N"F>3Y#W MN^T6)=?N/VCR=54VN,7[;@)R%NVHGK-G>18H;=>["C(@MAL-VF_,)]O/[;EI M;=>]07]7Z-H*_QOM$5_3IMK]5IT1N`WC1$;@&>,7$IKO"(+&EM8ZZ4?@C\;8 MH7WQ>NK^Q-<,58=C!\,]AXQ(8O[N(T)M"8Z"S&36=Z/$)^@`_#7JBDP-<*1X M[Y_7:M<=-Z8SG2SMJ>49M5U2$4G3*%_;#M?_T"";=&H0F3$1>#(1>S99 MS>?N8O4)%8>IP).I@-Z#/7!96WBRMMZGLX!\>RO@R32NR_')ZLX7QBN],%^>X[S3S6#)ZLF?VP\1:="OW,BHJN MV*X;?#5@N<)@MY>"+'[;!V$^I6@WADGVLSD&\X*(/!&5C0E&P/1I86&\;6UG ML;;>8#*7+":X$2-'A#R"3#P9M$*HA5D*@@54&F@EP`4MJP`K\@;:("VXDT`99RG@&-L<6@ MN1P2#B&#%QJ)-9)H)-5(II%<))(CL*]\@2-$!185/(0UL9+S#5@0=&4(4BT9 M0@9+-!)K)-%(JI%,([E()$M@8Q(MN7W@\,V`!/>9\QX'C/2G6[^R0T;L?J]P M953_V9)?#(8@/4Z216".)1E*-9!K)12(E2DI3X?BY/[%(L)PH(\+P M:2322*R11".I1C*-Y"*1LH*#]/&L2+"<%24.K;O(01AJ)&)$6B/N5![B>`CB M0YQH0ND0(RPV5SFBLB&("^6BD)2[#66MF#RM*":D-NR.5?D28%C4<`;?&&H' M=@-63Q`1V91>%XX8P14=11R).ZKMVHHO8Q3/)^%HE$\YDK4<62L;H[A6SE&O M)9M#BH^'Y[M-2Q4X0[ATP)$WH%!'$4/@E3BHRC8;CU%#R>,BU3I)0IFLG)J,>DS:)F@S$11W)#I2R->129?%"V*J\3_GK433FZ MJYOQ**JKU$(Y?]O+RGZ1ND3PZ[^M'R*BK!^*9G#&CZ>JJ_0K)-49-&0_'VD1 MSM!B<#;F44M6ZBO[3L+?TQ^A1"7E:%3).*(JCK)(<_ZZ%Y$M(G7*_[:(%3OB MXJ)H!ONZ8)%2LX6DI",6C3,BX@@V1:&A,I5B%N5,J6NN\C[A*J-PRM%=X4P6 M=I0.YUP$5HC0N[$=#1:`KP:'IQS=;))Y/#D:]2>KY4!/X;$2P M?4PG$+S'N.,?R!<,UY?;?P$``/__`P!02P,$%``&``@````A`'J*+GHC`P`` M1PD``!D```!X;"]W;W)K&ULK%9;;]HP&'V?M/]@ MY;VY$0)$0`5$W2IMTC3M\FP2)[&:Q)%M2OOO]]FY$`-#K=073`[')^>[V!_+ M^Y>J1,^$"\KJE>79KH5(G;"4UOG*^OWKX6YN(2%QG>*2U61EO1)AW:\_?UH> M&7\2!2$2@4(M5E8A91,YCD@*4F%ALX;4\$O&>(4E//+<$0TG.-6;JM+Q73=T M*DQKJU6(^%LT6);1A,0L.52DEJT()R66X%\4M!&]6I6\1:["_.G0W"6L:D!B M3TLJ7[6HA:HD>LQKQO&^A+A?O``GO;9^N)"O:,*98)FT0PH!J;BB]#4F(H&$@HSM3Y52 MPDHP`)^HHJHS("'X1:]'FLIB94U">SIS)Q[0T9X(^4"5I(62@Y"L^MN2O$ZJ M%?$[$5A[$=_V`C=4&C?V3;I]L';[9C?Y0<>'M7_/R.SEBYPV6)V[&$N\7G)V M1-"/$(YHL.IN+P*Q/FFMPI#&_V41TJ=$-DIE98%E2)"`RC^OO>E\Z3Q#N9*. ML[W",1F[GJ%JHV3C$>"`W\$T9/<#3"L59;I_W;8'3E'X9PY[1K\E'@&&0ZCC M!SA4*M"&1EH7IJ5MR_'&I*E)V0V4P?88,7Q#"WR`;Z4"#07+J1]"UW2U[4BW MC`^4P?@8,8S#\1H;OW[H^W959.VOU]UVB+YA=._M.L33W1R:WN/N1ZC^*<*5DFFL0XQ#'WIF MHG8#J<]T/$8,KVH,CVZBVQ549--.BP1Z1.B[HAT4[657$9Z3'2E+@1)V4$-@ M#G4=T&$^;7RU_PS?PMS2M_PY[D=P_J_P)U$\N8)O@FBCY]^Y3A#%VO3L'V0K(&LP31C$B:8_EK` M'Q8"EZUK0U-DC,G^0;U@^`NT_@<``/__`P!02P,$%``&``@````A`'LW$_K% M%@``+W0``!D```!X;"]W;W)K&ULK)W;'QX_GT>3R_&S_>'OX?/?X]>/YO_Z9 M_G)U?O;\;^\+C_>/[7_OG\'Y_^^[\^_#@\_?;\;;]_.2.%Q^>/Y]]> M7KYO+BZ>;[_M'VZ>)X?O^TKAYH?]\^GKQ_/UI?_.YK_1P?S&]O%Q> M/-S[CP^WO#_O'%RORM+^_>2'_G[_=?7]FM8?;M\@] MW#S]]OOW7VX/#]])XM>[^[N7OWK1\[.'VTWQ]?'P=//K/=WWG]'\YI:U^_\` M^8>[VZ?#\^'+RX3D+JRC>,_KB_4%*7WZ\/F.[L"$_>QI_^7C^76TZ9;K\XM/ M'_H`_?MN_^/9^_?9\[?#C^SI[G-]][BG:%,[F1;X]7#XS9@6GPVBRA=0.^U; MX'^>SC[OO]S\?O_ROX^,Y/G9[>_/ M+X>'_[-&D9.R(E,G0G]99"HB(Q5GKB+]=16C:#*]6D2+I;G\2,VYJTE_^9*C M]J36WR?]Y2M1U9$++%T%^LL7F$3SR]?\6KEJ]-=5F[^E&@W'WCWZR^Y1@[TE M$&M7D_Y*S6,#CMQ@1'W--KWI=+99QT,2'3L+_8,O%KWE]B+N(>8?4O---QAQ M)S'_<'6GDU5TN9ZMQOM(Q)W$_,/5]#KW6&RXNYBA=+SFF+L7=ESUPS2^>;GY M].'I\..,YCX*U?/W&S.31ANCQ@/47OTX9'\V8FFH&I5K(_/QG'H5#<9GFF;^ M^#2-%A\N_J"IX=;9;-$F"BUV;&'F`2,;:Y!HD&J0:9!K4&A0:E!I4&O0:-!J MT'G@@F)]##CUL+\CX$;&!)Q#M67@M8"*+EMPE5B#1(-4@TR#7(-"@U*#2H-: M@T:#5H/.`T%T:0Q"=.?4K8>?-]Q[32UZL@2]=QE&;VMMS"`_=G'5P7='DV.$ M@21`4B`9D!Q(`:0$4@&I@31`6B"=3X)HT[P%T3:3R(F3AY&A^8?^'$,[C58J M_LZ(?#D:Z?@?38[Q!Y(`28%D0'(@!9`22`6D!M(`:8%T/@GB3Z$.XC_>RXUU M'V8.S]81?]J.UBKPNZ,15XN!)$!2(!F0'$@!I`12`:F!-$!:()U/@JC2DNJ$ MJ!KK,*J.R-R\`Q(#28"D0#(@.9`"2`FD`E(#:8"T0#J?!"&D'G5""(UU&$)' M^L2D7PGL+'$Y0K\VL&1&3X+CA!"MK\)9(SD:<>=-G5"?MO32F;-9'I^E^;&6 M+[T.I8NC$4N7ED2]UT$X3#:+BZR)61^^?+N[_6U[H%N@!87NHEIC.:'AL[MF0NMYHX$O7KV-4\#%8Z M>)EI:)3!97*X3#%ZF?*5RP3]R^1*)X2N-P]CY]"4'C5>\&;A7>W8RF;J=H5N M+OWQG"IR`R?.BI9=)@^()DLU*%.6"2^F0\A6OVU4"^[82CI"S$BT$H?, M8O_8@Z,K%?A4*HK5]%)Z@WTBL)5<,6=,52*@Y?,0PIM<4I(37F:B!; MU+L92IM5I-]:[\WT[6K4?^Q.(S7"MV8M;QSSNY;JMSNQX?X0(TH0I8@R1#FB M`E&)J$)4(VH0M8BZ`(7-89:?NCE>SU1-=D6!]>,ZC=2`V3JC\>A;(;*1Z`-* M1(FM4D09HAQ1@:A$5"&J$36(6D1=@,+HFY6KCKXQ/S%SC=P*.'B216JEN&4K MO]5@-#@EOST`):(D[0%6&5KEB`I$):(*48VH0=0BZ@(4MH=9.OOM\1@[1'YG^5WKU)U8I\0 M9;=2]Z/LD)?;1H!B1`FB%%&&*$=4("H158AJ1`VB%E$7H#"D9IGNA]0^54], M[2@9@N>X0UYRYZS\[,ZA(+V+5FHYDX@5]_H4488H1U0PDCRP9.1/;]%*Y0Z5 M6+$3-:(&48NH5>N*U8L5^=0$*FT=G=.^:S::8Z#D4 MM)JU"EK-(4F[$E=Q(2AE)*'(6#Z<@=1&=BY6'(J"M?PF`B%"PC/I8.>3Y6C*R/T2I:Z`F]1J&&T:B+ MK;-R+B[I#&3X)J]CF6".FLM*+ARTKVUR_//PG1Y\@^^O::[D-[93W.5PJ.\% MP25G.H^WO>SD#=I>IW\HRUP\G:H<=LM6_IA0`WXG-L>Y'U&"*$64("S&BB<5[*DJ/L\<\Q$JB[+0D1TO0 M*D64(*&3!%EB')$A4.T!\=:I5CY3JB=HDJLN&*-J$'4(NH`HI`[-9$QE8M4?=;^,5!:>BP'+ M%`X%#6,=_*DW%-&(U[$TK!NQ-Y]!0"YG<\X1)R*:JP23DD-\4@.*9 M168VE*$Q5PN51*S8]111ABA'5#A$;P]8JQ2K$2**-:(&48NH<\@Z$0Z- MT[+8&6:QC.0&=XAB1`FB%%&&*$=4("H158AJ1`VB%E$7H#"D)HTYH2_;K"?H MRRX1\GNI?I&PH\%HIB/:V^7^$3/RZT4ZE4C8RN:'D9J24RX6W8S1J&[.5E9W MJG0++A;=DM&H;L56;N](Z=9<++H-HU'=EJV>""FK-%42C820:K6B,^--QQ5XK;*#78>KH4/!60[^5 MV[&1=,C8(6][)7&(ME=,G&BS($R64U3)4"57*C,5[P)52E2I0I795/6B&E4: M5&E#E:G>6.@"E:"]S`N08,9\UWJY5PG79PZ%VSMK]8IGQU;2*6.':.O$ZX$P MD[+5E6U#_9HZ1>&,JXP*YVSEA&$'#X5+KC(J7+&5%9XM52AJ%&ZXRJAPRU96 M>+I67:@+A,/&)^'1QG_;1@^]P-.K7J M>P>#2WS]-^D-.$39(0G6CJT$Q8@21"FB#%&.J$!4(JH0U8@: M1"VB+D!A2$U"ZG?<]ZWB;%KKI\-SA[P=!H?\E^(.F5U`K]>K!4XB5MSK4T09 MHAQ1P4C.8Y6,0B?41ETE5NQ$C:A!U"+J'!K84Z-L(VR/5R823%-[!7K"RDO. MG4/^"3I&_L2/QU+%BN\Y190)\AM1/2!RL6*M@I$,O9)1Z)=ZMUN)%6O5B!I! MGE]ZO=^*%6MU#M&[`D+A<-%)ZBO-@]GHW**@>2P*FL=9^:O42.\F):PE26OJ MD'\L5:R\,.@$.!:0WVJ,)"=-$*6,)!290VH:5/L"N5AQ*`K6\IJ(D3A1 M(:H9B1,-(ZG8(NH<&A@;)N_^&X*/*6$O3!D;E9' MC3J-0^,>MFQE/52GUKI`-AQ8.OD>G_<6-L?VUP,.F812(GBE'K([9^4O$;BB MG/U,'%JZ;3@Z6ZR_J"!%H8R1[%GFK&V/IUU-H+WL?7CNE%Q%W*D8!<\L.'3% MEY?AU3`2CUK6HD6]%R;E5\<5>ZVPH4Q:[*_G7FDH8ZZF.HO,N1_/`_4TW]&T M9RKZ+S(8R<(C<8B6GV:_])?H?3]9ST^C'_ZD` M%6PNHB4C$:T8T;UXMZJT:K82K8:1:+6,1K4ZMNJUPH8S.?8)#6?,5<-9I$:8 M&N.[A;7RNG3,2+IAXI!)Q7X>F90K2I?.&(E6_B:M@BN*5LE(M"K6E2_0A%6@\B]2H4T^FG:L8C#I; MD9:L\HQSR)U*C>:KF?YVDQ25,D;2J7-&/.KT$Z]@`QD;I4.>0Q4C=FBE/XA> MHT[#2-QI&5EWH-5<"`?&EMXW>%^KX78"+;/[69#&E#=,5+:R8ROIDK%#],"5 M5K-:-+7W[Y;69F6BMG]25,H8!2[H=LJ=%8UG(SZ?+*/CU&G^H1[#!8N*QZ5# MGL<5(^OQ:JU3JQIE&D:C[K;.RKD+#>VB3NTM4?_9D=3%:QL<;WM3T)1U+9RG_PJ&?L3FRXN\6($D0IH@Q1CJA`5"*J M$-6(&D0MHBY`87N8I-6?M%]9$]D<-UB\.D0M+CWN2J6].SJ=U4_KDHS%B!)$ M*:(,48ZH0%0BJA#5B!I$+:(N0$&4:35^2I1[\W!`,9+X[1#%B!)$*:(,48ZH M0%0BJA#5B!I$+:(N0&%(_Y:,>HD9-2-O3MN20.T>L:$RB= MJZ0HDJ%(+B(C@2I0JT2M2K2,0ZN96L+5J-*@2BLJ(QYU@5;8=,.Y^8E?P[4\ M9N8\AK8.O7)JE:VD?\8.F7Y-PSE:D+Y?7 M+R\*E"^YXJC?%5NY72WZL9/P1%.-R@W7&55NV6K4\2Z0#WN"WA70B_FW;0S1 M;R+!2L:B?L*QE[2_>F1_3N5A__1UO]O?WS^?W1Y^-[]H=&4:]8C=SRTMKC;7 M]O>65,F62LQF!_4\*%E32;\RTB7+2_KUIOZ#?KID/MV84YX#:O,9E?2ON52= MZ_E\VA5^!ZU")^9+( MH9(5E0SZ%E'>.L80^[[TQGW4>*J'?P[+'`937],E:*AF* M*/V$UO40WY+4X-5):-">&F:X73;7]CRL=LFTRM!-4)L,-@E%=RBXE(%N3)*) MX:"D-.>.`=>@($(5FJ(1V18JJ<3L)Z`:G>_8F-,;6$)'H#;F$`>6 MT$FHC3GG-%2RII*A^RGI.N:P!]:AXU$;<^8#2^+Y:F/.R6$)G8NCN`V5;$EM M.ZA&1\TVN\&2F$J2P?N)YVLJ&;J?F.['G*!!W^@8VL82(O(H1(: M#XTY^KPX>3U40E]5N3%?1(D>T++6AWRA!GJ\V]`,CR&,:;D.C(*<)9XC'$8T.NZVBGA[T MM:T;\]VJ>`WZ]G9Z<@WU=/IF<2KI^_/%48Y^KO'[S==]<_/T]>[Q^>Q^_X46 M/Y?]TOO)_N"C_8\7]R4QOQY>Z(<::;.'?FR.?IAS3[]T<#FA+8TOA\,+_P&PO=V]R:W-H965T/NC+> M4=N5N-F8]F1J&J@I\*%L3AOSKQ_QMZ5I='W>'/(*-VAC?J+._+[]]9?U%;>O MW1FAW@"%IMN8Y[Z_^);5%6=4Y]T$7U`#=XZXK?,>?K8GJ[NT*#\,C>K*WR[<" MUQ>0>"FKLO\<1$VC+OSLU.`V?ZD@[P][EA=,>_BAR==ET>(.'_L)R%FTHWK. M*VME@=)V?2@A`V*[T:+CQMS9?F:[IK5=#P;]7:)K)_QO=&=\3=KR\%O9('`; MQHF,P`O&KR0T.Q`$C2VM=3R,P!^M<4#'_*WJ_\37%)6G,2&+^X3-$ M70&.@LS$F1.E`E?0`?AKU"4I#7`D_QBNU_+0GS>FNYC,O:EK0[CQ@KH^+HFD M:11O78_K?VB0/4I1$6<4@>LH8CN3Y7P^6RR]YU5FHPI<1Q7GUI,'3XH>"*,2;08VPY8L\B2'41V5`%D0IB%20J2%60"<`"$[@3 M4'1?X`11(4ZP'`(&!&N4M%D$:Q*J(%)!K()$!:D*,@%(:;M?DC91@2DO%(#M M>G*>`8V!1>QFQ5P.V?,0[H5&(HW$&DDTDFHD$XGD"*P;7U`(1`4F%5R$.3&3 M\PW&(.@*#U(MX2'<$HU$&HDUDF@DU4@F$LD26)A$2^YO"FPQ(,%#YJS'P4C$ M]<%V5[(7>Q[$FH4:B302:R312*J13"12HHN?290$RXF.Y#;]]QH)-1)I)-9( MHI%4(YE(I*S`^.>'CP3+65'BTKV:+,Q[C80C@56&5S)L:?(01SR(#7&L"24\ M1A1R9*&4!S&A3!22V9LN=%/(AE$FM""8\1+5&VUY0',:%,%)(L@7U>M.1.ZG`28;F3 M8#GWD:SX'K?72$@)^"-V65G](A[$NAQK)-%(JI&,$GOHD)2H#:A+-(MRN",A0W+#A5S&$8LBE?:^M97;,;M]TTT8>JB;LBBJJ^S#&;L[ MR,I^@:SH%ST-_N1DL8F(8B-%#NPOPNJ@]&L_-H3:8_40,K3@*&+(HYZYRAH3 ML_LWE82AFTK*$%5QE5F9L=N#B&P1.4?]W_7$IHBB]F M_HY^$%`?,//A(*PGO/7]_CX>>#QN\KA,N?=CE M=!Y[/NQU.D\\'_;W.WSIPR8'W.()PP>(2WY"O^?MJ6PZHT)'&+SIL%ZU]!,& M_=&/A?.">_CT,-30&3XU(3C*3"=P$CABW+,?Y`'\X]7V7P```/__`P!02P,$ M%``&``@````A`'&8MJ&ULK%==;Z,X%'U?:?\#XKWA*Q\-2C)*@KH[THXT6NW,/+O@)*B`$7:: M]M_OO;8A-C"==-27$(ZOCX^OCZ_-ZM-+63C/M.$YJ]9N,/%=AU8IR_+JN':_ M_?=P=^\Z7)`J(P6KZ-I]I=S]M/GSC]6%-4_\1*EP@*'B:__/O9+DE:L8XN86#G8XY"E-6'HN:244 M24,+(D`_/^4U;]G*]!:ZDC1/Y_HN964-%(]YD8M72>HZ91I_/E:L(8\%S/LE MF)*TY98O`_HR3QO&V4%,@,Y30H=S7GI+#Y@VJRR'&6#:G88>UNXVB)-@[GJ; ME4S0]YQ>N/'?X2=V^:O)LW_RBD*V89UP!1X9>\+0SQE"T-D;]'Z0*_"U<3)Z M(.="_,LN?]/\>!*PW#.8$4XLSEX3RE/(*-!,PADRI:P``?#KE#E:`S)"7N3S MDF?BM':C^62V\*,`PIU'RL5#CI2NDYZY8.4/%11H*D42:A)X:I+0GTS#V>)> MLKS1,](]X:E[3F_K.-4=X3FB>SBBI^8MTY@003:KAET<\";,C-<$G1[$0-;F M3S%T&?U90B&32+)%EK6[3C0D^@-$(PN*;H?;MKG M0`RVY6CDNIOW`R0Q$6OLY7O&QF![;(5$D%7##=->*KJ@+A4F8LD)X!B\/12I,)]-%N\W3J!J.-2"=MX[#8$Z,U^]+;:_1K4= M$PNR!6,=-@2_[9Y`56U+DX*LC`V@1'=44;8`K*BW"]#UUTR*@GHFFO=,A&4> MS`=1UZ28D*T)B^7MFG1I-34IR$K*`$JPS*,FV=$6@&72$"!M%"XFO^$B9.IY M7$$PK.FB13]A7=0U829DZ\4Z:NC]A8M4U;5H%\%J6$CX M5F`"O@_DWQ-\#U*XO_KH]`-CHGW!`;HOS,W_````__\#`%!+`P04``8`"``` M`"$`]I<+>#`#```\"0``&0```'AL+W=OU@^O)0%>J9",EZM<.@%&-$JX2FK#BO\Z^?CW0(CJ4B5DH)7 M=(5?J<0/ZX\?EBTPI^R;@HB8)'92RA,4^.):U40R)H013HESFK9<=6)F^A M*XEX.M9W"2]KH-BS@JE70XI1F41?#A479%_`OE_""4DZ;O-P05^R1'#),^4! MG=\(O=SSO7_O`]-ZF3+8@;8="9JM\":,X@7VUTOCSV]&3]+ZCF3.3Y\$2[^R MBH+94"9=@#WG3QKZ)=4A2/8OLA]-`;X+E-*,'`OU@Y\^4W;(%51["AO2^XK2 MUYC*!`P%&F\TU4P)+T``?**2Z=!Z,0X"C/97JD6E* MC)*C5+S\TX#"EJHA&;4DL+8DX3V6(.+#>UZ/@?ND_0^&2%K.]Q(0N8M MI1UQ9$+%AS+UX7EG]34+]`\LY_*'@^)N6]`MX3VD%VY''.$@TA9^VU<--OHZ MWFT;,5>+:;5=&PE-\RY<1^/V1RCV>8-6?SO*9N]1IL&NLC9R[LK=122V(\Z[ MX0#:KNC#/(4S],YR:A975!MQSGYH44B4\*.^^1=0TS[:#Z7-2.3:&.&WI!G$L5&]S`^BZ"J5_CG$;@(<;]/@.%5DP/]1L2!51(5 M-(,M!IZ>,Z(9?\V#XC6X!B.,*QA;YFL._U(HW*N!!^",<]4]Z!?T_WO6?P$` M`/__`P!02P,$%``&``@````A`(8E0-%P&@``F)```!D```!X;"]W;W)K&ULK)W;BY&[B^1/T'D@8DD67SWC[\>OI[]N7MZ MOM\_OC^/+J[.SW:/=_N/]X^?WY__SS^S7S;G9\\OMX\?;[_N'W?OS_^U>S[_ MQX?__(]WW_=/OS]_V>U>SDCA\?G]^9>7EV_;R\OGNR^[A]OGB_VWW2.5?-H_ M/=R^T'\^?;Y\_O:TN_TX5'KX>CF[NEI=/MS>/YZ/"MNGUVCL/WVZO]LE^[L_ M'G:/+Z/(T^[K[0OY__SE_MLSJSWG[V<+TN+UC[>$_0/[A_NYI_[S_]')!CHWC.UY?7 MEZ3TX=W'>SH#%_:SI]VG]^>_1MM^LSZ__/!N"-#_WN^^/P?_/GO^LO^>/]U_ M;.X?=Q1M:B?7`K_M][\[T_*C0U3Y$FIG0PO\U]/9Q]VGVS^^OOSW_GNQN__\ MY86:>TEGY$YL^_%?R>[YCB)*,A>SI5.ZVW\E!^C_SQ[N7=>@B-S^-?S]?O_Q MY2YV=W?SR_[!_^;S2*O-0H,O,B]'="Y$C% MN:](?WW%]<4ZNKJ>K^G@1^HM?#WZ>]H!278X7?K+%><7B]ERO1G.]\@A5[XF M_?4U(VJL(Q76O@+]/9Q;M+A:N;@>J48#<_"0_O)QUA>SS3):_JSFM:])?T\\ M-W=0W3"0%C#QC]F"JR06I!9D%N06%!:4%E06U!8T%K06=!;T`5#1 MI2'X=T37R=!E1W7GN>ZL-Z.-&_2'/K_4)O'!Y!!R("F0#$@.I`!2`JF`U$`: M("V0#D@?$A5^FLC^CO`[&9J0Z,\AM-%JH8-[XXW(EX.1C?_!Y!!_("F0#$@. MI`!2`JF`U$`:("V0#D@?$A5_FL!5_*>77#QI.^LAS!R>&T^&]=TP`\>>1,.< MOM9-D/A"&HR')@BG?>4:+5).<,U9:]<\&1>,[N(0`TF`I$`R(#F0`D@)I`)2 M`VF`M$`Z('U(5`CI\JI"Z*[5L^4%M<*)5VLGI*/KB;Z`V^%T,.+^D@!)@61` MH^&!TZ+-`4B`9 MD!Q(`:0$4@&I@31`6B`=D#XD*N`N<5(1/]YI!W,=5T9!MT64($H198AR1`6B M$E&%J$;4(&H1=8AZA71(W5H^G`?>W(E=BFIZ,2/=C.NKVS'/5A)QP64TD72S,L9HAQ1@:A$5"&J$36(6D0=HEXA'667I)P099_3 MA!TW3'/&_9$(4((H190ARA$5B$I$%:(:48.H1=0AZA72(75IR`DA]5E+&-)# M(A/,N.O(=MR#E71<0&D$*$.4(RH0E8@J1#6B!E&+J$/4*Z2B/#LMI1O,]?3` M*)AQ$26(4D09HAQ1@:A$5"&J$36(6D0=HEXA'=*IE"ZB&WYT'7_Y M%@!D-+$JF]->Z'C7:X;I'*/KPT(@]LC?ZQ[N:WDTIQ6PK#/6YH9-*E;\1-0MIZ?9PR=CK)Y*9S]V"B<2C M>;`:]F@Y/YQSPHC6R<<"/\HO13Z3BAR&7%"H939-"['BBB4C&8T5(^V7R9AJ ML6*M!E$K*/!K8]8"G5BQ5N_1?%C$ZN9QJ=H)S>,S.XG?S6Q$JGE&I)K'6ZGU M]]K<^4E92Q;;F4=+Z=ZY6`5A6)O]P4*L.`PE:X7-,^F7R0MJU&I82_QJQ2KP M:V.N>)U8L5^]0KIY7-H7-H]+YD^?S<;DD?(K/N3-;$2JU4:D6LTCN3>3^HI+ M01DC"47.\A3=8#2:O:]"K-BODK7")@(G:K82)QI&XD3+2*PZ1+U'4V/#I7[_ M?O#'!%(%?T1NTI3H;,Q%(G;/[E`R0&.7HY-X--\<4,KH>KB/-UM>7'?>P M8ZO1P^6%/85>*>NQY=+0L'DG5@14^[`D\%EK.(A&M%"3VL9<9^/9:$52THZ^ MHER_4F^UH,XN#;(Q$V2&6CDC\:M@+6J]'VN57%'\JKBB^%4S.NI7@UHM(_&K M8ZVC?O5<;_,YE=+,\%E*)0S$J&"D5M^_OEA?C$WP[!D`_&G8B0R-2,UY]H>U+"5:+6, M1*MC=%2K9ZM!2[>42YY/:"F?:X0;HZ4/IPP$JW4H\71?I=Q M1='*&8E6\2JMDBN*5L5(M&K66H\]**+'&6=F9=AP-5%J&8E2QTINNOKSP^+" M=,2>JPPJNJ5<:AVVU-M6&#Y!%Y=N9B-R1PZ&FG$L9BOICHE'"[F"I(S&*\@O M\RA:S7&I M8_23L19JJ1:92I91GRL/`I\K!F-/D;K:&DG]`:% M6D9'7>R\E7=Q14\1:Q=[EE%SU$)6(1UJMV,0SH_'5XF41D!(/:(51#", MI&7'[6:N*(%/$*6(,D0YH@)1B:A"5"-J$+6(.D2]0CK*-/F=$F5G;B8KCR1^ ML=N$36R$SFEF_QO:PZF8]O`H;`]`R7#X]^=+OT]P92]`J1AP%#*/YC*`C4[HJ`]DA.,J9\,(T50@BA%E"'*$16(2D05HAI1 M@ZA%U"'J%=(A=8GQ"2$=\V@54I]:A[W4;MC'M!/I@ASN43(*ZT5VR9ZRU9B' M169*SKA8,J>W8RNN: ME*CGXD%7-[#+!T]HX#%]5`WL,TJZ=A^FH;7)G.*Y-Y+,*6$DN7[JD<]NS$R6 M<071R!F)1B$:XDYD4^J2*XI6Q4BT:M%RUP43U(8KB$;+2#0ZT3CB3\\5!RW5 M0&[C6C70F]9?@XJ^WGND[A[8NU\Q&TF'3#P*MC%2CV@;P\6)DG*=E&:HDJ-* M853F)MXEJE2H4FN5^543'N-2&^C M7)M;*3'=8QEF4NF4B4>T11'T0)A)V6HSMJ&]'9RA<,Y5C@H7;.6%8:<,A2NN M&Y?)VY0N.4J1X4[MAJ%9]>F"_5*6#>^S?+M8'W=AHK;K;:M/Z*5 MW%*)O56`$D0IH@Q1CJA`5"*J$-6(&D0MH@Y1KY`.M2?(7NYN3KGL+2A"EB#)$.:("48FH0E0C:A"UB#I$O4(ZI"YG/2&D/@H5TE$]+PNGN*\RX M'DDOC=E*4((H190ARA$5B$I$%:(:48.H1=0AZA72(769\`D=UR?.8H5TE$^+>.F93AT7(^DE\9L M)2A!E"+*$.6("D0EH@I1C:A!U"+J$/4*Z9">EN,N,,=EI#NN?8I`K*3C>BT) M?(I6&:(<48&H1%0AJA$UB%I$':)>(15E=Q/[A.EA,-<9#B,)5HPH090BRA#E MB`I$):(*48VH0=0BZA#U"NF04IYR2DB=N0FI1ZKCPML3+C4T2P5$*:(,48ZH M0%0BJA#5B!I$+:(.4:^0CK)-VH[?FEUB2E""5BFB#%&.J$!4(JH0 MU8@:1"VB#E&OD`ZI32SIY=JDE[58L1,-HA91AZCW:.*6%+VH<-)$@FG"7/XL0>T5'9]801U0_.V>Q1I6+%%3-$N:!0RRP6"[%BK9*1#+V*D?;+/()4 MBQ5K-8A:08%?=KNL$RO6ZCVBIQ<(Z>'B\K+7KZSIH7D8%R-2S3,BU3S>BN:F MH'E,XIAZ^='/X09XYE'X]H18A5IF252(%8>A9*VP>2;],H^VU*C5L)8,NU:L M`K_@[0FQ8K]ZA73SV%SR;;,9II@43]>0JM5&I%K-(]G237U%38T-E_J%8^-MP?<)9)", M+D>D[G]$\/8$6P4W0#RB>VH]BQU>BAF0-Z):L'UFFY[A)S M78_<-K%$$%Z=\%9JB3!JT,\I0*&8B6C$2T9J1FG:QX7Q`1*OEBJ+5,3JJU;/5H*4:CCJS MGCV/YS:#N]',\NI7>=(T;5$SCC8F] M&77FRA3[BN&H\XCVU`[3(R/_\D2T6,^OS/,K&2KEC*13%XQXU-DK7LD&,C8J MCP*':D;LT#HR$6]0IV4D[G2,1G>,1L^E$V/+I?C_]LK$_920V;3Q2-_IWYAL M)68KZ9*)1[35(:TVRE.J/CR:<>U6)M!JHTTP>',65QRKL+#7V(0G"-_-&;$W33 M_7C;O^Y&_R!CAJQ3)B1K[YBM!"6(4D09HAQ1@:A$5"&J$36(6D0=HEXA?0FC M1E7#[">7,&=N0NJ1V@2]AEGP8,6#)UD!2A%EB')$!:(2486H1M0@:A%UB'J% M=)1="AY.9C^)\IBQA\\!KCR27AHC2A"EB#)$.:("48FH0E0C:A"UB#I$O4(Z MI"YE/B&D8X:M0NI1L-NY&E$P5R<>N;=B9'%_;2X7J5AQ]\Y82W[-.V`+ M1EK>;,Z48L7RE4<3#VJO_I:`PI(S&=-\^S)VQB#Z4V03.V4H.5;"N'*ID-'VHBD5^="@] M'D]+8E>8Q'JD%F8SN\R)V2KL<3[9DUPA]59^,1)=K,R`S5B&KD%!BT$8O;(< MK)"*W&(E',PL?BJI,WTP%,Q*ID=%2^8JNAH@Z62\%>/W37SMP$:T2FUYD6C'W%\,+` M*.AU'KGGI@Z="IZ.SZ2B6,VN;-=CJZ#K,9(CEJ\Z8B45IX^H0^I6ZB>$=%S8 MA[/AVJ-@K8(H090BRA#EB`I$):(*48VH0=0BZA#U"NF0VGSF^/)O[9,4:><; M1G3Q._2LF=T$C\6*YZ8$48HH0Y0C*A"5B"I$-:(&48NH0]0KI*/L\HD3.JY/ M/\(H0T82KP$EB%)$&:(<48&H1%0AJA$UB%I$':)>(1W2T_(6]_.-=GH]Y"W2 M<:.-6=_&7%%FC`11BBA#E",J$)6(*D0UH@91BZA#U"NDHWQ:*K/&5(:1Q"]& ME"!*$66(H5T2%V6$,X%;]KS78^YAKJV>13D0&PE M*/%()2D1O%:K$*AAZUV9[LA8K=J)!U"+J$/4>33PB ML[8IUMO:`S.O09A6=!+\&%'B$=W)<5NIE)F9Q7`J!AR%S"-Z>Y=1+E9>QNS! M%F+`=4J/5,.,I_%#;VJ4:3P*O&G%:MJ;3@S8F]ZCJ18Z+7];8_[&*&P*;R4H M\58_>:]>K-CU#%&.J$!4>A1TD4JL@J%A7^ZOQ8J=:!"UB#I$O4<3NP^;T_*] MP5RG,(PDRC&B!%&**$.4(RH0E8@J1#6B!E&+J$/4*Z1F_\UI6>%@;D+JLT+Z M_5L-=X3FYED,^-B29US1D=U"[8*LVG(/TNV$OF* MT5'YFJU&M^?V5T4:+A?AEM%1X8ZMCOK=L]4@K]O[M)1U@RFK1VH7`%ZS9R-) MR1-&DD2D'OUD$X`KBE;.2+2*5VF57%&T*D:B58N6NUS8M\@;KB$B+2,1Z41$ MQ@7TL)XK#EJZI6PF_*9UP`839(_4GA>\;\]&TD$3CX([WZE'].*`"Y3-53(4 MR5&D$)$C@2I1JT*M6K2<0^NY6<(UJ-*B2BOZWI,.O>C$B- MO<@^/A>SE?3/Q"/W[L%ADIZ8;$=Y>OS*12^*[+-,*)R_2KA@*UK-R>'MDT@E MRE=<\:C?-5OY9PNB*Y,T-ZC<*E M;H(H190ARA$5B$I$%:(:48.H1=0AZA724;:[!X+>#1<*4/?UZ_/9W?Z/1YHMHBOW5,^!GSWM/KT_OUDOMFXSCIH` M2I94,DQ]4+*BDN'^J"W94!WJ61-J&ZI#T9@H65YMW1MS4R41E0PW8.QQEC,J M&2ZIMF0UW[I'3R;45G2F]+C$5`EY37?])TH65(=>_)\JH3JTWIHJH3.E)UFG M2M94,LPSUNO%ADJ&1_.@Y)I*ABS+ELPH;F-2;4OF%+?Q%00HH;B-C^1#"<6- M]HZFO*8Z]+#H5`G5&9^WMFH1Q6W;D%IP2H>>W-BZYS+P"`65N$?J&1JL-!+.%0R%6EZ*8VFQJD2>JR(8CU50D\$4:RG2NB-HZU[GPA]HY?R MMNZU(BRA=_.V[LV[J9(EE4R=3T7'<:\?81UZ86_KWD+"DF0Y)]^F(DIO:E)T MIDIN2.UF4HU>?MS&DR7T#N36O>$XY<&22J;.)Z'S<>]T81UZ,7+K7NW"$GH_ MDLYGZC@Y]0/WXAW6H5]OW;H?:,42^D'6K?O-52RIJ,3]C"J6T,^F;MTOHV() M_30IJ4UY3;\72G6F2NBK5%OWS2E4HP\B4:AD*@;TJ2J:NZ9*Z!>% MR;>I$OJ97_)MJH2^0[1U7QE"W^A375OWL2$LH2]V;=WWN*9*YE0R=3X5'<=] ME`CKT&>\MN[;1%B2S"+R;6KZIN^W472F2FY(S7VZ"=5B*HDG2^C+:-MT\GP2 M:A_WR2U42^A\W)>>L(0^E[9U'WS"$OIJ&IW/5-SH@UU4,ASG\G"5?O[P[MOM MYUU[^_3Y_O'Y[.ON$ZU=KX;/]#W=?W9IW_@?+_Z7['_;O[SL'VAY>W[V97?[ M,93)GI9(P]3=@_,OPXP>RU*H&;048 M#UU(,_57UM8706#X"BIF3E$M45,H73&+5_T4J*(0'&:*KRN0-AB/1I\">+$@ M<\A/ZIU#O_=XT=CW.LT5;_F9AVQ3(^&01'5="LXLOC+\(KA61A762UXXE"08 M*@FR2X&OM;";<$2"X96DG)40H^.P8*4!$KP*R`VP-FE+)K0)26,O&N!6:<^( MGYBVL>\],@,MG:G?,"V8M$BKA?67[ES6QNKPF]+/9@5@#0D0T`N[XQ`[/(M) M.)YT"#SM(UL//1-4['/,A"W!+(HET]9%>3+DW+'H&?>$ME6DDNR=1*O&'9EOL7\K6A_CH?^>PS/)J>C\Q%^"@,9 M"5X_PO`7````__\#`%!+`P04``8`"````"$`Y\02/S$!``!``@``$0`(`61O M8U!R;W!S+V-O&UL(*($`2B@``$````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````G)%!2\,P&(;O@O^AY-ZF:45&:#-0V/-^7:GG03?()SJO6U(AD.4K`B%8JLZO1TV:5+E#B`S>2 M-ZV!&O7@T9)=7E3"4M$Z>'"M!1<4^"22C*?"UF@?@J48>[$'S7T6&R:&V]9I M'N+1[;#EXIWO`!=Y?HTU!"YYX'@`IG8FH@DIQ8RT'ZX9`5)@:$"#"1Z3C.#O M;@"G_9\7QN2LJ57H;9QITCUG2W$,Y_;!J[G8=5W6E:-&]"?X97W_.(Z:*C/L M2@!BPWX:[L,ZKG*K0-[T[/#FFL3[?85_9Y44HQT5#G@`F<3WZ-'NE#R7MW>; M%6)%3J[2?)&2T*%\K?&I-]]D,U)/`OXDG`!N]?_XY^P(``/__`P!0 M2P$"+0`4``8`"````"$`^L#6T[H!``#7$```$P`````````````````````` M6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P" M```+`````````````````/,#``!?&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*EZZ[)?!0``:AH``!D````````` M````````.!(``'AL+W=O&PO=V]R:W-H M965T``!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`/H>'J:X`@``O`<``!D`````````````````OB```'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`/MBI6V4!@``IQL``!,`````````````````]BD``'AL+W1H96UE+W1H96UE M,2YX;6Q02P$"+0`4``8`"````"$`(C6@&NT$``#>$P``&``````````````` M``"[,```>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`'1,3QTU`P``1PH``!@`````````````````WC4``'AL+W=O&UL M4$L!`BT`%``&``@````A`!Y'VO60`P``%0P``!@`````````````````SV4` M`'AL+W=O&UL4$L!`BT`%``&``@````A`.>5%W*@`@``L08``!D````````````` M````@VP``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`/)E>W6Y`P``(@P``!@````` M````````````N7(``'AL+W=O&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A``BR$%K3`@``:@<``!D`````````````````I8$``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'J*+GHC`P``1PD``!D````````````````` M;HH``'AL+W=OS<3^L46```O=```&0````````````````#(C0``>&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`'&8MJ XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories
 6 Months Ended
Jun. 30, 2014
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block]
4.
Inventories
 
Inventories consisted of the following:
 
 
 
June
30, 2014
 
December
31, 2013
 
 
 
(in thousands)
 
Finished goods
 
$
16
 
$
7
 
Raw materials
 
 
130
 
 
31
 
Total
 
$
146
 
$
38
 
EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A-#8P,3AE-U]E,#!D7S0T-31?.#0R,U\Q9C,T M-3)A-V4V.34B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D-O;F-E;G1R871I;VYS/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DEN=F5N=&]R:65S7U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]V97)V:65W7V%N9%]"87-I#I7;W)K#I%>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A M;G-A8W1I;VYS7T1E=#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F-E;G1R871I;VYS7T1E=&%I;'-?5&5X='5A;#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M M<&5N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X- M"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V$T-C`Q.&4W7V4P,&1?-#0U-%\X-#(S M7S%F,S0U,F$W938Y-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A M-#8P,3AE-U]E,#!D7S0T-31?.#0R,U\Q9C,T-3)A-V4V.34O5V]R:W-H965T M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)RTM,3(M M,S$\'0^)SQS<&%N M/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2P@<&QA;G0@86YD(&5Q=6EP;65N M="P@;F5T(&]F(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!O9B`D-#`P(&%N M9"`D,C0X(&%T($IU;F4@,S`L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S M+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPOF5D.R`P('-H87)EF5D.R`W+#@T,RPS-C(@86YD(#3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\ MF5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PP,#`L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]A-#8P,3AE-U]E,#!D7S0T-31?.#0R,U\Q9C,T-3)A-V4V.34-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO830V,#$X93=?93`P9%\T-#4T7S@T M,C-?,68S-#4R83=E-CDU+U=O'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E M(&1A=&$L('5N;&5S'!E;G-E'0^)SQS<&%N/CPO'!E;G-E&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#4S,RD\'0^)SQS<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO2P@<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO2!( M87)V87)D($)I;W-C:65N8V4L($EN8RX\+W1D/@T*("`@("`@("`\=&0@8VQA M2!F:6YA;F-I;F<@86-T:79I=&EE M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQD:78@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@ M/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQB M/D]V97)V:65W(&%N9"!"87-I#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2P@26YC+B`H M)B,X,C(P.TA!4E0F(S@R,C$[(&]R('1H92`F(S@R,C`[0V]M<&%N>28C.#(R M,3LI('=A#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2UO=VYE9"!S M=6)S:61I87)Y+"!T;R!P2!A;FYO=6YC960@2!B96-A;64@86X@:6YD97!E;F1E M;G0@8V]M<&%N>2!T:&%T(&]P97)A=&5S('1H92!R96=E;F5R871I=F4@;65D M:6-I;F4@8G5S:6YE2!O=VYE9"!B>2!(87)V87)D($)I M;W-C:65N8V4N(%1H92!S<&EN+6]F9B!W87,@8V]M<&QE=&5D('1H6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$X+C=P=#L@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$X+C=P=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2X@1F]R M('!E'!E;G-E M2P@8V]R<&]R871E(&EN8V]M92!T87@L M(&AU;6%N(')E'!E;G-E#L@1D].5#H@,3!P="!4:6UE6EN9R!C;VYS;VQI9&%T960@9FEN86YC M:6%L('-T871E;65N=',@<')I;W(@=&\@=&AE(%-E<&%R871I;VXN($AA#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE2!W:71H(&%C8V]U;G1I;F<@ M<')I;F-I<&QE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6X@,'!X(#!I;B`P:6X[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4 M:6UE6EN9R!I;G1E28C.#(Q-SMS)B,Q-C`[8V]N"!M;VYT:',@96YD960@ M2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RX@)B,Q-C`[5&AE(&9I;F%N8VEA;"!D M871A(&%N9"!O=&AE"!M;VYT:"!P97)I M;V1S(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(#(P,3,@87)E('5N875D:71E M9"X@5&AE(')E2!I;F1I8V%T:79E(&]F(')E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-#8P M,3AE-U]E,#!D7S0T-31?.#0R,U\Q9C,T-3)A-V4V.34-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO830V,#$X93=?93`P9%\T-#4T7S@T,C-?,68S M-#4R83=E-CDU+U=O'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)TU! M4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE3L@5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7 M24142#H@,&EN)SX\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!O9B!3:6=N:69I8V%N M="!!8V-O=6YT:6YG(%!O;&EC:65S(&%N9"!296-E;G1L>2!)#L@1D].5#H@,3!P="!4:6UE65A2!T:&%T M(&EN('!R:6]R('EE87)S(&ET(&AA9"!B965N+B!4:&4@05-5(&ES(&5F9F5C M=&EV92!R971R;W-P96-T:79E;'D@9F]R(&9I65A#L@1D].5#H@,3!P="!4:6UE6EN9R!U;F%U9&ET960@8V]N#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE65T(&5F9F5C=&EV92!W:&EC:"!T:&4@0V]M<&%N>2!B96QI979E6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T M:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0'0^)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P M="!4:6UE3L@5D525$E#04PM04Q)1TXZ M('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,&EN)SX\+W1D/B`\=&0@3PO8CX\+V9O;G0^/"]D:78^(#PO=&0^(#PO M='(^(#PO=&%B;&4^(#QD:78@2!R96-E:79E9"!F=6YD:6YG(&9O"!M;VYT:"!P M97)I;V0@96YD960@2G5N92`S,"P@,C`Q-"!T:&4@0V]M<&%N>2!R96-E:79E M9"!A;B!A9&1I=&EO;F%L("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M)U1I;65S($YE=R!2;VUA;BF%T:6]N(&]F('!R;V1U8W1S(&9O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!$:7-C M;&]S=7)E(%M!8G-T2!$:7-C;&]S=7)E(%M497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M1D].5#H@,3!P="!4:6UE3L@5D525$E# M04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,&EN)SX\+W1D M/B`\=&0@2<^(#QD:78^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)TU!4D=)3CH@,&EN.R!724142#H@.#`E.R!"3U)$15(M0T],3$%04T4Z(&-O M;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S@\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A M-#8P,3AE-U]E,#!D7S0T-31?.#0R,U\Q9C,T-3)A-V4V.34-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO830V,#$X93=?93`P9%\T-#4T7S@T,C-? M,68S-#4R83=E-CDU+U=O'0O:'1M;#L@8VAA2!4'0^ M)SQS<&%N/CPO2!46QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=) M1%1(.B`P:6XG/CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!724142#H@,"XR-6EN)SX@/&1I=CX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2<^ M(#QD:78^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!I;G1E M9W)A=&5D('=I=&@@2&%R=F%R9"!":6]S8VEE;F-E+"!I;F-L=61I;F<@97AE M8W5T:79E('-E2P@8V]R<&]R871E M(&EN8V]M92!T87@L(&AU;6%N(')E6EN9R!F:6YA M;F-I86P@2!B96QI979E'!E;G-E'!E;G-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG"`P<'0@,"XR-6EN M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(V+C8U<'0[($U! M4D=)3CH@,'!T(#!P>"`P<'0@.7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!M871T97)S(&%G M2!F965S('1O($AA6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D M/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`P:6XG/CPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,"XR M-6EN)SX@/&1I=CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63I4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A&-L=7-I=F4@9&ES=')I8G5T;W(@9F]R('1H92!O=&AE2!F;W(@ M<')O9'5C=',@2!D979E;&]P&-E<'0@ M9F]R(&-E'1E;G0@=&AA="!A;GD@2&%R=F%R9"!" M:6]S8VEE;F-E(&)U2!B:6]R96%C=&]R('1H870@:7,@=&AE;B!M86YU9F%C='5R M960@8GD@2$%25"P@2$%25"!W:6QL(&)E('1H92!E>&-L=7-I=F4@;6%N=69A M8W1U2X@4V%L97,@=&\@2&%R=F%R9"!":6]S8VEE;F-E(&%C8V]U;G1E M9"!F;W(@/&9O;G0@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)U=)1%1(.B`P:6XG/CPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,"XR-6EN M)SX@/&1I=CX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M28C.#(Q-SMS(&5M<&QO>65E6EN9R!A M;&P@;W!T:6]N#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE65E6EN9R!A;&P@;W!T:6]N#L@1D].5#H@,3!P="!4:6UE'!E;G-E(')E<')E65E#L@1D].5#H@,3!P="!4:6UE65D(&)Y($A!4E0L(&%N9"!D;V5S(&YO M="!R96-O9VYI>F4@97AP96YS92!O;B!T:&4@061J=7-T;65N="!A=V%R9',@ M9VEV96X@=&\@:6YD:79I9'5A;',@;F]T(&YO=R!E;7!L;WEE9"!B>2!(05)4 M+B!!9&1I=&EO;F%L;'DL($A!4E0@'!E;G-E(&]N(&=R86YT M6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'0@,'!X(#!P="`R-BXY<'0[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE"`P:6X@,&EN M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@ M,C`Q,RP@86QL(&%W87)D6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)TU!4D=)3CH@,&EN.R!724142#H@,3`P)3L@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@ M1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,RXR,#PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S(V+#$X-3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q M)3X@/&1I=CY#86YC96QL960O9F]R9F5I=&5D/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E M/B`\9&EV/B@S,3$L-C,U*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU+C4X/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^,36QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(T+C5P=#L@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E'!E;G-E M(&9O"!M;VYT:',@96YD960@2G5N92`S,"P@ M,C`Q-"!A;F0@,C`Q,RP@"8C,38P.TUO;G1H"!S;VQI9#L@1D].5"U714E' M2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#

6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS-SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-C4\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,S<\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS,C0\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR M-3<\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L M93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S8R/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(X+C`U M<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2P@26YC+B`R,#$S($5Q=6ET>2!);F-E;G1I M=F4@4&QA;CPO:3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!H87,@/&9O;G0@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93QB6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^-BXP,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#4Q)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q M)3X@/&1I=CY#86YC96QL960O9F]R9F5I=&5D/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E M/B`\9&EV/B@Q-#6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+C0V/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z M(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T M,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@Q+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,2PY-S4L-S`Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+C8Q/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV+C`P/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG"!M;VYT:',@96YD960@2G5N92`S,"P@ M,C`Q-#H\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE6QE/3-$)TU!4D=)3CH@,&EN.R!724142#H@-S`E.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E.R!/5D521DQ/5SH@=FES:6)L92<@8V5L;'-P86-I;F<] M,T0P(&-E;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-S0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO65A6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5#H@,3!P="!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q M-"!W87,@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(T+C5P=#L@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2P@=V%S(&%L;&]C871E9"!A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(T+C5P M=#L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,&EN.R!7 M24142#H@.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!/5D521DQ/ M5SH@=FES:6)L92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A M;&EG;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV-3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,2PQ,#D\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(X+C`U M<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#(X+C`U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)U=)1%1(.B`P:6XG/CPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!724142#H@,"XR-6EN)SX@/&1I=CX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63I4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W M(%)O;6%N)RPG2<^(#QD:78^/&9O;G0@2!B92!I;G9O M;'9E9"!I;B!V87)I;W5S(&-L86EM'!E M8W0@=&\@8F4@;6%T97)I86P@:6X@&5D.R<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!$:7-C;&]S=7)E(%M!8G-T2P@0W5R6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!72414 M2#H@,3`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=% M24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXW/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,S`\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXS,3PO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)W=I9'1H.C$P M,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6UE;G0@07=A6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^-S0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ+C8V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO'!E8W1E9"!H;VQD:6YG('!E6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXV+C(R('EE87)S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)W=I9'1H.C$P,"4[('1A M8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN M9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE M($ET96US73PO'0^)SQS<&%N/CPO2!;5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@ M8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE2!O9B!S=&]C:R!O<'1I;VX@86YD M(')E2!F;W(@=&AE('-I>"!M M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-#H@/&1I=B!S='EL93TS1"=#3$5! M4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@ M,&EN.R!724142#H@,3`P)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I M;CL@5TE$5$@Z(#$P,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,BPU,#`L,S,Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z M(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0 M041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^-2XT-CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#4Q)3X@/&1I M=CY%>&5R8VES960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I M=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXT+C

"!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^ M,BPQ-C4L-C0W/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U3 M25I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=( M5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR+C@U/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U!3$E'3CI,969T.R!415A4+4E.1$5.5#H@,&EN.R!724142#H@,3`P M)2<^(#QT86)L92!S='EL93TS1"=-05)'24XZ(#!I;CL@5TE$5$@Z(#@U)3L@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@3U9%4D9,3U6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXR M,3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^,34X/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO'0^)SQS<&%N/CPO'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z M(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E&5R8VES93QB6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT M97([($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^-BXP,#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#4Q)3X@/&1I=CY%>&5R8VES960\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#4Q)3X@/&1I=CY#86YC96QL960O9F]R9F5I=&5D/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/B@Q-#6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT M+C0V/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4 M+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5) M1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B@Q+#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^,2PY-S4L-S`Q/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXT+C8Q/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXV+C`P/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^ M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\65E(%-E'0^)SQD:78@'!E;G-E(&9O"!M;VYT:',@96YD960@ M2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@"8C,38P.TUO;G1H"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXR-CPO9&EV/B`\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q% M.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#$P)3X@/&1I=CXX.3PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXW,S$\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE"!D;W5B;&4[(%1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^,3$U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!" M04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X M(&1O=6)L93L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q,"4^(#QD:78^+3PO9&EV/B`\+W1D/B`\=&0@3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]A-#8P,3AE-U]E,#!D7S0T-31?.#0R,U\Q9C,T-3)A M-V4V.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO830V,#$X93=? M93`P9%\T-#4T7S@T,C-?,68S-#4R83=E-CDU+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2`H1&5T86EL2!$:7-C;&]S=7)E(%M, M:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-#8P,3AE-U]E,#!D7S0T M-31?.#0R,U\Q9C,T-3)A-V4V.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO830V,#$X93=?93`P9%\T-#4T7S@T,C-?,68S-#4R83=E-CDU+U=O M'0O:'1M M;#L@8VAA'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO&5R8VES92!0'0^)SQS<&%N/CPO&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA&5R M8VES92!0'0^)SQS<&%N/CPO2!);F-E;G1I=F4@4&QA;B`R,#$S(%M-96UB97)=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!0 M87EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-#8P,3AE-U]E,#!D M7S0T-31?.#0R,U\Q9C,T-3)A-V4V.34-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO830V,#$X93=?93`P9%\T-#4T7S@T,C-?,68S-#4R83=E-CDU M+U=O'0O M:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO MF5D(%!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(%!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!);F-E;G1I=F4@4&QA;B`R,#$S(%M-96UB97)=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO65E(%-E'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPOF5D(%!E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E(%-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!);F-E;G1I=F4@4&QA;B`R,#$S(%M-96UB97)=*3QB2!3:&%R92UB87-E9"!087EM96YT($%W M87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)S8@>65A M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO2!3:&%R92UB87-E9"!087EM96YT M($%W87)D+"!/<'1I;VYS+"!'6UE;G0@07=AF5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P,"PP,#`\2!3:&%R92UB M87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!' XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Liquidity
 6 Months Ended
Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity And Going Concern Disclosure [Text Block]
3.
Liquidity
 
The Company has incurred net losses since inception through June 30, 2014. Since inception, through the Separation, the Company received funding for operating losses from Harvard Bioscience and a $15.0 million cash contribution at the Separation. During the six month period ended June 30, 2014 the Company received an additional $0.36 million from the exercise of stock options. The Company is currently investing significant resources in development and commercialization of products for use in the field of regenerative medicine. The Company expects to continue to incur operating losses and negative cash flows from operations.

XML 17 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Current assets:    
Cash $ 10,065 $ 14,008
Related party receivables 82 22
Inventories, net 146 38
Prepaid expenses 356 421
Total current assets 10,649 14,489
Property, plant and equipment, net of accumulated depreciation of $400 and $248 at June 30, 2014 and December 31, 2013, respectively 1,038 575
Total non-current assets 1,038 575
Total assets 11,687 15,064
Current liabilities:    
Accounts payable 434 244
Related party payable 41 90
Accrued and other current liabilities 350 161
Total current liabilities 825 495
Total non-current liabilities 0 0
Total liabilities 825 495
Commitments and contingencies (note 8)      
Stockholders' equity:    
Preferred stock, par value $0.01 per share, 2,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2014 and December 31, 2013 0 0
Common stock, par value $0.01 per share, 30,000,000 shares authorized; 7,843,362 and 7,742,080 shares issued and outstanding at June 30, 2014 and December 31 2013, respectively 78 77
Additional paid-in capital 18,294 16,466
Accumulated deficit (7,513) (1,974)
Accumulated other comprehensive income 3 0
Total stockholders' equity 10,862 14,569
Total liabilities and stockholders' equity $ 11,687 $ 15,064
XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
Overview and Basis of Presentation
 6 Months Ended
Jun. 30, 2014
Accounting Policies [Abstract]  
Business Description and Basis of Presentation [Text Block]
1.
Overview and Basis of Presentation
 
Overview
 
Prior to November 1, 2013, Harvard Apparatus Regenerative Technology, Inc. (“HART” or the “Company”) was a business segment of Harvard Bioscience, Inc. (“Harvard Bioscience”). The Company is engaged in the development and commercialization of regenerated organs for human transplant.
 
Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets.
 
HART was incorporated in Delaware on May 3, 2012 by Harvard Bioscience, as a wholly-owned subsidiary, to provide a means for separating Harvard Bioscience’s regenerative medicine business from its other businesses. Harvard Bioscience has been designing and manufacturing devices for life science researchers for over 100 years. Harvard Bioscience first focused on providing devices to scientists involved in regenerative medicine research in 2008. Since early 2009, Harvard Bioscience’s regenerative medicine business initiative was operated as a segment of Harvard Bioscience.
 
On October 31, 2013, Harvard Bioscience contributed its regenerative medicine business assets, plus $15 million of cash, into HART (the “Separation”). On November 1, 2013, the previously announced spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to Harvard Bioscience stockholders of all the shares of common stock of HART (the “Distribution”).
 
Basis of Presentation
 
The Company historically operated as part of Harvard Bioscience, and not as a stand-alone company. For periods prior to the Separation on October 31, 2013, the consolidated financial statements presented herein, which include periods prior to the Separation, and are discussed below, have been prepared on a stand-alone basis and are derived from the financial statements and accounting records of Harvard Bioscience using the historical basis of assets and liabilities of HART. The Company’s financial statements from that period include expenses of Harvard Bioscience allocated to HART for certain functions provided by Harvard Bioscience, including, but not limited to, general corporate expenses related to executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. These expenses were allocated to HART on the basis of headcount, time devoted to HART activities, percentage of operating expenses or other relevant measures. The Company believes the assumptions and allocations underlying the financial statements are reasonable and appropriate under the circumstances. Both HART and Harvard Bioscience consider the basis on which the expenses have been allocated to be a reasonable reflection of the utilization of services provided to or the benefits received by the Company during the periods presented. However, the amounts recorded for these transactions and allocations are not necessarily representative of the amounts that would have been reflected in the financial statements had HART operated independently of Harvard Bioscience. Accordingly, the financial statements for these periods are not necessarily indicative of HART’s future results of operations, financial position and cash flows.
 
Prior to the Separation on October 31, 2013, Harvard Bioscience used a centralized approach to manage substantially all of its liquid resources and to finance its operations and, as a result, no separate cash accounts for HART were historically maintained, and debt and liquid resources maintained at the Harvard Bioscience group level are not included in the accompanying consolidated financial statements prior to the Separation. Harvard Bioscience funded all of HART’s operating and capital resource requirements prior to the Distribution. After October 31, 2013, the accompanying consolidated financial statements reflect the consolidated financial position and results of operations of the Company as an independent publicly traded company.
 
Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred.
 
The financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”).
 
Unaudited Interim Financial Information
 
 The accompanying interim balance sheet as of June 30, 2014 and consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2014 and 2013 are unaudited. The accompanying interim consolidated statements of cash flows for the six months ended June 30, 2014 and 2013 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of June 30, 2014, its results of operations for the three and six months ended June 30, 2014 and 2013, and the Company’s consolidated statements of cash flows for the six months ended June 30, 2014 and 2013.  The financial data and other information disclosed in these notes related to the three and six month periods ended June 30, 2014 and 2013 are unaudited. The results for the three and six months ended June 30, 2014 and 2013 are not necessarily indicative of results to be expected for the year ending December 31, 2014, any other interim periods or any future year or period.
ZIP 19 0001144204-14-049404-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-049404-xbrl.zip M4$L#!!0````(`"Z(#44,AGCJ4TX```?'!0`1`!P`:&%R="TR,#$T,#8S,"YX M;6Q55`D``RC2ZU,HTNM3=7@+``$$)0X```0Y`0``[%U[<]LXDO__JNX[8#T[ M.YDJ218ERW;L)%OR(XEOG3AE*S.S=W65@DA(PH4B-00I6WMUW_VZP:X0YIFMQI_]V[VOG??5X MC_S]W;__VYN_5*OD`W.81WUFD>Z$7%"?=CQJ?A=Q>V+4C-HAP1\:U7;0KS;J MQ@'YKWKSQ&B>U`_^F_SOET__1R[O.J1*[N_O:Q;TX,L>:J8[)-5J/,X9%3`& M]//'V>TU:=2,Z-Y#U[/Y"?Z?`-F..!E0SW^[-_#]T53PO`>A4V/_CT_7=^:`#6F5.\*GCCE%"W^$ M]MGGN7`/&L;18RW")^(&%AMYS,2)7MCF]3[U3,^UV7Z/FGZ5/8QLZE#?]2;O MX?>X(],-'-^;3(M-,+/6=\?[T4V"^'&X=R4^2WD;>PB3'=1'`SOP'U3.DK:]*CHRIF-;N2P_F`_@I\_KC.@#GSO$=C`W3W094+> MH"*<"`GQ6]8C4C%._,F(O=T3?#BR$;_RVL!C/>@1=+T::W'M05A[9!\Z"DW& MN>OX[,$G=\STP1))X\PCDFPVQ68L\O.K?^R]JX,&MPZ;AX>M-_NSC>.A]F?&FJ)@ MQ#SN6K,4@%Y[/AA>]BZ&6=V(^TGOQ5UEV+$RC0ZKS7HZN!4UR9*4&3R^%,DP MZOM1P1YD!'M01L$>+"/8@^($>[!%B#U0";$'6X38EPNV0,2VOM6;*,Q&QS7J MWYI&:1';J-9;U7KSI8@UZN`Y"Q!L6]PXI4-J&([Z.9"+[ZQ*,L??X$]I)7,, M?PJ2C-$HF1)F)`/:U,AH4U&2:91/,HU")5.Z4&,*,S]N9S"MN.!#YLC2Q@L2 MBZEHXMO'L")QQEUAL_<#%FB4]Z_E8']CU MD_&B&Q80`ND]-[D?TDVL6"QO]Z*$\62:"\S53A[A_,U^;LL3^U+*8!R0@9X M.)EC(M_*)'QO""ZE*,MHN*@"%]6L2VZQ2<-%%;B4HH2FX:(*7%0K#.8[H[8I MUP+%+3,9'].NS;+![KDKPT&/8@)VR\7WL\D9R'8PI-[W<@(H#H"?YBQ^V[3KXIJ"FE[PRHZNCJFIZ<5.^[(^_=LM M$[['39]9=[YK?O_J<`B=[KYFGV_?0W>=R:CD*)EA([[\J``6(V5+C9.J88C& MZ69QJIX]+0ZIJUB>U'C5=E7I0L!J5E0US+595ASH/Y(':WAK*UZ&U%WC5)OA M=2'UN9MJGK*KC'KFH`UVGHV9[8Z0]QFZ=V7IZEFZ\"R1:H505"%V!,D:,2M#S!*)H`ZL MU0^L%4D8=T`A='"M>'"M56%=JK":<'S+]4&-`%LKQ9J4HKQHUJC9Y-X.'62K M'V2KEW,JMC2^$F70`;;B`;96@^740%>OMS2XU@JQMKV!.DQ2/TQ2,6O83H70 MH9+BH9)6A76I@JY%EB9MF#J@<=Z3V16QPJ:3583@UT M56E+PR2M$&OP"^5%LD;,RA"CZY!;&5BKF&=NIT+HX%KQX%JKPKI40=3*ZKU^4/LM7+.54[=WT5RJ`#;,4#;*T&RZF!KEYO:7"M M%6(-?J&\2-:(61EB=/5Z*P-K%?/,[50('5PK'EQK55B7*NCJ=6D";*T4:U** M\J)9H^:9J`D<'D)&@)#8[(P/&16!Q]Y%Y,E'XN[B>]DAL+<%_7^]NUC0.1?N M0<,X.H$GEN_[&S#\[0X)G!G%XF,`V>PL8-//P1",F>]ZLPA[-FE9@<_VF#/@ M!7-FE++T+NF(E> MI%H-'TV=S1CNNM[D@@O3=K&O#D#SS';-[R3"Z2WK+7Q'9D^2_)Y"Y]8W8^_= MWVS_%-@EPI_88'\^M6\_7'T^(?61#W\?3LG[F\^=$V+@[QTP%H)\9O?DUAU2 MIQ)>J`"E'N^1O;_U_5."W?6`BK@_;%Y]W_YT=?W/$_++3`^_5'X1V/:7<)CJ MW=5_7H9CR4!B\FH'/Y1Z?:OK[Z`/+ZGT"`,9Z1X'D9B*I3I6$<[$TN3O^U[F9X1=EN28 MS//KR_;M2=?U!Q&"\TD^G4'WZ=):%K%+AZ/3GXS#^CP/"A"W0@M`IB8L,Z]H MZ03$T,PB;H_X`T9ZKFV[]Z"L)RK*I-`)RRC8M;00\L+5YXM+I!%,3&(SC'K] MY[W'K.GTX\?UGT_)V5M]?SF^KK]Y0[&-$'2="38*;D!8_?^^N;W$S+F M@D-G3UI10FW>AV`3+5F>2?UX>?7A(PJV`2;Y"5N"T2CS8N!T_GD-M#FN-Z3V MM/AF)PA8:I__X\/MS=?/%R?DIY[\;PY_\Y8<)L9WA]&#OT>$'M2!J7MN^8.W M>ZW6S_.&;?',/VTME>/06`&#$9YBW_M37?Y'C-$#$:[-K0B^*HG@*"L"D`&J M`(`<<-R8D\=_!`[#7[O>OKS5K%=2$6$`IG&P$SBX8*;,@Z>P8$QCH;G;6,C& M6-H%E(3#5:B^T@PVFEG%;LUQ^XH[*'RQ@ZTO[XN+J M\X?J;3AX*TX,U\]J?9Y7XU#Y*=0(W6F$'BD_@P4"5!&/66SH>TOOR9!"D,.I MO3&'^6P6UV*.7I;V*C;'ZQ=`<;9MA5+)\[[-NL:[QOO.X+UI[#+.!`I^-:3;2:/!5&'&^YEA2X/>;9$U;LR4_[X>^<_7B[7M M]TNV]]5:N&/O!SRW-W M.*+.!)XP:2`8N:!C;I$/'F,P6.:!4"S'#>/H5)#S`>7@I1U"'8N<7]Y4<$1J M"Q=&L;C'3+#`N+ESGK1:$4)5>H=G'BQ#V_5B.H$@CC^=N\(G;=N.7E8+=9'G MJM^J(=LXK!VV4*ERM:W6;"FM<`50_QZ0'KYU),C(8P+WA8"*P04O5K$[!AHG M9ZI"/K9O.U.JY(Y8>$^0>]!6T@ML>T(X]-+WI+;>"7M@ M9H!O=Q'P0F-N(HD][E#YF._)MU8F%3`)WLC%3K&I.V00ICU4R"!`10;*W<"3 M+6W6IW;2DU1Q#E&50)V6)@2)K9$.<$9-,[0.2$4X(L>V\>N4@O2FQ),K%.BT M9X/)D)?I"%]$"Z^#`3&9YU/N$!B=XV)42`Y-H8\/12*4@I`O9(9/35LWFS/@ M05X<,G^`]("YD\8QZH[A3;"`.=W)F4$YN@YZK8CYA(JDQW!*L%?`";'8V/7# M(7#:"7K.,?-74#RXFXCVV0)FT)8":5+Z;$S!JTNUH.E<842CPU_P(V0(MP<1"@AS4#ZXTQ:W MUQ+<22EG:Z6$&;7&XX0)_O`D67*613+/<#N%EX2#1"U#[0B9Q7IJWOQ%]]$C M8UHMN\JH2#KI\`"J-<&H6^(*D!.ZTZ2S0OQGN2U\`0ZVW0?#\$+<5P4>]#'="@U!ZHVG M'J`/!%^9E?UF;XB@"UX4#<;T]9'G6@%8D^R8*8?91QT9@MAHX0*P:M`03!1D M#>"$00P9.D*'+$<$IY09KT;N,,8()R1[0X#I_#,`LP8.&"W.[*XQ5"]-UR\7T5%<2FKB"6NX)X6*(ZWQ2" M%:SM%5`V*UV=KQUFR#*UC,*]'W!S0!B%_T7EA-!Y=UE8I0#&V`/$3P(K',D(X*AB9Q5FQV%94Q8<0FH$ M1`G09_:N%1[N%^;'@MHL3LZ&\J`S(2,-$%QWDG96P,:!008=&! M8K)F,IA3'",I8#P`W3).2XH`.(DB!G7\H-.N6R(.(`]T[0@^N! M%_*.Y8JP5A7/Q,PL9!K(0J\4=-I[6(#)(5?V-@H\AI%<,\FF4_QQKG`<`Y@+.-9\C4$&3M-A M4YD#I>=$.[,14OK(30_G%B+LL'D8=&%!6\ACC,X`%Q"#362(O7SP=*#TX3CS M:__%+=W_N"_;R_7]A5!5'[G*,I MWF>"[1ENU8^]N*74&'&ZWAV&)!,.`6R9K_!;X^WJ=R,DG-Z.D M[)>84Q9-@\C.7C5<)&_31G=&R4/&&<_II$'5WFL![WLXMG49SI M]GH<+@%C\1)]&,6PX5=2G/*`P_RM$2C? M(=9Z4>3%K_/L:!8MDYIIW94U__"6:5IIJ,YA"@;).CIT67F8GFLLULY%BP43H'] MR>[1(*1NYUXB2\)]0,&-,>9D-A5$NT-`%WM^I,=S_&#ZRV79059W<%TJ*LB$ MX\6:%]$4H3=?<4(5S=H3D`0`U@RW)>!-/-,6=R*$&ISK=F6-"M@<`LEYVIDP M[[CW\6]):4EK15$E8I2WQ'37';-HMQ9XD$A/4N.76\:4L$DLFC3BN_+=Q6%-N=TKFI-203OSW!S8*+0KYVU*5KAQ$ M:IKDKV>_T([:OHM`[H.9K[S/[NNKR(`Z4FAIY6*U`5U9E"S*51WFF1Q4%E)= MW(L""D9M;`/.ON\Q&GIOF/P>Y5ZTH!0%BU&4^T18,15#1R8(=PMB M7T9/BRG:=[+'5LNW'\#H#F'2)VG5Q$VK/;D>,%X+G"Q8,IK=:Z-/QU[9Z=CA M&IH^'OO9YT9J;"L>';,VAR$^=G2HKV*E0PE)V20\&.])3_Y*IOTV\5RJ9 M&3A\Q8QN"3`H)PM])+8V^UNH^R\YZ.,E1^4O]@KQP?DW@2]\B($A3"J1?5A: M7AI1/XBHWQD>CP.N)H.A]IAYM,]225Y&N7CVH2^8EI?3)FD$K1)!B\.5#%K" M@"4U7-I*:8R]`&,?L!Z7R@P_19I%UWO*O?3N;U@$+!&LE`R.%3O_/2\T/J,V ME0MI/HD_(92\5+HIQU2*$P2+/%%XDP<(EO;`X8T>)-BHM.KU2K/Y6NN,&D9P M`T=J[@#,F[7&QLZ95POAVBMHK_"TNC0.*\9Q2VN,]@G;"_)6;;?/&E?X8PS% MKJI\"+<@E;-\J;QU*[1L5"3W"GU29I5FKJH\$'8$Y[L(9(W4,B)56V1MD7S49OC+L4FO&LU*O77TJ_*SI\%9 M%B=:+&";M>9.UQE58$^#5?6(3R-5(U4C=0MRDV+7;GYC`E_L?75[]U5L+`14 M(3M5@;TMLE6ZCJ*1JI&JD;IQ]E1"JC*H?&6T#BJ'C6/M\34ZRV%'#VI'&]MP MK`)8%4Y0BET\.<>WDFR;6?L]U^LQOL&-9BHDJN7:>*Z0`$JQ%-,TC,IALZ77 M8G31L!Q%PU:M=:S\;&IS7"ISK#3@=[I*K@)[VC1KI);FR(9BUVXR1S9,G;6Z MRWGRD_X(LEMBN?C%[P(\WZ86WK(W9YM;@/4"_SD=E" M/PK3.*BU4(I*?Y]"V<^3W#WG"W7R(XP#CS'YB9+'OSTB'PF_GN,Q,6+XY1*& M'[6ZQ^_6)A^S@U_"KZ((_;&2E7VLY+BEOU7R`@?1/%RQKU>.P]TYOG=*!"_Y M9$4'[5HJE$_2L&7.#T<+E_Z*IB[]#6Q>65&RFX<\+XV2._Z@,;*IU0$EA*$= MQW::A*+.?5]R;:AT8M!`^7&@+'/FNQ(F0R-!FPQM,K3)T$&E#BK7OUE,.0:? MRB)?<2=EV!^X@:".M=2;X,JQKN=6SZTVTUN!]*U7Y>UG,&?E>\LXU`R6G4&- M4-_MLJ/&^X[AO=G86"%+XUWC??TK\YL[:5`%O"N2 MNA6[K-1Q?4C'6-: M_0(X7HL%WAZ- MJ$?]0)!;UI=KX[@63CK,'#BN[?8G%7+EF#5Y@#NY_#/@_@0O`&[Q,9PCR2]/ M5*_(R:K76GBXN=)350#!J&=2_BCN\-A\RQVA]G0G4GO.7)Q*MTN!ZEKRD'\N M1""_.,(D@C'%9(>R!>287C,"=,1/XH@%V0>]! M'40&MHGRU,A%X.%3>/7QSU945LNWTV8B MW&V[Q_?TM'ULS^R=^V4"BY+-&02:`MS6_OJ;62`)$*(`@2BDBMB=MBU$964] M^5:5E4G^\C03'P5N@(R#B.-KX-LSS:#!50SE53,]@DQR-^OM8W7<5416(D$"BUMPO9J09GUFZ8@ID$O:XKCS6&EETRK^TO(,,;RW4"2 M7(`*@LS_S+,,5]&P(0N:]95\I&,S$X_`KVK`@8A..%++`JU?X1RGY5 MY>]W6X4G^IX]?.NYC@L^<+&KZ(WCET34GHCZ)\'#*#`U(0Q=O!*J/85T% M`7CXH3N,Q9NIDR2"RD30;G':IN1%==*T9 M=//I;[CSUR!8">D<"W9!(,DU_J29[-1&T$8-YO]^1-06D5I%7(>#5@TNI/ M:DM[%DM@CDH%P(F@_13CGPNNXW9=@%02L4C57JII/N@RG M"-.32EDBM=&!4K5';*O$C]I")1'"9!&F)Y*>JF=^"3KIG=KIMD:=P3^$7SZ) MSJ98T6H1VV_75R-!@E6"M1DNGT2J1*I$ZA$$)]6>XOQ&'+SA^^[^X5>G-A=0 MA/!4A.D=D:Z2&RD2J1*I$JFU3T\DI`J#RG>3UF@RE/9>8K,96K3.)#,1P"IP M>%+MV#X=%NK5,T@@;:+2KW+TYJP8@VJE!K!5:#P5V^KW?;LMX<2HU*S2\V>56!& MK8EL6EKW]*16%S=0.Q!&V5^KZ6*1.09,:Q^GGT(3BG73LGZ[E)YEE2UIM#&) MYCC>/-SJQG/\SF_8LF>.O66P[0CK4K-N3Q-N7N*L>^/HF^X][@LEA+4U.7R_ MDD9W'1G)IB-Y]'V_WVC3?7#/1(@%S%-$]Q$5R6;*OS!-$BKRC2KE*/AP?#BN MS2\%3Y'$8\'Q M@?PTVR!(D(MIUP1+_TBR:K_9IN8:IN$NZQ)X$1(B1)B>"$IVE271J"/75$KD,:V>E,@FKZD@SD.U>PN7 MQJNA$TM7?C>(*?MPB;Z$S=%0U<8SXE?$D_L)4OZD_#5K*;-O)J3="RGK?@-[ M\>IZPXI,>>,D)\5X+^0[03$CNJ*]$JH]AR]^.'CS`R]WQ.]]>)9.*/NDVU%[ MRIVI6>&[(.DW0)3OFJ/\1YE@&+0'@P@@6HKGK(CY9&K3/\\?IB^VB1-B,SE? M4`-O3P"5.C';35FNY@&LS%56(DO\@!>2SI\TO+HTM><+8CD:+JU"WO!GO.]$ MY8T+F7X>RRNL*]MT2H0*C=#:;B5(@$J`9@%HK]`QH(2HA*C4H;+]:TGQ MQX.&MX0P^)AK]$_B&M9S76N>>:+-5$HBA-3RWJE$JD2J1*I$JD3JCFH_`^'7 M4D)50O7DE:H@P4FUAR-?B$6H9K+P1-/GAF4X+M7PGOHIQZ5%\^@%6_##,Z"I MNS#CB82[A/O)P/VD-QTEVD\,[:.>*O$N\7XR>#]I[2Y(U%;MD=*C[4+,YNRH M5W;*03M7UGL@Z[KM/>'X]:]ZB3W:LAZ:Y^2+0%M7979O4U6Y"RO%1(J)J*Z$ M%!(I)$(R*\F6M-1.;?N'4E"DH`C)+&E-=@>FC2UG'ZTE/6YW&E),NFR2L^Z'F?%&](_<&N'K M]]/U3_J:F/"/=//C2C_\\-YSSI\U;?'ATG"FINUXE-S./H?P=._#Z;/MN,[# MBT;))X3[<[PCUZ'_7RF&#I`0)NZAO[' MX.RGV+(5EC@EM<"[;YERO7`E_6MS#-_.M(BQ3<6PF?H?SW&-V7+;HKCV(FG# M,2A(WS&LLQ@4N+9P]=5V=Q!\.V*-4D22K]CPVT^EFR(E(MMCOSG&$U_H^1P) MV%X9%T)2PE)D(G)29!HI7D#IMFYTFK;YFMISQ84_,PL+_[:4[T29:TOEB2B& M]6J;KV!]#4MYU:AA>XXR-35C[J^O29XU4UE0>TH(2C[\E1JL[PL\S]K64/BS M1I>@$#WJ$.QF\X2-88CCM-$KH&#\X?^6K3C>]`5&=5U"'06TM>YWC]%Z;*F.O:" M4,WOJ6-3<$:<%V6&/46V6]$TQ^;E,U)Q$_X1TV77[V*(6? M'G&HXL9M6(EQ*T&>2FBM4[:([TG2:N5@Q7&9',-!USGH(>5WS0%(5-(W1WS- MZ1O!SZ[M6*0+G6-[^K5 MYL(E&7AV^>R4W;AZTYUS+^XIISL?CEE)_D!?AN-23*28\-R(\9%+286YE)D] ME+0;!\W)!\N:T;4[$VR3(1W.H;Z8NL:KX2[SYX7]\;-&7S6J?S)L9VH0:THP ME?\7=@SL.3@X_OY-FY.+-\.)9)&-2L\B>PSG1"F&HVB*X\WGF*YHS_P+"8J] M8.F%F.Q(B>-28XH)5?YGGF6XBA;P`MY$69:58[PI<^#$BZ,02X>',=T!(?Q#ZBK-DRY90JMH3O-([GT M>9;^?FVQ-IR)P>%7L&%%P"`<+V2.E53[1RC[>2+'/+F7NZW"*A/SUG,=5V/W MBBZXU@VX^_4TSO2*:20A_ M4!3G6+"$PB37^)-F:M:4*)JKK.ZDX$44I>#]DR9MME>B-!I_(M78#)9:3Z:Z MK4>^KU9',(091@#6>T)P#S7KM;6^*B6`B75D%:!;ZX=(.U6Z;;1B70PE16)CQ#GIPAD MB=0F(E5J9*F13P'GIPADB=0CB(^J/5I;)7S4%B&)$!V+,#V1]%0]\TO02>^Z MO59G,"I2F4R"\TC!*70]H%Z[=]+[C"),3X)5=(]/(E4B52+U"&*3:L]N?B.L M.\*[^X=?"Q6G/9KH5(3I'9&NDOLH$JD2J1*IM4]/)*0*@\IWZJ#?&G;'TN)+ M=#9#C_;;HY.NE"IP@%+MX4XN=X*XHW*#!>FE'BMR>/=ECH3I M2G+`WB97?WGPQ1L+RS\:KZRS"580S-3=9"R[F\CN)K*[B2QS?YIE[B,LD-U- MY-++[B;"%'`6@AE2[1^C[,ON)@?BET24[&XB_1'9W41L#DJ,R>XF#7..!4L` MD]U-JE<:C:_;?3KIK>4FRW1&@]:H4]NAJE@R`GVDQ:_4E7"HPT"<>+\6&[<](-KP2^?U[MH8IL;B+$]$0P]H)F&Y9J MR@>=5J<^32?1?G27'*M-GAVW^Q*L@H!5JF;9Y>04<'Z*0)9(/8)`278Y:;*> M:F2%C'KFEUCQLM-MC3JRM%;=TQ,)G4+7;^FW)_(02H*U&6`]Z6)#(DQ/(E4B MM='!2;6G.++-B4#3.R)=)3=2)%(E4B52:Y^>2$@5!I7O)JW19"CMO<1F,[1H MG4EF(H!5X/!$-CF1^>>-KJHOS`;,.[4_:O4ZJCR)D5N&S=@R[+?[LN&\5,?' MJHY;([6^&$DL?!\Y>H]!&UG_/LPVM35AQ1I4 M*36"JT#AK]Y6N^W9;P\E1J5FEYH]J\",6I/Q21\4B#`]J=7%#=0.A%'V5]G7 M1,"^)E?SA6DO"7D@]-68DATO->$E[*?;V3V9VL^6\2^BW\$:V?"J?#-N9&@3"5VQTDJGQR:3TQB>LJ.KY$\X8:-],62%O^#-9]S)Q7R@A MK/E)>E<3]@A62VQAEY0%P?4@YK*E?-<<1?,9"=^!7_Q^*XYL@[)7&Y3Q0'9! MR6&`>L.2?0GA9G@ZA8$C+,C3#.,1==F&*;\P91:J3(Y:;?,KJK?-;Z#GFHJ2 MTRP?71@E#\:;Q$A=9P]",$,:CN-4"555E"]X\M0X-DB@[`^4(M7DA5`9$@E2 M94B5(56&="JE4WGX;#3A)LB+(M\9UF;"[HOM.9JE%[I:+MS4Y=K*M95J^BB0 M?O2B?/P33#A9/[(9R@DV?8(2HW*"HD]08E1.4/0)2HR*?NVIO+MM2<''/7&( M1JGT2J1*K4J0V+3:H]'/E"+$(UDT4GFCXW M+,-QJ8;7T$\Y+)6U6]M1XOW$\-[KRJZ_$N^G M@_?NX*3UNR"A6[7'2H^V"X&;LZ,FV2E'[J=;^C7KR;FL^,J\8%GO58J)%!.N MF`S&4DRDF$@QX<28PZX4$RDF4DPXH>GDI'.*CKG*>,GUP<4J1'[UEV>XRQL+ MK_\9KZP,.9:9RE2*7.W(6N2<V6/_X;R^? M3"W`"`MD@7)96E06*!<$(T=8I$P:CN-1";+:L*PV7#=03KS:L$2"5!D2*%)E M2*=2.I6-GJ`L8BW75JZM5-.GNMQR@H),4!8ME1,4?8(2HW*"HD]08E1.4/0) M2HR*?I&KO,MZ2<&'+%`NYO1DZ5).)N]0^"64"#UIA-96OTH"5`(T6WWR(L>` M$J(2HE*'RD(2)<4?LCZY<-.3%4I%UTX2J1*I$JD2J4>(U/IJH4JH2JA*I=JP MX*3:PQ%9H#Q]>K*@YTD4]!Q/)-PEW$\&[B>]Z2C1?F)H'\DVM1+O)X3WD];N M@D1MU1XIR=KDA65=ELF493+A9U65N[!23*28B.I*2"&10B(DLY)L24OMU+9_ M*`5%"HJ0S)+69'=@*BN3%ZQ,OGGSG;;$2UP7WS6JLV+=MPM\M?.;9GK^<([C MS?V_/2+MN,>Q5P))550;?WPA055TP*^B;196 M^4XH43S<`'%MA3BN,==P39"&6.(_4;[=F6/_2L.++TG!)D)\6R$6Q:X+E M#259M=]L4W,-TW"7=0F\"*DR(DRO@CUY06_J'(XE22F0M34%K30!\&_"STJ* MKQ1?*;Z%Q%<03Z3:^/K>< ME/O2'HZ/&VRF;A+KLIJ@<4TNW31L=[O*DFC4D6LJ)?*85D]*9)/75!#GH=J]A4OC MU=")I2N_&\2LS6>0\_[9MEQJ/'GL:_B'.QC/'8^//M)'?BG:)LY9J`B3OAGS7F)4G;A MW%J[+O[T4BCJ`46=SG`0H0A?GVU(M9O,A#YG2(#YF#ODI4>0!??$U%Q<=NH: MQ/GLT>UU29O]()V4<3="1]J8^]&WBU7#=/JZQ>F[L5[AKS9=?B,Y^#7B+=TP M0E!XD'P$[&+(.)V`WCCS^'>4+#1#Q^U'RR&YD3/A$#(8QN0X8;2").W@3;>3 M3E*_J^8G"=0E<7/+55?E:95A?Q(A)C).3B)V\2--V3*P]LCD:.LR<;(=D9P5/`ZG`\2B`@Z["[9LU1N^"W#/M9AIU.;<]R M'?#2T/?*K58X2K??BQ&1.%Q1HG;PIL=1N]U^$:+`E#_:^SDW/8X2[JMQYV'' MB/O0MHMI'-T\Z12D#;A+/:)_-;0G3'Z&!T$GW;HOA(;^E)V%''7=&W3B:\L? MO222=W&6YUT/U?U)#GV4&Y5'*D+,+F9QM'E_L@QDTG9 M;5TR4K.+.QRMOPQS9+8./GIV,4.CK(8=1*$WUF=M86#)U\QLX;G"X^XDYGDECUB8L%U\XCG+P_YP6(2P M>^)JAD7T*XU:(,4.F&YO[C&GZ)+,C*F1W=#T.6KU?#10>Q$:^8.70>X.E@XX M:OAY(;>H*Y/UC7B9(78CG&*[FQIO:\'96MC03>T/N3NHN/'+NSO?F0E]3P(4OXT.CJC="IX=<> MSU=/;9!FG/H@],/=QSR)%.SEYE+0X[9828RB:;P:`5)VL&D(<^:J/DI8I4)<>O6 M/PEP0ALMRQW([X60W_OC9XV^:E3_9-@.!!;6%-7\+V3^1*A.C*_D63.O(.YP MEQ=OAA.=39I9&0"#N['CT#122YA61*#WF%::(8)I'6A6_9(7*\V>#7SY/."L MREJK-$,X8`?@>\S*PK(9E"4>X#7(.]#F\`?MF:B9$+C:*[XG4V*\XG:Q/R?/ MP?=OO?[3\A-,_05[L&_/,VQ%%QXEX8EV8)[A*>XF>S7%%Y@O6BW=F[J7V%`Q MR$NX>*:$X';#(Z'SW&9S.#K[Z4[M_/[#^TSOWW+6DHNR4JI9S^Q+GY;)F2*! MM;WU7,?5+,Q2^>8AG]/4\C;D\`@LO#[X^S=M3K;7(FQ]':3(":_&S;=KT!&# M3J?7FX2T2]9 M$6#_6?9:IW"4LP_:NAFDMM<9C&(!<:XY'(@+>^&EEP$OG>ZH,RB5$7LB[MJF M,V*XX#@$WH_A^P=K$%:-GCZ?:SU5'?8&Y4D9=\YB,GDO<`XR@+,_ZG74!K,Y M@Z=2#F:'&32>.AP,^TWR4_)Q;R\PCC*`<8)^7HEH/"3__DGP`@71+UX)A>AJ MI;SOJ#%-/9?;!Y.QG;\_%H3^P>@-L[8+RK3=+=%AR3AI$7F]%X(G&;G=;_?Z MXG/;R>669N=XZ=["N).%[YU\X4UYLQ>=\?M`?JQFA/RXW3\2[J_>+@3RNYGU M>V]8(OMS\:`!*["7"/0R:_U)'JU?[QKLZ\77*13]C`MR/F@/Q@>,;(YK@?:2 MF4'6)>JW^WD45Y.6J+"[6HZ4##,N0;<]+G&7I6FA05F`'V4V$L-JPMN#<'O% M(L>E'K-A+"GL\46S`H*^V=8K<8",LH_<_K@G>&Z(M>78#NFOP&SG_N'7\/., MQ,?E(F%Y,IS1];I#M11)R,LD,5KEB08]Y7M1^ZW1 MY$#GBSG9)/3R'%2()AF.+H]Z@7YC4BNL_&0X,54'_6&WC)`E)Z^$7J/#"E&& M\]S):%)&S"+L&@51E,"BE.'X^"":;HM3HB_2864IR_'S2#V(+-6X4ERONR8A MRG">#:LS&)1QG"VNTYUG=0XK/1G.RT>3\4'T7/VK$]O>8"[FI>:2:\V@W)NO M!Q6KK$?R@W)V/DMD8>.6];#RF/7T?]@N)3FTD0N;>F[+6]WZ'4NU4T6JP:&X MV>QE/J@PJYU,B0TGO]#1$+2!\IPU@:+?'AUDI7,RM-DK?6"1SIJH<2@#+>Q: MAX[)&RC2F=(_#J6Y\["RP0M\8$G.FCYR*$D62;_Q[YA:K**Y4\:#*V8G/E%.K9 M*DY8]UP+Z/Z2-4]J=Q3!A"DOMTK6.[RV+4UF53EZ*L:O[*5B>6P!EZQM.8<%8+;6&\:MLC<,IMUN[Y8[R2@!GA^='=VMW`,JZ7J5RNR'% MZJ[6/M?ZG1U>MZ9>K/YRXUA6LO[AM92*=:EK'+NJ\'IX';!&HEFXO5P?;F\M MB-;KFF[&4IP'=H!XO;ZZM<&C#'Z5K8"$]*R3&56_]\/KDZ;6MXU8`K9B<^5U MHAB,Q9JK`-Y/]M9"C>-6V7I'R"WFU[5LD\ZI^9X??<[&VX+0$>,7FRFL<,^Z(-=?ZG1U>E\GN ML-D<*UO]9&^"V3A65>+P<'SI>)/SAO$L-EF.-ZRJ9:C:PBE&ZP2A"\?QYJNJ M;`N"*5*_V2:\QH2YWP-!U>^'17J7QCM^=$&.VJ,R\N6R3[E^+E<`R$A+UJ/G M,G:#N::$W`!7*7'<`R&YF\+C/O*XHP[+N!F9=&OA+]VJ;7 M'MZVPB9)FE5AW59UD*&JX1:#4K8WH#.\`2S9^S*W MME7C;,F??!]2=W) MWPS5TBH@U6]PEH.C&:J%<0CTA]R'N)T\S%`LJS3B0E6=<[`O0[DH#H6ACN`X=9BC>6BZ5>=7G,(-!&HW[O=ZPFT)@LI+*3-Q.]F4P0:-1O]L9IW$O M(W&%U.]<3,Y9 M7[<_/LC,[\DKL3RRJ[ER),LI-H/LZ6RK07(.OKN]O#KBY(;UHR?Q.0E(S/&* M$9`]9ZO@X&FSYR1!=7N99O_9=MS;6?!I?@!$VA^GLR`R4A$RTIC!RWWOQ^QR M05*R@")[9OG>9*1QA)>RWCO"A$ M1A9D9%>6>Y&0PHEX)TU.YF0*&:F)5?E1$N\SN2W`W4%,GZ6,7P:Q:5SDJ=Y^ M["I69<1F0%V\?>&V(A@>B+-9\,G+O>RJ_>+$[DYM*P!8CIH?1.G1*:Q MDV<$AI53F06A'`O1.QB1::SDY>6-"Q+)22(L@$Q>4MVP%PVH.!240W`*:R>\ M0D*3X?!P!&<`[(1CK$:3`S(X`W8GO/L28%WW(?@6PDPM!/$"@>2$8Z7Z\>N^ M6V,6)2J-;QQK-!@,U7*)R@(^CN'I=L8E:3:VK//P--AN7!-X*OVI;SBN&2.I29Q M-M1F1G^5]Y@;K]UX47H^7BLDOWY.I6&!8]*VY>V47:@=8^Y'6MH"<+R(JDC+(D79=S$K M(2V-:]FK+V0D[1MQ]_"ZNKPRNMM6+#)@$6I2V,,K4[MM*0I3DP%'O$*RV]IX M;VK2>,.SHEL:+Y6:*XU:H,*<5;[()\TQIK@S9YB>&T\7R(*D>&'4G:DLYYWV MH+>ADD-(.72G\353BPJ?[I%Z(+JSH#-KWP6@NSLZ,-UI_,[:50#H[G4+TQU+ M%(]D.X=2*O:'?7HJ']MB&O6C>TS%:*MTAFD+EIX%Z,\PMJ4JT`RSB%)ZXKWH M:YA!Z+KIF?-LAF-U6,$,6:<'O)I`R0NX,<8K"3GBX&X;S]9GCU)B39>/5+,< M))AEQ[#?3/\V@_X_GN/B81&8M-L9^$3YY917Q3*\$U$)R;4R)@T:'+\BMDMS M/+S)H!AXA2V/FS%IH.&$W\,:0),PP![J@A-Y;\=%*#O\6_%4I92F\92WX]\==$=%*4V^L5<`HIS0/=[G)'GP!38A>47IHGM6.4BI9")I3,]@M"J,LS2K'< MP/TIOIA.;<]RG3MMJ3V91?C+VUWN\4B.D5`6S2EL[G,,5\QLE4`RJ)5'NR1E MW<\>YN8AI())I"T!;ZN[OW4(6N),8/VH1_2OAO:$I;W@JQ")L!!FG:(0^JS` M$O$.>6,9=/M2>*`9IZTG+U-X^U"[U!F#)_Y92X"#%'/3LII4\B;8$XKD-_,BAI%CL6]H:U]ZU"U'@>1FQ]]J/O M(+--6<,R5$7R?04./)8P_B'\#,%A*P>#F>[H99&;QE^.U]"+-7?)3?,.X;@V M+/AJ!;IJP'$+MI"^'X$'F6[:^O&:?,;6K]S97LUF9.K>SJ[>IB]8"@U+]-U: M.`"8+_P'3=BK9J*9*VEYLV\F[$O<@2:;MKB\'IN1I2U[OLG?]"L$QH.'`@N9 M_>YO'D(JF$3*`L4K"VW[Y)-^=)'*G\L%"#2E2UC*A!*5D6(;W1CQV7%T-U;M@/LSN#M1";AS0O$V$3B>V`5J(ZD^>8UC$<2Z) M,Z7&(CB(QB07YW9V1XD#[V!*Z1&H_F06\FR&@[.?_M-T/^K&J^*X2Y/\>/;+ MQ?V7FV\?E,["A?^_?52N;[\]?E!4_/W1F!-'^4:^*_?V7+-:_A]:R@.(YDPY M^\]G]Z,2>]WGKU<7]Q^>;/?%?]/Y]<4O-U]__Q![U4?VV?YX>_`OK_ZC@S\GL?N_J"0.$B3/)##Y?#=GN#HJ-^H0_J&TVYE-! M4@(^%1[^]I705P/65;-TA8FK8L^4L,!F).^]2T,_(Z[$$+`U%?X4M/GBX_]6 MAYV/*=,2B5[XP0BO$R/66)-=V008QFZ^75XAV9TV('PEY<4G%>6]^`3?@0M' M0>$HW^Q75FA945L*.@0MY6>_'YERL5AHX&Q[CG)/GMF-[G8\_7]P_KG]5/RHXQ@M10D]@)H=F+4,/_4/YKCF*ICP% M9E9QR#/;TP1A7=&R:8Z6-.C60^&WMY5'H"`85@$=0*QG[9GHBF$QVO1-W1&F M**;V?$[HU`#CY==A0SKHB@/P/9L^:Q`?S6!N+QZP5W$Q)6V!VZ#MAJQ^X^#Z M8&`5(&@I-*A#PQ`00@1^,J6>@1NC"M"F^074V6,N"H(QU4S@ES:;M=@? M-;8YCD_;JX,+17,,Z#:>(2Y_CMQV@DO9I!_(L0"K#K@8S.4 M`?J`0]X,(@J/(1!P;$R)3Z=IS,`9#KZ]0CNA_H=@`D#_=SK*$OZFLIMU/71H^CM^5RA``W M79V)((1<[E+[.K8%*AW\E?\H,[)4!]'8PZ:+LNR/6`$:*&%89W;LQF. [3&,D<`ZA M#DX,%I4E.AO,?=%<10?H1^WF$YEJYPE M"!'OJ\]$/>N[8^LY18B%4:CM/;_X?AF6+0H.Q5"W),S4P2,<4-@Z*C+@#II[ M_*I_FXFM$#OJ\1]DDIZT3)>AD2(+)95`)?'>[E#\T,%?6?S?FF)L19H9U(;C MIA>0$9NBMXOB'3*DH.%V1FKHDEBV&]A;O!QXKIFV158ZIJU<@_>Q8,<)J#^" MD!3%\416?YQ'"^?@6, MA?X04]LX3B+%?@S!LD71MX+HPZ:ZD\Q@!37O,WO79GF"45$;,I/(WFB&4O4" M+1@)BR-.52)=`=5@$GR>K5E(5D7'DDG45BU_E9611(=S2JBK@=LW`POGGS8& MOO4.H]$*AF.Q&BAJABK3F!O^BUN*;YA,91T`;.BB?LHGCD_>R-1CU@O[/*'3 MV@IFBY813[$\=/4W+S'8K1W%U=Y:0:P/@+(]RKYIDF?D4?`FQF>#)='`!-F@ M.#'&9B=$SG<`8@)7;'\S8KUX+T33&0J`,!#,=7R[>EY;GWRW<$5PBQUB4_SF M)N[<+`T-H@H@B[Q"=(P!#,R5.-'-$<"V`;&O;^VU36\['Y4^S>QW#UP%<-)7 MZ$M&,D6/07-LBVW$LU'4UV?:G"6)!T*/JL(? M!.#C;NY`;J\&C!JAH2A9KX_I*5A-;C<`$^;OMF7J(20$?-CMC MB[35+[EG,6^)UH[]#@4 M5'44-V=)H%`TE'L[V)W;O0%H&G]YAKY1X/X>GKTR`/[>RR;]!3X-MH1\(+4` MAJO='N+#);#3/FS]72A4[A%7:0YF#DT=T5O!WN*3&YCD&#F;)Q403N11`@^> M(3Y:@.5Y)>9:-`)+O!9;)(OIGJ`S#=='2ER6Y%T@U-KZBJM;DA?:\F0BQ5HK MKJ<(/[#$X81APQ$8Z(J9"UA(]OER3B[0:6GN8D0-)"J->."-J(C&S`OOR32F ML-R`3)T5X_#]VX9(9N-4"2LPXLM34/YD%?*'FC*A?+#=`-SD0!$EJ"D"]W43 M&>!JFF9TIX!L"W=DA]U"U`[0H:!'`$4<=2^6ZX+^%`#=09O'5A`MU!+(+69XKG M51O-_*O%`A;6FL^)'&%^N;BX.^S64_-P$R$7.`KD^O_B!_MNV/QJ:1!>XNJP M"I[&7+E>`^6&K?I!=ZD:M"PEX^@Q;N2-8#V>-)/Y:T3T39BM M\580\H/JQ$FDD!=2-2LZ]AA]->#ZSQF'*^WUEH<+;.V+O/CK,/`)>.1ILPT M@VY>'7/4PGI_`[`DSV\;3*W@T"G),!2&B1\"<"FL!"3MF(QMV`#C:.PQ?X_( MV&@[MNT)DK&V8`Z+.**;:CLXL8[@\R)WQ?/"7-[,D[]YL!K,WQ;"G2.V`;(: M&\_#<2P4X4MXR3P4D/1Q-9=KIOGBMIHT@A./Z/RM"/::]4[WMFU?_;))6WW" M#2#*/"GOFW-26X.Y^F!EO1/^8*2?53TE=_Z2OK5?X M1[KY<97IN,F?SI\*O55,"-,59K`$EGNQ=I_N`.X08CK[)%`/*TF@/MHLXG*R M@5=OVG78SC?]:U>LU'1P)7)FWXWG(:\^*"DIN4PN/'CS.=HW4$XA45$VLJ*L MA(4IO'LR]?==@Y;.X>>H[:<0,.M1A`,'S7MF__8'[=X`3V0%SX&NP`6^L7Q[ MYIN6S430#FUBD=#Z/N!&AX:G@Y]LW*>+7!7H3RKN+AU__P48X5\%L MAEKNX;//1+F"+[)3PG>/X)E-E8DZ^,>'<*[$%9ZZ6>NCD<_!0=Z&P'NRP!;& M,/I]:+N/9>WZ!WBX=W8!?]39L&!X?P/#S+3LNO7#FHHOGN%[GC"$3]`8Z?Z\ M=I"B&1NKXUT8U%X=8^EDQM+`?'JU2+JOP^:,&6ON),:L9QKDVB0/8I#UX<\FE_7#35"ZTUBX?>VAMY%>>]?;W-@>12/3Z%&X9I%D'FW3!.]<'2YA,R+PB M=F#G+P`$$98-@9CU3&C:0C$.&U:P@\Q2%L%99P=3&+SX7B0`G>5ZLUNFZ.Q1 MXE+;6?B_F7[\,`.Z@$OL%:W@`#?JQV'$PXA&ZH/GGLBS8?DIEVRC>NT8HMRB M;$4/53%5DP0':\$IX!Q$U4#$^ZF.VF)A!M!:\=F_$^LD;ND7".W\R;&0"0*J MP"L-YBBWFBKT)-%6?\\(;V_!X[@ M=0BF[U*7I=M^@[&4[BIZ2SN*78=`,$(\`NIM'3TE;;A>^#L"OEW`C8-KT'+` MQ//_J@1Y)X@R3"AAD>XZRR/P"0./(`1"9VW0?$V]BI"7@(Z-KMSD4FQEAOBG M(6"E@`*VQVW``\%V>Q*.FASL9@M55P'NBT;=#U_9J2Y8*8B*O]CP.+@J4T*M M2]\"@MK=)\0=R1"WV2%NKT&!Z!K*XD6.$37:Z[2'PN=05YV=Z]]^8D?.H?-H MQ8E>FUOGUT?CA=-BP25@GO&%2"-H6=I-HG0$24+#KD@++82O[ MHD:[DWQ5@^V:KR^4L!U_=RO=Y7*3J!??Q$[<;D[D!;ATJ-WPC6`&2YU>I]T; M)D]O';F2-[RXRF*\#9R#NP^+33IJ^#+LU"^!RC;&@P)PBA/:=]KD)QE6MJNR M"VKKWC3P(+UPT$?`8[V1 M]3G1F MD5/CAM[[>Z1?0*+CMT]^^F_NTDCAUX;'IMM MP2WOR3-K'F^YW_"D-_^PO;.?W_R++`O3USW[J M=#KJ8-@;#@?AH6.O#H\=5(W>+%QQ/`[.?CH_5[OG/=4?>]>KMZ=^;9B$?H:/ MGFU:9.+#LY\>YA#`0;BXV;$-U&^8#Y%QPF0\4@U5W,-R_F2;!0B`6`;S1_VQ M(B]+6.=-P4;6$L0)]1I+J!8U_@/^ES!D>M.ZFV_7V/&L/YP,)A$DI`S.2/WA M?YV?7]NVRS95'H*;!##(^?EJ)J9A_?EA!H_@'L]7^$5Y8W^B-EJ8%]==?'C_ M_OOW[^VW)VJV;?K\OMOI]-[CQ^_QP;/@>1>T[X]G,%GFCYS]Q%[^?NOM\/J!P``160``!4`'`!H87)T M+3(P,30P-C,P7V-A;"YX;6Q55`D``RC2ZU,HTNM3=7@+``$$)0X```0Y`0`` M[5UM;^)&$/Y>J?_!I9\=(+E>+U'2$WD[(247!%Q5J:I.BSW`-F:7[MJ\J.I_ M[ZQY"3;VV@Y0UI=^"B$SZV?FF9V9W;6=RX^SD6=-0$C*V56E?E*K6,`<[E(V MN*I\Z=[;'RK6QU^^_^[R!]NV/@$#07QPK=[9<\](L%"8$Q>58:^/[ZH5I7\K">\$RX&U=-:[:RZ$JPL)"]FDD:DIV'CC.$$;$IDSYASHN6&B9)KWY^?EX-_XJBDE[(4/^!.\0/796)RTJ5 M4+_9*S%;?66CP\[J)S/I5M`'EG4IN`=MZ%LA@`M_/H:KBJ2CL:>`A]\-!?01 M!1%^Z.;:^[.:TO^QR2;`?"XHR(JEAOG2;D;0HLJ$")>,QP2Y#*2``3!%0%5) M5R/Z542S(YX;SB3WJ*O"YIIXRO>=(8#_.G2:T?:`=4/D\-[CT_T: MM#'J&KM#/"?P0C,?$&G$!ICYP%QP5U:HP?<3O^&\QZM[W(EF%L":0\(&5>5.ZO@^7+U3>A@NU9?II@?EU]_;4@9SIS%R![I@1=> M[VM<8.6:8\"["81`KC)1KN4VP&XPV1!1W$0XJR'QXQ:-T82]E*C*8#0*1[,I M1M!*OR_X*-EORPMR+=Y`XJ7Y6`U+O(K%A0L"*S$6XBG0P=#'S\=B0,T.C>,7 M?S;&W[%(B;M]@=9@;]\&<(^FM<%3V:&%F1$+2';XZ]7*PH[>BF363DU@;57L MYY]!QU)4K"RL1%$GLW!F`@LM`6-"W;O9&-L1R)XT*?)EX24%?C)![TP@:&'6 M9\ZVGCWW\W5\!':M^6)_!]&K&4+0= M8MN31V=([@8!+:W&E@IO;@7Q0$F/>E35:G1DQ^?.\Y![Z#&IG.K/->&4K7J< MV;&!*Q]Z(V(_+Q'QN1"QP^#>>`-G=G%/$C:+HQQTE&%]V'`<'C!?MLB<]+P< M;5>:@EGL9#1?:4883!2NKKK\%0O+5*52$:8SQ.`^#>-,!.!&4_N3/P21KT;E MU"\5E3EM,GBE6JA)RFB+#."K4+>1)&GP!,15=A\P'!<6_DJ\`#1<)4H;0%9^ M>A(M,+BJW?#1B+-."$;90&)]#49!V"G=0I\Z5-<@YE$N%8-Y##)YC_4%;M@2 M10[HF\SAH_"8_C/X3_TNF>E;QV(CE8KFPM8E<_Z3,7N""3><'&$S<->3L&-` MO:>,RB&XGSAW=6NI-`4#XC[)[:GG>#'X!C=W:\AM,GW$J2HH\7(Q%)4O&T%1 M]+F[/`,.(PK<)W:$Y(2^?\GLFC"*R1TK]E<(U#T1Z&2?L@`;DA>W7D.?BV6M MPA(%\F[F"X+Q01D1\R82$1Z$H2;RA/@&389!!5*?F`]X50/F86((;$_$`SK! MX'2[M$^AS3%+$J4-H/@_F#CQ@$ETA<%$?Q*(L"5X7[NTBT@90*PF/..$1*`; M3$0;L.0'VAW\%Q$#*$@(G.WU\PJOP7Z_X1+7=4NHVBW#B%PY&(B!SNX?[>-7 MG.5=;+GJS8NL`7P42$H)!IC,31LDH#>&V+W?8BQY/+P_:HE=F["T>B9Q%H^Z M[5RF-<7@!->!L'%!X(]$/,.&L;J31HU2F6C3V6'PFXVVZ)OL5`T#*"NP6$XP(']M^W_C*ON0.WXX MD>,`1ZMUG/FQ^P[9"#@KB,R-FA,'=@NX$[)X+A,<6]V0Y\ZX@3!(G]#]S MP]^6;+A_!M)?WD*?%9J'NF`Y`^50WBCKR<'+`]G'R+5X<97W\8[L@4DB:[)7O?R@ZT#=+?5%'9-_) M>;P-^&U;(N_E*A`,B>_S>@/<1^S.OH'3)*JC;W M>ZBT$.E;NF^(]2W;DVG_V=B27_RYW&+#O*%8*/Z<[PUS_(]`KS[ MT&\H?(JZ)CFDSDT(J127J9Y('F)W+_?`!H33`7?W+QF-<4[]Y01YAP@F>0>V(#(.6`R MR>T&@S>YT"8'P%W?C2]H+PA1JR^P1%*XT_3(P/@/??@>7`!_/+7 MMTFX]TJ2-(BC7S]U/A]^VB.1%_M!-/KUTX^GZ_VS3WM__?=__9=?_FU_?^\K MB4CB9L3?>Y[N7;J9^Y2XWN_I(O]>YW/G\\D>_4=W?Y"/]KN'G=[>?QT>?>D< M?3GL_??>_]Y_^[^]J\>GO?V]GS]_?O:AA*PHX;,73_;V]^EWPB#Z_=E-R1X8 M%J6_?AIGVB@>WAX=+!(^&F6\LM;&JRD_GFT2-LY^(]O MMX_>F$S<_2!*,S?RWG/18ECY.OU^_Z#X*R1-@R]ID?\V]MRL<)74KCUN"OI_ M^XMD^_2G?7#84>?S6^HO[8(T?K;\3+F`XX/9'S^!N_;V?DGBD#R0X5YAZY=L M^D)^_90&DY>08BQ^&R=D""6Y258P/)"HK2`]N0^ MAR3]M$?+_?%PLX(4RGAU$]]]>7&A'N1I0D8DHN0=T-0'X@(/P-Z6%M]!37L- MR,]!Y)^[:9#>#>\3DI(H*SYT23(W"-,G\I;E;M@(0;T/:$!T$4=I'`8^;57G M;DBKYN.8D*P9`8+2--AZ&_R1!WZ0334XFEN6!CMOHE=@+$X"DLY+;V0BJQ@- MUCV0D-)S#W^80O\)C<2C=2O5X%35HO746P^\D[BZ;!<7J,%B=N?4IH)(2C1M M_T1WS5G?U6]TU;W6;FJU6L,FQ!#H$:%ICD@5>\]:I5+1F%(\P[I()?``& MXKL7,N\<8'"FGDS(&)P9O)+;.&T_7-;YE$&4%VXZO@[CGWH!E4K58/ME[.6T M8'#.593!&'X3#>-D4GBLD=GB`I<6NXFW,'K^S_)WEE/D(,H._&!R,$]SX(;A M)SE*]F1],=>FL_3C`GQ16EN3X-^T/L71OD^&;AYF&@UDE*W1W'CB!I$9:^=% MMS:V*&=_0B;/)-%IZ6JY;QM_+1D"[WXX0)KX`V=-/G M`E^>[H]<]^6`=I0'),S2Q2]%U[E_V)FO[_\R_]EY!'O)^;H]@P2F[:.BVSZ? MOB>Y=Z=%__@3`()GR`WT[.G"JM!])F%AJZ.O<*=W],Z+LF MH:\O*&!@4AP;)JLU0CQ??F5?I6H/',(DG1MP\MS%N@#M/`4/\ M0O](IU]QXI/DUT\PC9\UM2]>'&708B8K/9M4W,Y7;RDQR?8029'%Z'9..9\US^4XO56_&>"-#P7;\L3;' M7_V1%\L^*@'",IM^'1(=B5TOS.3TNMOB?#D.MOM/;'5(="_-ST-R-U08`*G" M=0[&_"Z:KS8JT.GU[%-L9`ZHP2_L*G-JO\I)1%/P3W$>2((9T:9;6JU6:O^GTCO\T%<^$Z]AU\\Q^W60[K)`.[@IS MT]_<,)]!3M-\,ONM53?7_$-.[^1/4PNU^8M=]>:K27#BP:H$M0%AJE;(03VA MBCW7$G]0)"_5R>X23&!*2#5=B1CUJB*;!(+O2=0B3@[GV*0VH2X29T*9,D,A54H3IG6,$(HJX[2A15D*C3\G2H^TF ML4>(GUX#[`L8B9/@.2_FKO2'67"-2/"5YW:.+8HD+>=%1)!HCL]/[)P<6NO,%L;PYOKLA,[QJ;6M8;;[.+U5U>J=F+4O8%V$;@K- MOEBNR^;MO#S.LT)0C81U\44VCGX($UAJ!\\I_24FV@>MYK0.4&P;UQK`&/8CVR>/;/P M(D_H9%&9D;7TS@F"Y1##UR)26!"0;2?3Z'115P9_=DZ.L'B>Y5!.9[4P'-E> M[&5.Z,*I=%HL(`M8`AY$V9P3!%OQ=?F1`D*V3[DXD#C]3D0\E9,Y)PAVJNOR M4@$@W+2SH=F0%S?PK][H?B>1-QQF>N<$P>YM76;X2#CK56N*P0HRU7'>.3&I M%QCBI(J`PT7'HL8)J^ML2@/;BC->?^3!"YU:BOLQ43;GQ*0:H'LF)D7"87$>T;L'IE2`5YCD,3,XIP@T!8GK.7TG'P^' M*YM:PU/<0&G@9').$>@,C3B38.+P9DUK@"J6Y,1?[5SNLC%)2C^)FYP\OW.* M0)UHV@(5X7&(M29>5.'6&OJ<4P2R12/*.%@XN[#6A(N2F4KK+V9ZYQ2!D*%W M8K(&CD.;-8U#K5=G8S(OZ5FT0PMJ:P M:,PG>:$`7(+#O4`T:<#IG"!231N1QL'#"HC$H M)LQ)=(MM.N=LYW04/DX.KQV+QZ=XKP3HN`;AO>P@I:=E\H3LBM9(GZR?M79FIY0:7/@;I2-AVE"@K MH3%R*BLEWN=1_`I+W&#&$/QCG1CXR;DE(S>\*AZIX0Q:C%1.WZ0$9&2@XJ$P MZ=B.1IF_L*MS:#$RI8E\5QL@&PQ*$(7GP)HXN-;5O8-&$_W6KAO;7F.7;2OP$\, MWK5_U<`\5%IV[QHS/0`PN?@0WK_&[I@O,_]AY6-RA0 M[=CF0^?0[@)(T>O*HG:!9\?V'P`3CL63`;+0;D$L^XUK\'$Z)O[7./:51N>5 M#(`1P5F`AD,=`PFRG8>EJ0_NSV]0*9/`#95(*J=W.AT$@?X-.:H"0;;1T.1* MJDX'001_0T*6]@OW"JRL>4IGBZ=/B1NEKE>LUEJ%3FF*@V9:IK(JDF5U.A8/ M)"U?)^*Y_GRZ\A?9W=5-RH/::')'5;C&4B.',Q%O#O9C15:9F'5,KK/KW8W= MG-?:*[8./UA\:U<#':/!XCI6;!WNXIJ'9]=6;)V3K5FQU24+[8H-5BMNY,$\ M^"9*H>,NG@`4=Y><'(#2I"ABM[,48D:VNBM@#DE2G$@H'A<-HM'=D`$AI0$C M*?M/T@:L\S/@1Z.;J>'E M^>/&Z6"4D&(D%3\\+\T(.!`(@_J;_&H-J..++0S:ZW2MOQ6J?:+`Q;E5<7V= MKE$%L5%@7^'%JK.K=F]7:!^8C&.$:N%S(]%]["'E;S.-]CR(4R\@D4?/N(O' M$GX.,-UBX!"[\C(&`!D`;`%\%W%:W'@U?\0@+?>;(B%`D`V`(KB*HXT<*TF"P7 MMB59`2^.!SW5B%$EE042V_Z$65)Q3.%F< M(PS33[6VQF92C`S9QD4%Z#V,2_"#.R*=.FVSE`UF)`ABHC3-F"JX]&T4L!?= M]TGLYUYV&:3+(T=+#?*))!/>TEN6#ZQ'<)UI/59J`,,7PE9L1C^[,$FFYP!A M""DP6SS!\P@&D_-U@P8)K*Y'A3?/I^])[MUIL5_R$Q"JK/S:%^YT>OKN'..8 MXV7!:\`/7E/-"E7.VED@78YFM#1EY+NP=BQ\HG!=STHZ@&_]N%`]JCA3E"HH M9(M!:35/>?7\'5ODTS/6+A*YFKR$\920TOTQTC&0(I!) MZ[1$-J\2@%9C\1K&2O9,*J7&1U,NI"T+UNL9?=:I65QDK_(B*]MN,S?O&70U MCK&FA<^E<9'V+MEK?>MAIV=Q2Y1=P=EC`==X=)?DS1>=/7*D4^EUV:"'X[QQU<-B)LKF<[BPIEZTX`+'D-*>%.G(HF_SOQ)^ M3JVI&7+_G@6,1_#B%ZN6,S8?I3@XSM=W@FZVZ+DI`A2"U^+[D.A(['YA)C`< M@42K2(`"$@X%UM;CC??"YW>_WN59FKF1'T2C[[GL00+=WW(ZQPCN\C(33F#8 M:9QZ:.]1S98POT+"++V)[DD2Q/[7)$Z-A-KPOP9N1:!%X:Z+7+=Q(B>L'7ISRO^08+1."/^X)4D M[H@L&NQ]$GC"^PTW8P&X'\.35ZCK<"U7N`!4;K%;N6(4`&`L$->=UNX%%.];;WBJSI69>E24DKNX`J M!&(G[JF*!@=SVH*]UWF;NF2A-R_O9KO+QB1Y&KO1W%G?X^B5I.`,<]IL71N< MSLF'9JO7F9SZ;.^A8F/P5R=U5JKSJ@E`P(?JJ]67G,J\?1MD4O2_%0W9:F5> M-0$(V'W9>:.^Y%3F[=MEDZ*?3\LLU^>*%4##AX"MVYV:MH(%'XH]IMU-J>]X-V!;3L#I6HOSL92QT`@[T/>WZ"G M.B1SOMN%2_QN(NB,FI3D$N<(U)R:WA.TG:N6=7-JE?D-T1R+%7>E11F`^0&CULK7R*5,I& M+1++X)!=QF>,1EP'4$WQB?G6.P)^&@\B_Y*\DC!^H0#FC_*HW'TGRPWH$>C" M"@V.S:PR0F07VCV2$,H<@=G?W.1WDL&_54F5906\".3+QHRJP4-V=]U7$L%" M-`2C!_X$G)T6M[._$E5.E?(#<@0Z6V-B:V!$=EU=HXM.3M$\?;3Q.7#5$0J@X6$U$VW\A=/E/.9BZ#34BL`P".(4=N@(EO' M+0B?F17NX70_GB5B[!?VFRACLF>)RM\J7QA!=P!G-J9I/IG]IOA<4>TBH9*: M7&T;?\:H7Q'-]'AD%W9&EHO87+TWN?JR(;44JDZ6$UZZ7-7_=8V$EI0@:NO:\Z)K&O3=UFM;C6L MCU",Z;,?!);BT*?8;TX,ZR,XO*KH?P4DR(3ZQHO-94QN:1;V-:4/XVN!Q!S-46=:U\)V[;1MX3E)Z#I1_;>97*U&UT M*RIG.X]R4#%'O%W'S^)T#TUJ4J:WXPK'LK;C9(AW8;NMB70,1>&0CF4$*4C# M!19D^V1-]V'=:""L32<"U.3.QZ"4:EV:;/(/+7 M=+K#0[%,J909\"`(^F+5>][XHX9(W][61D3[[B$"T4^1!2D.?9M9&Q/MNX<( MI"M%_RL@079R1?8RO62JI9(=<)N4=(Q/P=0Q(CO$(C-<.D]0*P"P&U5`E*=R MZD0U([H,%]G>VP:IQC55W!SG1@[AZ+V?YWT.)CU/RLT#4!'<0%6G*;*)E0#$ MMHWS%&3T_"4@IK)H[H:2@9>9'J`AB9-K-M(*0&';TZB8^H\@&S^08JO8`Z83:4];\V2G&X'1TR=@"Q%=E6`BO<$_F2\XQIZ-U$!I(.NM3#FRR`A M'I0M'6E7$P(H!#&`C9HBFU06/`Y7UL*7'^C^BF1`7:8!"":5:>.#Z!H0#A?6 MXI<+\^3W$KVG`AA&95#E`6_-L0+OEPWG^-^:X-/(_[@&GB9$2`<2:RK--W#B M))](*5E)!Y`0J-*5RLZF@F$YAP1K^LDW]TV-A'(Z@()`FE8EH6HY9R>YI8Z1 M$N_S*'X]\$DP\S_\8]WM\)-S2T9N.)ME<(9F1BHP?"NU9"X4#@P_"W[L)/64+3=>-IM)> MGY$:X%F42=D5G-WQFFL.>XD@Z@;+7DR0"S=>]P<]\B?P<7^F'."UOWM/5V5"\<@S6:>B8=^NT)("3-DH">0"BZ[!_` M3_KP^$/EJFQ^/H",0-8UUVEP-!:Y2S2^U1W_D;A@,`^*K;(#+,X'A M"(Z);XI+57]H?*>83>0R:JY\G8J81D$6,!I!\.Q&291Z8V<>Y<7SLFC#)RV[ M703"H9G32%9=NC.OZG[/*7=WP^*OZ2#/QG%"[U$U48=YWP*7[L91;!.U5.RT MG7FMEMD8OR9Q:N3\*/]KX-;=.&6]L1ZSY#9L;\$"O$D<%;.4"_@'U.@X#GUX% M?NZ&U-;',2%9.E.UQR0+/$LG\)?OVZB7N5DFP(AA MR=^:M3(:9(?_6>;>Y5F:N9$?1*.:M)5R`EH,B^S6W%4@(3OA7UKH-Q@#%7(# M:J,/6IH@4AD6LC/\);MK#'V"7$ZWA^#UQ<;DL>%@.WQ?,5@ZY'%R`#P,(23M MV"I#P7;$OF*LVE`GR@9`,82*M..L@@?;6?N!Y^63/*2]^"5Y28@7S&]A?0E) MX>K('TSB)`O^6?Q^G\0O),FF-&PB@[_16R->YEH>CV1=GP`'8@@[J54A]&)' M>(EO>1-AZ9KT;G@'.&8GG@$&W8=)R)B*+*_DEFYP;N.F0L_>ZQ]--Q5Z]E[' MY#A0;5.A]_&&)4MB[%E_PU)$6.U-A=[NO4S9[6%_F;+PNKI.W=N]ERD!T]9L M*M0E"^VFP@-Y)5%.A+>$S),XW6.D2VO^`+9J.S+IGSX-3Q^,+TP4KL9*Z0`) MTB4SGP4&`&0Z?A$Y!K/\82!:,952`0JDJV`^#17SD4GS\[5)-*+/I40I20?/ M:9:XGH@2;AY`B'15RB=(`@:9$$\CZ\`=8UA(7D+3#N-B13PW73B>"/(!4@27 MO$B(X(TU4ES(U/='$D*9(S#XFYO\3DJ`1>L@;B;`B"!RH!%W,E#8%/BO)`*4 M(96I_`GXF"*DQZ#D]$ER`EP$<0.-.%1"ADV@KR"M,]8!)`3A`HW(XF#!)L,O MS;R)O'@RTT@5"'I/#;`01`6THV@=#;;[:=_MNP;D%W$$1N=@][O6?4Z&<4)F MZ9[<-Y)>O0%\,#R(W&1:S,N^QQ%5+L&K80%Y]@:J@&R#7P4W(XA`:%1IC'L% MVYVX2R!S+YW#*"1>17)R.-T3!/)*"](YB+!=C/N=9$J=^4HZ@()`=6E$#@,' MMOMQK]PD`E3I(E3IW$T#CRZC@C#/A'$EDIP`=^M4&B5(V&[873NKOG)2N!1K MH4YLLP+!.5LG^K1!BNU>WU)8Q5TV)LE*@,%[+P1=TMT0A@L%?:]AB>`>!#)2 MO8K0"BJVRX5%"*YA_A>,HHL\24CD39\2-TH!R"SLIOB_V:7\`_]_\C2C_EM@ M%JV]C'P0G(M`#FE5,SB+.X/N,G/'`V%X5,$,0\Z M65%2D4^Y,1'61.3WU6CZ%#\0F+%Y04A6['Z*%;VD(DP9^!SX%8':8+XRF?,= MLHA&]I5WHODX,P-@PZ`W&&.-,YD7^`)9*&3Y#*&`W7(RP($@,&33G%8]@"PD M$G`G!.K<)9G]MX1T?JVDPMB@7@CX`$&DQZ9K05W_8(N^K-I_F1,:[U(\)TPO M+TV*X;$0T.M5%%%!3O<,081(7?)4JX`<.;;8S2J&F^@5K(V30!C'*3[A+RX@2^/K)9E!<`(@E%,,?%>42O5IY* M=CND>0$R@M@34_0RP2*,Q:P.*G1&HV%4YA0#CD"@X1D/0/G4,D`U0BX.N[5QB7KL$>(OSW@FP7->F$U_F#U3)1J9Y+D!-@(5 M5">%G"%)U16<&F!-)RT;OGA1[6Y8NF=7D7]F7H",0"G=+/L"1W"XMR:CMG., ML<$"G(5`@#5?:W1XB5.EK"FW5\,A\;*[X=6;-Z;/03[`2'L749CTFF+X#YV: MO[HAG;[7K%1MBP:'(5!XS5SE MQ4/`D7\%?4XVO8F&<3*91=HU/MB7$N_S*'X%.,&LAL$_UBL6_.0LOE[ZZ*W@ M0)\LBW/4-F:IA>&\XWRBY,[1H4EIAWFH3\V)JW5=CN'C@-_Z<9^CKLDUEM(! M/SEM["Y-`FK'COD==8TN:S0<\RN\SAE].'AV[)@?8-J68WZUR3)\S$]U2)L- M_P]D5%SL&67?W0EO.&,EA6'#XM2MZ:#&1V+D\%P]+BX`3.*&-S"_>_L[F0K) M6$L+&"SN.+=C@PG%R&$X53KF,5G70>JYX7\2-[F*_$MH_QQ&>,D!B<5]X*:D MB-$8.1!6KYEYQ. MGN.00\%*&ACW+&XX-G4^`X*1XU4UAXEZ;U"J901T%C<(6PX@4EQF#CS5%0^> MH%B)8$"3`-@MI***P,SQ(E6G#\`8GQIT';J\9K&2!HRVN$G:U.T,"&:.`-6M M[#.M6SQQ8J8%$!:W'=M6?P84,Z=VZO(QF\_-S+N&WV1Z:R4]@+&X#=.6%PX< M,R=NFG%#Y]KJS"Q3`Q"+^ZEZ>%D#(SX&P]PW^>6`?N+934GAB/\'4$L#!!0` M```(`"Z(#46R+RI/ZBH``!"&`@`5`!P`:&%R="TR,#$T,#8S,%]L86(N>&UL M550)``,HTNM3*-+K4W5X"P`!!"4.```$.0$``.5=ZW/D-G+_GJK\#\C>56I= M-=K5>ET^V[E+:O3R*2>O%$EV=(CG;G4OG?@P?)(0GBQ0>` MT7YP63M$`]V-7S<::#S^^&^?US%XAEF.TN1/K]Z].7X%8!*F$4H>__3JY_N+ MH^]>@7_[UW_\AS_^T]$1^!$F,`L*&(&''3@+BN`^"\*/>44/WKUY]^9;0/[X M^FBY?3SZ^OC=-^#7X_<_O'O_P_$W_PW^]^:G_P/G=_?@"'SZ].E-A&LH:`UO MPG0-CHY(.S%*/CX$.028L23_TZNGHMC\\/8M*?_Y(8O?I-GCVZ^/C]^_K0J^ M8B5_^)RC5NE/[ZNR[][^UT]7=^$37`='*,F+(`GW5*2:/KIWWW___5OZ%1?- MT0\YI;]*PZ"@JE+R!80ER+^.JF)'Y*A,3QNEO3QE<]7,19]E;0O\V@8^DLT@+WY,6WGU+6OA=^?-5 M\`#C5X"4_/GV4BC0]ZVZ2J*WF$M;?-[`#*71>3*,X2ZU?<[OBB`K1O#>I+?) M_7U:!/$@OIN4-CG^`(?I>4]G5;_8:<)A^FU03LUQP7-KK%1.FS'Y]Q7FH<4= M_%S`)()1Q1^AEOA56CGUQ]1%DFK3L%5A3)QSFO7*2^M:!?D#K7";'ST&P>8M M&:#>PKC(JU_HD'5T_*[TQK\K?_[M,GF&":Y[=X;R,$[S;0:7#SD9O(JJ.2HD M9>(W+:I*.Y5^6J)D,$^W60B-=,.TWN8F>-#C!H^&F(8,^C`Y^OGNU;_6I<&^ M./BU(OCO/[+F.C(LLW:/!%E8,83_5`A1EG@;IGA\WA1'+7E66;HV4&[)1&J@ M@69_.`76/3:,$]SD1S-D->7-=/NIBSFS3G*/.S,W M9U2+-VC4O$S3IN"X2S7O-'B#OGH(,G@0YC$[3]09BSTR8U/![*D+K(%1*TH4?)3@B MR[$1:))XY?KT^J>+.)/.L8>U/>RO5TV^RNC@-,V+?,_Y3;!;8ZO)=?SBZ)JM MHW6\+KIP;KC.=-4&=!5UTEH7H`G\JF;/W.U$4.G:Q:0XL1DUK->HH+S@@`8/ M)P5*'F$2XH#&:&G2L!X'<829G'Q`4=/3B+95@Z]+FH,ZEP\Q!O>L9S#6"X/- M*O(3R/+06!?)7KGM83T\",S.G3+96Q!M8SR2U$O`I]LLPW_=!P^Q%H[UJ[`? M3>M+Q\75)2D)0VKB!2C),6))!<`KW)KV)1=O#^I(+:P&64$1>/SM^V.*/_*+ M*,`/"_2,BAUMM`=W^J36\&8@3>_\#9SP\[>*L(2:`%^C18K2<$N<%&UT6M'N MGU`."FHG,<(Q*2B>(,BIO"QL#YOR!F5M;\#]$R%(($`%7.<`19@]M-H!E*S2 M;%V6?DBWA6:%[BS3%.6510Z#N+U1XP;W\X=@#9>?42X9&=K%K'O_#I==>)+/ M@'S'@30NX8$#[U-KUTF+=6J_^\_2=8`XI]$C4%70&01J3B4@8&4\@D%;O2(@ M].EVQ)C\YR![#K+H!*4Y#E4QOZ2=G^#Z`6:BL5A*8G<,EG/?[?RR--@7!Q0/ MOS(*AU#0[8K6@*'=#R/@1(GRW!O0!*BGNRX5CY72PTM_XA,9M&=I/NZ'C0$!>+5H>$0<&$!Y^M-G.X@O(/9,PJA@/DX M+H]'7:]N89@^)NCOU2D6FD\S,Y+)VW1H1]/K3V9J56N@;$YF>W6;A'#?*F#- MLCRQYX8Y$SC%MCLK,MT.<,T1^*[`S%UOZ/;,7X)XR\3*\^V:_39JX!O3D!<# MXBA-Z0Z4K9AQ`6@[H&QH`>JF0*,MSXUU2JCIC*Y3X65YGCP'V%92Y4\Q5 M&J.(<9I$-QC=59[A>G6!DB`)41#?X5\@RY*JMWY,5+]U(YQ*+UW;:]:[`*V: M:<*]63>QS[IVL*_>JVTDDP*H:V,SH&?$2MKU,QF"X2?<.+9VE%^OFCQ(DY]: MI'97U?2DX?!;4@%,!B@=N%ZU42O-?EI;8C/HK-9"FW%/60RAM@\Y_-L6\W). MDOWWN#U%.D](83^H$?+.12=U24"+`E+6FX2?H@^X($&G`YPB2)D1E-#X@")A MGE"`(V]RALJ^T,#2X$SB'&@29I04Y5VC2)A'XA#D/GNDI7H%<";.+\H'3%FF MQXS5R!2=%J.":@+>F)3?I#G2/=^I16X_9M"3 MB@LA*K+V6DY%Z=5*CDG'<2&&<:\Y`*1HA494T!W(A%O/:S@Y7V21:U>(#[<+ M*!47IW&0XW"%+M&KEE#$-.[PT<,_=Y*+%*$9'IK&\6;]1-4%0N3(]6_Q-&&# M#^7B25]A^Z<"^SA6X<6;=1*QOKGS>PIE.W`TLNFOK+`[UR*;VC:&'R]FL&IU M"[V)\]GI,L^A5@:U6]`Z-#A.N[!@!92QK*V)I)K?N[OS^SOWL.V'0!>RLOZW M#=?R<*DV:KGRCL#+\]V/X<9I8:_`K.:_XCN@Y7_P!=P"P/1C7(H6BP%>D#_) M0CKZV7X0Q[CB^AW_[!:AQHQ9#1X;?+EC M**L29=HTN#Z@"B]LYU!J,R4*-P&*SC^3@P-0/=X(RCM(>_;SS6<#:3E0%JP' M%B^LSE0(R`IZ,)Y(8<.G)I68<31MU9VNNIZFJJ>G\^)9RS&K.*8,@K`U+76/ MY%X\2&>C#G>O;"".+,E)_V*91.0"@`U9N93'0G(R%_M59%+T[.:@Q1?TRH:" MGHBH22S$3T7CL:OI9=K4,L&]3#B^(EF7(`RWZRV;441P@Z<3J#X#\OMOCH\I MV>^__N8[$!3@W[<)!.^/%X"^>4B^G.'I!]G5!]Z_H[^^7^`92;Z!Y(0OC'?N M#4\'SCV;7#2Q;'M`^8"%UAQ3FD4=#2LM;D4CR[Z0-X.+E&\VOB1I'#-J250'8&7PEH/0&J$)Y^05(.1%?PNT+!`XH1?24E8:=FG](XPB,Q MN_-((]FD7X5U"!M(UX50@[0.A,B])9YDIL9(=KD\N;RZO+\\OP/+#V?@[O[Z M]"]_OKXZ.[^]^^??O?_^7\#Y?_Q\>?]7]X9C"LZN:0U#IA/CT\_MRHA<&I@Z M2]HH[%^JUTB2BOEX3^1!TE<-)XF!>)+^789ANDV*_";8D72.QMJ1@,!^N"3B MG`N?RH*@+.E)`LZ<_PTKZ1[X8-7Z2CPDZ]"Z&""VY>CPN MH0/=.0DE!:VPRH-,VU@IB60IE2SDPRSW!F8$SIZQQQ29+JIW1WS'5`LLZK])Q1VJI9N,K&+0MV]PJ]!;E( MRYMTO,DI#):/I>$@)?$@L6">>?,OUW:#ZX(X_F)I0'(EM.PRDM[2+C9>]_#< MLV.9E6*7!["[PLDU2WF^A9'S7==&$N1,@DV0@6=2&/S^^,WQ.["!&7NW<@&^ M7AP?'Y/_V`]XH-D63VE&+MS_%U#_B*CL;"EI6^1%P&ZFTMN]Y][@)&#MV?`M M1ZK=R"U-M.R++^HD1NMPVQ?/I(E-L]+:`JO/N=J;]X_^W7 MU%#^L/C#-]C\OAMK95YND16!MR\0%"/78HXDBNC]7D%\$Z#H,CD--@C/.&59 M$1&%_3R(D'?+G?R7\&5RA$LLF0#K%UX]"2B$]&,R)048'7#3I0$@JF MWK:"P4&2+5M',V@I]S:CC[JN^9A"SFK2O>*$)B3)`U<9?())CD?HRR1,U_`J MS?,/L+A>W0>?Y>EWLYI<).(-997!DJ7A6W4`5@EX3:KYBIZ=(F>)<%U>Y&*F ME;],UK?D1[02]Y8Z$-4]>?OAD':Y)&BT%.C%$N"HI3\/TD):$K'L4"Y8\G-O M-F(@J5?Z/,AO]N[VUTMZ"DB].[HB3X\VCJQX8!(#9.'2IU0B?PU&%WRF1U0F M>RCD"N'Z\-1M=X;R,$[S;0:E;Z:)R]M]"D3"-X__LBC8EW5_5;>6]ELO>^BI MWM2QYC!\\Y@^OXT@8CX5_]%UI?BGWZ[@8Q"?)P7)V?1?SMU;RAHJ^GGDL$!* M`%;$^?7;$K56':_4Z5S=S=H37J7-%[':T1WNNKU<]:_SZ[)%FFQVKUB-%K.@ M-$HFLY<@V2F?#.LM;3\+VLLSET-DJ?^RF$>/A4E4SN7R5/J>=OR_4KT.)J=Q M'@=<22Y+[X\%KGRX-UV[.U1!@:`OW+SQU7QP^_PSS$*4PTBZPT))Z_1]+Y$\ M\B>P6J^V@YK.`R^DVU6RMZXT^LG!]:3EF0+5^T*"\NXN+.WP+;FYM#XK[WHN MHZ5[X=6;8L4[0(UL\),5=H<7V7!7%_)DC%.K6X@2YZ-:S(3V7N0($2^!C0/4WP:? M?@H*F*$@U@)]N[P[S'?XED`>EP1UT7D1K[6/2%>$%M\>H;T/,4*PB^%B,4T: M8FO;QO!ZU;CV8'>?!4D>A#2Z/=FUOJB>KAQ6G_UDZT"YN7QL60_9TM"\R6,' MFG4MR/N_[<_>!+"C$,"E0,=WOSWLUP_$7B9YD6W)B2;%&YQ""NOX%?/>$QF4 MC_WNBSI/`VAV01=>6OJW!R"*ZQ4>UTB^DCQ!'Z+DL?'P\)[+_![SDO=_4K[= M.6TSUJ$ZL99T\)U[D`>9$R1=NY@/(2.6V2E3=(,T8PGFR\<,TDD674*[ M"^XZDG"[-FH:4!&!FLJ#G(Q9%[76WPW[9P2$_AQDST$6G:`T#Q'$\EPFH1P[ M,@J[H)'RWD5+61CL2R_(OEE?<*+NAQ9`=#O!YMF(WFA49^533>K@7(12&M$5 M?=S")7/P\@M>X=0N=D=X('ZZ=UD'U4K(.H2=W#B9=&`U@UB3?U+B3=9)#W.G$_C(B]UB3Q?M]@Z97@;ZZ M/Y3(\B"X[W!T`S/R0_`(WYF@JD7F'E=M*=3(6H`]A8?`ZND4);2$/3)B,>LF M2Z-M6)RAG!W7Q$W5ZV;W,%N+EK34='87MC3DZ-D92DA`DZ:Q&DJH9MIU$*4A M7=RF/3NA1+?D:!-*6G4E#2H*GOC>!U/%X*MU3PS_%F\ MI>%3D$4DG:&8K'3*V;]AH<,G=W\`^0Y(`6\F';VJY2X"$.O5XOX53T`![L_49D[,,S20*&0'"HKQ@\><$%?GMW<_*LW,*.@?I M$[D<_%A?E2\/M5`*\!K3Y%]YD*(SZA\^<:+=.?:0Q@[67"81_`RC^Y3>,UE= M`Z`QXNN16\>=IE1=^#$R4-*1"UY*ROVM%C[%#B9]UP6C>X M%([ONLCT9N0WZT-3=+H=G<_7FSC=0=@XF:@4D+LXP4F`6PX%J[FCE;F!&4IQ MO!EDQ94/>FV=5&]IQH8>SI/HD+7@UG+5(KH1G;7IQ=MF2&L5NBU;@PXTC,QKAU(Y+:8&6 M;_!E3XR<;3/L?.D,K-V):.VJ'-&+MHM'UP MD8R./N?T/XWVJ^,$%0?-8&>66YT-'9,+38O]V"F9K\4Q5NU;L&)5>^'3;-GW MU&&1H7$?CL=LH.8_(7I\PC!9XO@^>(358'"3H5!VH,0:!P?G/?5U:VVEK^(# ME(S4`0^@K+ST)4##;E!KZ\4M#UK5T"$-/8:.SCKG]%Y@NOV6(UW``?G:>E7/ MM;LU9.3P/*ZIIF=UNCV+N2_=[X[5O]+U^K1>[,0M3.Y_1_@$CUSPV.4D1VLQ M(_GRST'/W`\>K'U;=N">K8I/[<^_U'5S%TL:$SJ;`_#\;)MXX[9-^GCR_5.0 ME.KXD";/,,?BSK=?UIR'P_'H`_0[@_9E[;R?H M"\&9NQ>U.=<'-1W$*#;4=TXV8HUSG"]A=&HOBSD9G+HLO*"QB=.NNZ&INS3O M^0K0?"K7<:V'L_(^L>';\ZPRJW\)CO47.FPX=:Q=%EZ08^6TZ\ZQ,E:\V4CM M3N4ZCK54%KMBXR6[UW[SM^=>9;;_$MSK1;6(Y]3#]G#Q@IQLGX[=^=F:FY?O M:G44K^-M7]JJ]W"O8,_Q*ES"2_"]]:)(9R&?AO1GV'0N`I3]$L3;65*:D[+W M@KRU4:]XL43.9>THJX#P"@BS@'+[I2ZA#^G&NE!;?U_,>KHEG;V,P=+)7N5/5DC#7F\04-M.;]X\^JO^Z@^V5D!Z8;+KZXA(&'8\8HG_02 M!H[VFI^?`X+A\#'*,[V$X:.Q;]?/ ML<.,P1<%_ M7:]N89@^)NCO6!@:15()52^WS]2>_?AG)KUQX4S9#C&Z_8,1K"D@BG468-\> M(=RW6$YPF:GZ\P+]K"CDALCY(6C/?B^3,%W#NP*[&.)/KDI6%6]+2:FLVY)< MAJY%L-*@+@ZJ\MX\'J71)UU,:G>(?,$E%;?:&+, M^7.,$`O_M$RB,_@,XW1#>#O_3-POU'F444WMXFE EZ]CA2*GI/0H,.E(2* MEZ%&2U7`3+V$,+%H_CQV98##GLTU*3V M8VZU-%SXS$@H\&HBKRQJ,J'\L25=U'&!N1'D[%G1CS"!61!COI;1&B7D"7D\ M!&5U@]GXXJ13F?8E;+?&@$: M'+!)X)X'KQ*M%O$[V3Z(H>#5\@I!5E!;/_[V_3&U=/++;_V,--^T(PPQ`?9, MB3*MXZNT9I,32-]K:."$-R#0?FBLKK-E3-*$Z&@U1&E(M];0=NVHX_X)Y:`@ M'T&,2/A=/$&04QTQ)[,I=110'=%A'J2E-IYK'07[EMZ`^R=2&0[B$8E%`8HP M/5KM`$I6:;8N"1[2;3%!8^Y\V%2663FF:K46@RR`!4/8,\$(%P%WAA`9C<>&<-P'0L]T!= MXBW*/UYD$%XF!<2V4-ATB/UM'[8[%.C3HC,D'`#"`JAX>&F^4%/'I-C1BB@" M58K(A(HX6+BV[Q`>U8`\FWOX>9NMW*E\X4Z-NG.!<&G01"I*V M/?!YME1:R_V4QN1".K"1W-IGW=G-:IJ]7LZ"71YHQ%=)=(:>R=I)Y&(*W&[[ ML",^@3Y=^+R*A3D#/KU=90X47`O_5P1C7QR?#:.U,O456^R8S`-9>>0XE6<6 M9"26,P=2[CG[I\O-)[S]^[#H;R1)_Z(^%8_/T!NOUXOJ<;T4KX9J>ZE=%Z=C MS8XM[!\Q\*-H2;$#DQ*0Z)^XV*$-"5=DP)""PBQ![LG MS7N-QY19E]F+4>]103U2CNPLW)?TYL2? M5/?=\$!#\0Y1\Y^H>*)'UDGP\80V]^DY!GFQ4Y[[,Z[)/=*4LO('F?:%09$" M5MRC@X$#NU,)49.^M'G=1X9CXS13GL#H%G1P'4>'4W[RQ`IX,$C*MR%6 MK<5CI&1JI1CP&F7L'PEM\,5#FOP-QYAHA6!S+Z1\^41!9'?9 M1"5!M_MQ^:/_J`A:.Y,]0(1^G[061PPZ9`16ZD67YJ99.5*D)'9Q(N>^YR:: M<@VMO7?=$XAH=$4+(-K]<`!Y77]>+WGY;Y3X]!+)3&^-'$1:U).G,;Z0!S`^ M;(ECO%[1K_ER6SRE&3D//H22ZQP0%W6 MK6R(O%TK8G6PT)1C8[#2"+L[<-`,G-R9F)%!I6CD3*/`H$M3#F]R&?(G1^K@BPZJQW51$7MA, M+8&NO3`"_VQ%0Y"VG2")(*YMI(TK'?OH`Y5;V[C>%GD1).0LDJ&!M"B]L)*V M++JFTJ#RSUYT16H;3:H2R;7E]*!.QWR$D'.R!C!@?J1%[7*>;S!I:,_L/9X6 MC1+O8"9$!L"4K$_X-A5JL&8P#Y)2N30OC0E#VZP\F_X,$L7?B8\&NB2VXLN4 MAV-).=\14KBW#>$$H<\N%E[,RNB`3&DG'DQBEF&X76_I@Z-G<)/!$+$WON`FAN6QQ>4ZS0KT M=_K[39;B2+?8D1.,!?Y&'@&FKQ=)#&NZ)NS?\CZ==KA[X/=5@V;="U#7SAX4 M:=2/YU9E"PMZ2K98T")U,XYOC)]/67NQ-Z0TE1I6Y1<@@07961$T5!HU.'#O M+::V,NY6^EE,S-G3D1IWS0LI7#\7*;G3G7LHTJ>KUQ5=H'@;TO6KU+?P&29; M*#W-5Q=Q\+YCS1U_0)A]6@#Z;H9;#Z[!IWN@=KN:?UVQKY]M3C_R@KS'0[F0 MSC=:Y1Q,,-I\\C%X7K!WF6B)>0&J=4>5+L>9-UCMQ0(_+1`"P>*3A5F:YS@N M6"'9J-LJ9?_YP1:/W"M\Y"M@GV<&*ZE;!58=9C?TLWN8]G0^]P*@J.?M0?0: MQZQ!XXW/7"-,E-!8AZ^,_RX^ZK+58V"Y,EBTXX.'"0'+PC^XQ[H215WD:T+( MDQ?0I0&PE,ZO5\][0U#Y>^>>A-`CA(KV%.X-10MF1D^;^_>HN<1:9$0>/63> M`RGI$^9>&(F9.$$,V:MUZZJP>^-00TK_K7)/7RF730-4E+Z]3-X7@2O?)/?" M5,8)%K1HW)N-)N0,GQ_W9D)B,A'Q80*B-?'P8"ZMPSA[=CCEIASN02^$B7*F MX1S8;)7_"D_]=:#=+.T.W"V>Q?`NDS&O2<&O?,*X)O\Q+N`1MGFD"-$M@HGM M="/AX`)+=)HFF*TMYJQD,4WR$[A*,\C*W0>?87[^&8\Y:1:A),AVE^1>]`]8 M0Y@2:RNF0K$WE90IRYE:=93VG$N'@M0ILU9`<`CV38)]F^"!-EI9-VV6/+?1 M:!C0EA>@W7;]])H'KL"N:DD[E=H04UM!JG3O7"R8:7]:VX*-VG9VF-4RJCC! MP;0\RR.D<.1D^G@7.`ANRM.!$AJT9G+$,7EF?$#?]EJ,`C3W4?X"% M5O#:*6<=X5T^N8L?8=$.5<&R*#+TL&7/N10I.6Y%-\$Y3\_KB"*.6NT,K8YY MU'09NEQZD$[KM;.N;Y`8F3V/.Z?Z*ZE"FMTIPA=*U]"BMP$Z`GN$^#,`Q MP?4*3Q2%#V67'@VA5H%57=_GZ`SL!0Z:_L^\3,S\.-%(7;0Z+_8LV#+Z'^V M>4'V!U52R9),,S5H/T\UE^:X5)'::Y3M@:I!T&B1#JZ--L&^T::[\6*3A#6= M5@H+*X45#04%=0T>K-[-:Z!<;L^"=5J]0*`KB(:'DE*YN#Y`(H-\A!7&%@LW MBX\Z"WMF\K+-(B$75[BW6PWL]5PKH`<\BSMNJW.AUZO3('^ZB--/.J"?M*[.]6)K(02`4GAURE>G8[B=J]J]8C6]0WBYR=)G%,'H9/=S#J/+ MI-YCLL0#S#,J$,S[R]@']?7H+ MB491#%O)K/M44SZ=9:Y9FK._!C:/UK@%LGTS)!"M&P)\QAQ_-G1K6/I2 MD!OD2BG"YG-DY9D']R8HAY+>JV"NS*!Y@98$_.UBUB'?X;(+D?:-/I%'%/-.8);GL&"GIV,4/*#8ER#-'+H]&XX'X=:E M>9YM(3E7<`MIHO6`XGC:;QE'35T33?+$5O@]F3,8ZM48UAK M&J8%8,=#8;;%0 MW`[!67<&>K"1?!;M*+?-N/<7T]C'M!L`/?,59($MGW-WL7$#OO@.<\T8^I"Z M@5SV[BU&M'Z^VXDUK2)K.9905V7,R-\&NW#>X#/^V11D<\K:F2276 MG861A-R3CR4Q66XHR16O7WJ1EAHE\S**$/-A6.B-[,U+]Z9M#M^N^0[%[J'$ M`;.-_P990)69PP9&D(841OIK[, M\RWF&5ZO3NG%:/1(B&R>H*:U/SW0D*?G(7A*PT!<4=$#]^R".$KHUH;'RX4: MG7\.Z8&;VZ"`UPD19)E$Y']DU>(YB,G*AJ''&%^U M_8NHQVN#NZF:5DF&OJI20&H%>!"DSH2L@]$_&E4+W(;;.&!6W M_<(Z(B[%O<>8RDJXBZ\G-1&+5\KUV"(OEX$1!B2<9]2`DL]K>QN*D[LBR(IA%J@K;`&*)P@>X"-*R*L*9'@E M/[#V9Q7N/%$F%*<0#9*MBFJAW+L7@=GI^16IS5F]_YZ<![;X19O($./"5JAD&S_X(Q0!]NZ%=B_H4Q7,NZNKSTAZ'6U M7H'6K`.Y>\`&])X6.'$$22%W_.W[8PHX\LMO5PC'#A$J=M@:?DS)M3%$R"PY M0WD8I_DV@S+(F5=A#70#I.,>!:ZH`28'E!Z4%8!]#1KH&RUDE(;;=>6AYA'V MGH;(!=EA&.UE(UO1`D0G!$4*XEHA9`!YI`H)2X7LB=ZX,\&AD*Z,1YCA M6=G!9,,?[H1B=YFLTFS-WH001\X&M'8-3U,>[HJ%DHP:'",$#4HO8FKC_FJ! MR[RS3"./'(9O'M/GMQ%$+.C`?W1C#?Q3S4F#@7O!O0KRXM:0I>!:"*86@FAI MA_#147V%&'V]SP42AM%;^(@(-)/B0[`6`:2_J%5P"+CE$DC,L>S+`5+0+21D MBF["0:WE>:%PBJ&8!?%E$L'/?X$[*1:XL@[`P/,K0$-9$-"2`!?U`0\";?.` MD*IZ+D24UR)I_7;5R@&&:GN-''-),[C4Y)!RZCRZO`8=!BH"KG@[?H53+O M*R0:G@L$]UE`'N>]VZT?4D[YI0R=,E8[OLL?-SEFWP$KX+:O>W79[&6)(F>. M#?8;6=DSW8UWF>6!@I301=0@ET040C1V7R]Z7BKWP4?H]%%/>*'=07//5N]Q MM8H9*BOB9%9:XN8@T>1$'(C?1*6.U;[O\ M<;G?ZCL@!=SV;J\NF]TK4>3Y>0LC``#<4P(`%0`<`&AA`L``00E#@``!#D!``#M7=MRX[AV?4]5_L'I\^RV)5\U-9-3 MOG9<<;=YGN7;NI^QR[WH]DGG^O\[GS^72/_:.[?S$9[G^]^'K_^W=_/TO+>_]_/GS\\^E)!F)7SVHO'>_C[[3D## M'R]N0O:@8F'RQZ=1FK[^=G#`TK^_Q,'G*!X>=`\/CP[F"3_E*7][3^A*ZI]' M\[2=@__X>O_DCNT)4[#_VY\GVV<_[8/!CCJ?WQ/_$]A@;^_W.`K((QGL917X+9V^DC\^)73\ M&K"*9[^-8C*`6KAQFIGY\/3HD.7_RW7D3<8D3"]"_R9,:3J]"P=1/,YJ_6F/ ME?O]\6ZE^E#&FQO[[NNK"^1.DI@,2<@8.6"I#^0%'D!]-ZSQ(PF83SW`'Z;@ M4&'B>JSLI%9MQ849J.E5!)X3@LO6K]]Z$09J]91&7N9*_E4T?B4`N3;7HJ*, MV&X\IBESI`0\"_"-R@[BJ&\9_4%&JAQ'X:(-TI^`E67;D*3_N`A)@F8)OO0-4E=&B3/Y#V=N$$M!-4^8`#1 M/?US0GWH#@U47EB663^>E;ZI(R^*:;#O-V!4W:+-C`M)%%"??>_2#=C\XFE$ M2%I[B!"59GP,,V!G>8&-]7:;.+.BQ*;KW#%?Z4[SM>Z:KW6W^5IOXMEZ!3?9 M?T#G!4UK1%+JU6^=6D4;1O$$XR[))F?]0?^5S#J';*(V?HW)"(Q)W\A]E&S> M15;Y5(,HK]QD=!M$/\T"*I3:^"RL@7F7F?8]&8_=>-H?/-%A2`?@K[`8];QH MDDWY'\!L;-(/%7@D;"`*IG=),B%^(4DUX$KW\/F5BD'_2T*?^/.JL7*,Z1J9"@,U"")OY:,!TW^B6&4.]HLC M^\#%2\*4KW1>4."^D"`KWM'.ZQP=GB^-I5W9W$"9(I40[_,P>COP"3U@]6?_ MR(#L'W9F>M1?X*=%;0J5R-:&G-K+DD.%>RL5+O)[$:]6WHV]>?'PSQ*YJXK: M+,7!:S:H[7LC&BS\8A!'XUJ6G=4FT@4V2:"*T2O[E8VH4>R3^(]/,#,#F`,2 MQ\2_S^TDA)%AR(RY&:\#-WG)2ITD^T/7?ZX"-X'. M/)L"7;S3A$.U,H]SU.W:Y%M-V2K%FH#X/'=WBNB6)IX;_"=QXYO0OX811T"D*#G`/]]%+N5X^'2> M(:8S]\U;&I#X"F`,HUC>)%=2`FBKBY?-&B0'"I^_<\3\/<KAYBMV4@0C<=1F,VUGV#]39+^)&4GPBK[K(!$K"(6*VY^9XAF(52P^6!"RTDPR6,0BXLB'[Z')U`0A\AN(V<$6- M<"4-(,4HY"C9XH`0T&5#O:G:M!Y(3"-?/@7EI@7D5M6:31L;!XR`QET0:_+I M=([I%GY3*36E]&"!DUVF4P!(0"EFH685$5LAZ1.Z2`WHCW>?SC4X`C(WD6S` M,@?K&X);V2@4'BFNMDEH1+<7U46RGZB;U5G;K$&`ZAI<*XB224S8:9M+J,&/ M&@`YI3@XMB^T*.%O8E0%:WYSTEI[7#M";Z,5TN0'.^SQ'2H2IRZ%91W1:H*R M?$[WQ-IN8-&BK)+5&IY.=J=K=4]"GP'!GJ$NQ!:U,\%E$`OM+9-)+M=KHM'@ MY!F=[H;G9^HC6KI/?U"LVJQ;OXJ2-%E6_L&=9L?&=!KCAB4[7:LJ=P7B^`W5 M!/P6M6'9+2D+#5E2G25Q&NVZ4CFP(K$WL&K44V^(K5*0^,VN$L@6-3CI9=@6S7Z/SFJT0/Y1=\&7O)2^T70J.BNNF]4YLGI\IH(Y M5QM2)7QM.#W^$+@A.[6G.#!>3.8IN^0PXOW?]MWR\NJ11`G/>T".LXE_)^(7$HEY5DL4YMGKR0F)\ M3N^IPF'Y<#>?KYL_)]F](J88TK>LRI#H2,Z8-)-SC&)!I\>9&@F>\]S&9V5Q M[,+:E*U5+ZGB)_CRO>2&AKG"G6.K.UP&QE5#-L!SZMS$BE7#I-76KU4* M=(ZM'E0P[!BJ16]ER^`Y$&_"TV[&KT$T)>2)W>]G02.XU@B"64"\_N"1>-$P MI/\`FV='>S*IO9HS&OZFA#4=LE)(.PNZ9#\>NM!]9+59QJ]A M#(5^L:;]P2T-W="C;K`,;:,A7QHIWSFNL\?/7]?)"9&JG!I9G6,4.^_FK,Y9 M&NJ:H0UBZ-/D)2%_3@#9P3%/J7G5VGI+%(7[8VDEF.2?]XQUU4O;+P_TR=93HO1.#\4&M#G[-JP:-HT!&$/QS1:RA.?6P&8%JZ0-A`]>O9G MU76:K00-GD"$6)2.'H[]9`EG596.GG!*O%NK)#-*1P_'_JN4K2I*1T^X)8HY MBN$]&;K!319Z2M`7N104O$"`0A0>4M!R;4EA.4@"`8DVHM#&_)4DP M?0COZP)HYQ#%"58)9U6E]PS1A_8>@B&LKCHUF=)6WS,X;9#?%[XN6^V($X,A M4-RTK]QD15#:(+DOL-W2D"8CXG^)(E^+UY4,8!`4YXM%5"F(Y6`QI+._D?@E M2L@]"HX?W9]?H4^+J1MH45Q,[W3L/M^U(<-E*(:D=B@3"[W?B-;$'Y*!!5`< M`ZY)Y@*!(0$^C5(WN$>PL!3&W;5^9JS)T-"=M0<$MKDF6=P1$]7R1B M&).LZY5']%)F!-`H)!GS1'*.(VA:XUQ^S*I\3%&B+'])_`Z]A\CY5J^ M3%"YVI8/X6G&N[P+O8KA+A!X`-BY1Z6Q6J;*"D5`\ MZ65\TJX'O!5G^;(`9#`'N7EG@:9(4H0N6Z-+LH%U,`MW:RP*%NU*?`T`F+X+'(0M.A` M5HYN=OQ0F\^U],XIBA`5'*9DE/)`&%)E,3![Y28CV9@)?W9.44@)8CH$(^2\ MZH8D5PQL74\(N[546/)2,C>)A$59-N<4A2)0E5TE)$-2+@;6ZYR7/$5Q(*#"P^Q.35I7/92MUHN>F=4Q2G;:KR*L9B2JG%P/"*571G1\XI"OFH M*J-E#*94U_6SS59N3K^2.)VRI[I2IC3_.:&O;"$@[W]EV9Q3%-*1]MQ7B<74 M[6C[MQ%RFWR+0D^SX2Z3.J$S3_&66T&=A-&DX)*$G)UF2RSE#(:(9(%T%4N`$E94V#&V[EF(CL>HY"DW. M@!,H,`I\H+*"A\$''N8USC"S%ZEEIZ8YJ9US),J)8!DE`=?4H7=:I?F1AN$+BW[AQ"'.1Y,+S)N-)IC%=DP'UJ#P,EBJS,5 M`[-:JFX=\S,`!!0-35%5G!2"B4B4?H&VL@R@<2 M15F<(QQ17/3($RZK)-C:OLXDQ.YPC%%HF!SGX-4QL>B"YA?"`Q M^\$=DDX5N@O9P#@H=D=4]&F27D)F.;0E/];>0QSY$R^]ILGB=2E]H^)7*'2S0E5Q*,@:!N4T(6V$;5CP7OR$ML4"(RM6 MMROI`+Y5G;@:38(I;1E0&U:P`JO$L1L.LT$@N9PNTSRXTRQ8.K/%TB"ASRZ2 M?G/'1+GJ;>)S0`8*D8SC(8*=A\:,T(:E]"-A4Q$OG9V]^1Y26$<^?5>NIZ7Y MP#PHQ+3FJ!?M@RN-TH;5>/[&]QW,"]^)_QS=)YJUN.%7VIIS48`JKFU]\:O@]I;#ZK7B?8K[&4$R=B\D` MO54=S\04N8RG@?U.QS,QN195>0&)5K_CN MTS(+($4A@?'LSU',E4A,12TSRUD^C;[+]MCH6U9I2'0D9TV:"="BD*4T>=/` M8BJ&&6Y17"32W>N\:;!QX6#IG9>B3%G!5'2TW?2W?'V>]"=IDKJA3\/AMXEB MTFW\6T[G!(7^9F\'69`IHIJ/[U)(:&FZ/-#),4Y-'DYIW$'DV6 M9Y)$=^SJ2S MBUWS!MI@%ZK\-M"%(XX`Z@Y5TXP;!P1LD=?;GO2BN*2!VZL%9C,5^#"?]-Z$ MK?'COQ,Z'$&[O(#ICSLD\R'O(::>],7:[=0`R,-\3!>?SZN-:2H>Y,XL_X3' MV[@+BZ;:@[E:`(TH-D@LMPG3!C454!/%,G)3X\WM8[U95*H($(EB2PIYRZAA MTU8%&FUZW61I2K51O8!F%+N"N"=:!DR\<;C6=BZGT2]#4`3&P-TZ*AG35%3; M'5^0SX\W)&D\R<;N+"3@\\@-9T;]%H5O)`%3-BVWRK"SLK#6*U"D#@Q_ZM86N:BIB\TPL.I>7^EG4C5IO":A6`O%]A`WFK MUMPX8'0;5@Q*R\V69I9;0ZD60.''5K1Y@VX<#_N7:!,XUPX?F]BFS6DJ?O@O MLY9>DR>R">@U=`2W+HU5[])@J![0_K$MOD5+FPK&_JLMSG&VLXIU!!?XV&_? MMKD%+:Z=N_&&EHLX6UO%.@+]'WOXVS:WH+7]6MO[NFM1MON+LZE5J2`0_['A MOU5;"QK93C[4BF%JCG^-]G%F8(N6%C0O(P<*<$8.[]@('7Y-$R^($NCW^H-B MG1Y)]J+A592D2<;X2X%QG7>U-BO8Z9QUK'6&WHCXDP#JO0AD1^(WZA%!XPBR MNL"_^H-'XD7#D/X#`&5NEZ%4O=O5R/?`@"AV[DRX@:"K:LYL;8BRGK\\^@2$ M9_WV_0R\(A:7)!>8!L?65W.\\QU-:9,V!'$7@%0&^Y+F`_.@V!U2,EB)^"*V MED1+)V#/T47H7Y,W$D2O#.W-.VM"ZC?(-'*#J5!L;VCPR7<$;8R&`J';?Q?^ MB010YA``?W7C'R2%?^LZA"HK6`J%_E[;&_0`&@I_;M\5OI`0%FH!P+WPQS1D MKSRY+'2;KC]HY0>;H9"):SM%!92&(I_;]XQ:\5W/<,B4VYY$EHV`)PRZA9BP M9RBTM#(I@6`Q5!(CHTX M`M_GJAC&5%CZ\@XTS@VR+J*W==4[HHO]S(LDF8SS35"F&9!T%/E1$`VG]1_H M-?EU\*438[,9?F6*03A9I7(0RXIIOOY;N4B`AD)JVAJ+G.G5QN9KPV;80M"Y M"MPDZ0\R^`K90I@'S&)5JS)#JT#;E(-NPTY7$9E2MR@G!D/@4+#D3/'I%<%I MPS96+37R'-,K&$9; MZ:E3/226W[C=GN#80R$0:=*F@:4->S.;'Q1N8EU:$$%Z5K6=1F?1AJR#Y[5= M)/H)D[^\E/A_BP(H)H!F_`BSX&WI)_RO`U4H#KF9ZG24SR3 M>-Q1N7LC'P6"=EM#UO?S!NUG:M<3C8.;'@JOZ1OU2>C;F,\4OPUTH3B(N4/= MNMB,IC9HUX]ZXMR>?8;2)X`3SR9M[?W5Q:9:KV=N:Y39KO0I^=:G.(L#WH&X MG:X8D+H--$E*5H[#EGM M+>\*2KK17)R["/TU%??P4"YC:V4&\"A.G?$H$76E>I@L[P!N90NI>XA"C=,D M3XD$Y:Y?`UM(W4,4:I(F;1I8+._]&1G[\E[E#E8,[[":C[(WMN,D!_\,'U=, M;'2R@[&LRBN;3'CT\;5A/U&%5CE!TBL`#(9"@-`GMYYS%-&V89]O<49^.1U1 M7@T6Y@&SH#AD5X5$OALH(%J^DF:$^6>:LDLY8"4F@$W<0#$L<-.#.1`+F6@G?WVDZR@(X,?ES1%^?HQN8!Z53Y1!0L22GVT$A5IN$1T'&YID=#7/BC1Q.><;A>%4L1Q$;XO-6<$ M@4ONEHST2)(TINQ49=96OX`T6Q.F M^.<,OD7AGQ,WH`-*?)U])74F0(OB6-:V7$#7(@+^+9_U6ARP*-[(E+,OR0)( M42A96^5>:0\!\[NED&&_Z]SM6M7B-IGTFD(O\+/=4O-J&P//<[HU7W'M=E$H MDJ:\T;"O;V)405?N M*TW=(&^Q[/6B^(WXMU%\.V$OW+)CC"ZL"R0N6KDLL".*$YO-.F!-LPC<:Q.Y MW]H5X"MH1U%`?1:C^M(-&,BG$2%IDF]VC$A*/4N7@.<1,?N#6QI"Q:@;/$0) MU;T*K)'=Z1X=6ANCYO53OB>ZDA"JC$/TU#:OH._GH&K#)6&SH8F[1SCD30Y9 M"EKY4-IP@WC3@,/=(QRRI9PIP8`I@-.&@,/+5^)T1,128C`$B@-Z-=KJ&H96 M!!:>5S5S59C+].,,KI\I-;!@R"9ZLJ,J6@6`P7#H:`(J!>=8*F`S=&$90Z"G M5=@5%"IY1K`3#KEI`Q_@8S)TYQDK]]GUOZJ\YYG`/CCTF8TY+^(Q=*T9*]_] M29JD;NC3<%B1]$).L!0.861CYDN@#%U;QD!_0=BI,?9KY`:+H7CRM)H;:`-K M4=3>`N8*0[XDE],]1G$VL3;U?$!MBEE;`JLSZ$U=M$;TKFEQ MUVQAVJ0_Z(,=\M@"8`:V8QF3$0D3^D;NV1D""[MH=R%4FBSJJ+%Q)L@!7-9Y M5]3N7MDQ"F5&:E&][;'CCY<[>3L5Q[A4F`)9E;?'CC_>X\SWDXYQZ2M\IO2W MQXY;\A[GQMMCQ[@$$_VVNH:A#=MCC^2-A!,B#?DS2^)T3]#*'=(U;2`=60"MCB#GD0#"T([7^`,?V:J\E7Y`13 MH="E:GF`%K8V;3*5K%1EA`=SH)"H:E$M0&/L&3P\D[A.4RT[#FA&^T/8(#44)]KE@BF12%4 M5G.CC<":"N>,P8_JSBQ02)0;L:@W[Q!'[*JL6=H?>61&NH6%%1V&5Q/`$WK3 MY]@-$[!5?IHS^[_\5:0+_W\F2$T)Z`R%!&224RU%Z$RH M".UDX*.E6)`\1X_$BT*/!F0%\W.D:6$=D;F!SP$G*.2@YEVQ.>NU*+03/R2T M;$[$S0!VP2$(-<:Y8'8EL4:+(D`5XQ9(?*.8#&R`XC#?MCVB;(,6'=X'F\4$ MO/V:Y/\M6&D6\ETO)()F(6`_%.?SMNU#52W4IGL"9>S7$\)..#Z23.=_<.-L M4I#MZU1S,UE!3O<0.=%=^`9(HYA*;QQ( M\X&94.BT3;E(">K&5Q-0>\1#3%Y=ZJOO'ZFR@K%0:+U-^04/[<:7&E"[QH7G M19.0O=HR56S7*?."N5`(QDTY!Q>NJ9L#:. MIKL(W!833P`!=5]HD"\)POSTRL*ZA;]5[7LJ%`W&1B%*-]@U5;:&J5L3&%QO M,X6UL5TQ,/0O(D";L).QBQS6K_$(K,%6'4F3F[45/P!F1Z%D&]FLK86]31<_ M9H]8)L_1A??GA,:D3OAB_4+`@"A$;Y/NP'>XJC;9^!8(H@7C9M9MK`<#0Z-0 MRYMW/A-V,G9/!>O`.GM(M+F!M>('G&X/A<)N9&"MA;U-5TK`(!XA_B+V1$Q? M)AED]D/^VK%L1%7G!I.A4-M-.H!@*-4UAJF;)]C\9_X>>']0>'E#TWNX><%< M*!3Y[?J.Q!0"SS'P:,2N#7>-#7-@:!1"?_,^9\).`H?K\)M^!"$_A#98G^-?,YJ&:<_A)>L8,R>P5H`J^HK*+G7G$3%B5/ M:Z$"^C"TO5'R$VS`8D8E_<%#X7,VX@3,SI^`[1^B@'J:]VJ$F8`[:S$"+B<) M^&"27)/$B^GK+%0)Q\[/0.-E(%\C5R_,.3I$H<^IR.&WS+IXS4NN'LK=EEZ)^\ORQV ME/W!;('N!LNH0#KO\I@H'RBO\SXJ3)TSV(>G1X<9:/:+LS`WU.!+Q(Z51=#) MQ>$U3;P@2B8QD;7'JD5`U5&L=PSRL-IXZQFD1)?$RB/$^>>G2UMKW;H3 MYG(ZUN:\G%KIC(VR;$X7Q31696_^@*@$MK5F]/L!J^"+FY#,E/\/4$L#!!0` M```(`"Z(#44B@OEU<0@``(-*```1`!P`:&%R="TR,#$T,#8S,"YX2DFS)EFCZHUT#JY<92;SG M\EP>DKJDQ5S]]!X&Z)5P02-VW7";[08BS(M\RF;7C9_']\X/#?33C]]_=_4W MQT%?"",<2^*CR1+=88G'''N_BPR/W*;;_(S4Q873BV?.1=O]B/[5[G3=3K?] M\=_HC^'3?U!_-$8.>GM[:_K@06H/32\*D>.H>H0W)R%&$O,9D<\X)&*!/7+= MF$NYZ+9:"C?'_!5S'R\6&-C$@I,981SR\(U,0U1%0]GO!^GW" M@\R^TU+%$RQ(9JY*_36IO/&G5E*X,@T,?G]]!,=YI]1@3)F0F'EK$ENDTQ#= MR\O+EB[-3&/AS#!>K(RG6$RT:5J@&\YINT['S2!>%#/)E\48!?&:L^BUE18J M6&<#%G,.7;,*EY:6U.<36HZ!@A)S\N[-R^U520F`LE\+P+,L(SX\A[N5PT2,1:'Y4Y\R5N*<0N,'+`BG'HKW&Y0"H#9 M!:$KS%@$TPY,5_I>/5DL*)M&Z2T\4/V[JPB/`8[4Q<\O#Y;SA([S+O)B-?OT MF-]GDLKE`_CGH:ZU@2@TE=%BQ23CXI,I951S=MLNS)X9/'\)KE#B"^6<7;4V M/7S_W:;[6!!_P'[4UZ"F`&\:JZ:0%)^:F+'K2O9%>CCPXJ"RTA36*@B3#1X?[GKC_AVZ MZ3WVGF_[:/2UWQ^/:J&.$VJ(8?Z7#X[[6D>TNZ M:FDQF`X6*MD$6@*FMMLHA.:9$R;H*WF,1,G`W`-KEORC2?+1&/Y[ZC^#W(-[ M-!CV7WKC!S!`O><[L'P:OO2_]I]'#[_TT>-@5`_KX_K`+1;S^R!ZVR'WVLRL M["=[96][HZ_H_G'PSUI".PD'L`I\I>0-!MP-%A14&>8:(M%OAXU9O,\JVZ'" M"R(1$(?71_E`T17F/M716THWB,,1\.9B.Z(S!"MG#D)EZ>BE&V6P( M(\ZC1,VD+\2#Y@F6#T+$Q,^9\(C!I9>,QT3K4SLU=XY_;':.M'K5(W($T-H] MRBCH[I.10`F+@EV!1]VEK+K4(_T64Q\6(TEG6-^:9?QA4\85L&YWJW9_8*\0 M=<2A7RO6MVK]%Q*HU`26`7(YYI@)[.DD-)&BLM2HB]O> MU"7U@[0CE/=4RV2;;:K9/ETAK%++_#.S).ZF)$5T+8-=VB$C3V]^ZQ4:+,]R MF6)%F5F6BZTD0'EQ;I0;E/=3"V0Y3L*02IWVZ&6TSH<(\U8O%Y.!6:K.]@A: MN=()6<%9K=>^+_\QG@0E*4#ZV*S-1T,B@#XD+NK-K6/FN+PZ1@NS4)]LY[M: MM5/N9=P1B6D@QN1=QME>\UX(LZH'['.@#VD-**VB%GK/96J9IE6%9OFV=B)6 M;FJ5CG^OI2VX]6++GINUV=I>*+S94A^U*LCZ*L6[:1)9F&J-)N89=O:[:A.,^LI]'3"N1;*N3NDL]X1 M68\]MQ;O!.)=6(AWL4.\K3V2W>)=U.*=0+S"^\[*TBSDUH;*;B'_#]^`ZA_5 MSB]DBO0WQEWU^>9U0]!P$:AOD_6S.2=3$!HR/B?[)OLW"+KY'@:9B:K!\+6S MUG^SG=**,Q?I%ZOF;Z#!2;0@7,+BH961;Z#6"0,#1?8-K"CB>885X,F^80&$ M!.<;$0R`?2/:&#.GC2L9;_DOF^$N_^6S?@1A15PB5GK*HNJ(0')`XS'RM"L# M1-TY&$.(%%^`,.R^@R@ZOUD6Z/Q!$5% MQ;K24F"+!%)D3YRUJ[WB-YQF,!$J@:77SMK%043*3HG8,,GCLINCN92=/+$B MDP>N[H[5:.N0B@V5%4A?'4MA^P"+#80*GIZU)-F^[GHVE83IXY"O(DU9N/ M(-E2RGOIKYTI3G5TA.66S!TE" MM:AJ(#P1ZDRMO&Y('JN<55M!ED@C?ZQQ?LS3#VT8#0+E,;,5,8"IC%7I%Q[% MBZ027W;G@.1>/"&JHF1=K!+@WZSH5H3Z-5FAW]!(>!1>?60(X^F)A!/"LQ"3 M0X%=/PHQ97]JC+1+BY$9V55$U/\6ZZ-\:D^;OFJ$2B[.)J8=_"JB,O^T?79= MTHKN0:'",DU7)O[R<+>4M"9:$>CZI^W5MM39"5G-T3ZH,Y+,S*XB)/V;IM[- M&2G!/2)Z,TZTQ=G,*A8<;=\`,#6=35@F[#0/^#^@H,X20"$B,/DV=E- M*T>%4=4T"KV5!IU?Z"::IM"2AH&7S4;NT&Z?S7"UY%D1Y7/$5G\=)N?I;*+; MP:\BJE4KY'OWV<1D9+?K%0\:?XE@*.DO2#C+I0CD7=X$X'`C0ID]_XNGV[T8 M5T1M^FLAO32(_WV"8\=2A7C52E;3.MK_`E!+`0(>`Q0````(`"Z(#44,AGCJ M4TX```?'!0`1`!@```````$```"D@0````!H87)T+3(P,30P-C,P+GAM;%54 M!0`#*-+K4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`"Z(#45#?/UWJ@<` M`$5D```5`!@```````$```"D@9Y.``!H87)T+3(P,30P-C,P7V-A;"YX;6Q5 M5`4``RC2ZU-U>`L``00E#@``!#D!``!02P$"'@,4````"``NB`U%15<;0KL? M``!A!`(`%0`8```````!````I(&75@``:&%R="TR,#$T,#8S,%]D968N>&UL M550%``,HTNM3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`+H@-1;(O*D_J M*@``$(8"`!4`&````````0```*2!H78``&AA`Q0````(`"Z(#46==[EY M"R,``-Q3`@`5`!@```````$```"D@=JA``!H87)T+3(P,30P-C,P7W!R92YX M;6Q55`4``RC2ZU-U>`L``00E#@``!#D!``!02P$"'@,4````"``NB`U%(H+Y M=7$(``"#2@``$0`8```````!````I($TQ0``:&%R="TR,#$T,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``\,T````` ` end XML 20 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Details 1) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Harvard Bioscience Plan [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation $ 180 $ 158 $ 362 $ 294
Equity Incentive Plan 2013 [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation 115 0 1,109 0
Research and Development [Member] | Harvard Bioscience Plan [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation 11 21 31 37
Research and Development [Member] | Equity Incentive Plan 2013 [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation 26 0 313 0
Selling and Marketing [Member] | Harvard Bioscience Plan [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation 4 0 7 0
Selling and Marketing [Member] | Equity Incentive Plan 2013 [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation 0 0 65 0
General and Administrative [Member] | Harvard Bioscience Plan [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation 165 137 324 257
General and Administrative [Member] | Equity Incentive Plan 2013 [Member]
        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation $ 89 $ 0 $ 731 $ 0
XML 21 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Details Textual) (USD $)
 6 Months Ended
Jun. 30, 2014
Harvard Bioscience Plan [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0
Equity Incentive Plan 2013 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 5.55
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 150,000
Common Stock, Capital Shares Reserved for Future Issuance 3,000,000
XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 23 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements
 6 Months Ended
Jun. 30, 2014
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
2.
Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements
 
In June 2014,  the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-10, Development Stage Entities (Topic 915): “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation”, which removes the definition of a development stage entity from the Accounting Standards Codification, eliminated the requirement that development stage entities present inception-to-date information in the company’s financial statements, label those financial statements as those of a development stage entity, disclose a description of the development stage activities in which they engage and disclose in the first year the entity is no longer a development stage entity that in prior years it had been. The ASU is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 14, 2014. The Company has elected the permissible early application of the changes in the accompanying interim unaudited consolidated financial statements, and for all future periods.
 
The accounting policies, other than the change noted above, underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K.
 
There are no other recently issued accounting standards which are not yet effective which the Company believes would materially impact the financial statements.
XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 30,000,000 30,000,000
Common stock, shares issued 7,843,362 7,742,080
Common stock, shares outstanding 7,843,362 7,742,080
Property, plant and equipment, net of accumulated depreciation $ 400 $ 248
XML 25 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
Liquidity (Details Textual) (USD $)
 6 Months Ended 18 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Oct. 31, 2013
Liquidity Disclosure [Line Items]      
Proceeds from Contributions from Parent $ 0 $ 3,884,000 $ 15,000,000
Proceeds from Stock Options Exercised $ 360,000    
XML 26 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document And Entity Information
 6 Months Ended
Jun. 30, 2014
Aug. 08, 2014
Document Information [Line Items]    
Entity Registrant Name Harvard Apparatus Regenerative Technology, Inc.  
Entity Central Index Key 0001563665  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol HART  
Entity Common Stock, Shares Outstanding   7,846,959
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2014  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2014  
XML 27 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Inventory [Line Items]    
Finished goods $ 16 $ 7
Raw Materials 130 31
Total $ 146 $ 38
XML 28 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
In Thousands, except Per Share data, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Revenues $ 23 $ 0 $ 46 $ 0
Cost of revenues 12 0 24 0
Gross profit 11 0 22 0
Operating expenses:        
Research and development 1,214 1,265 2,431 2,425
Sales and marketing 88 34 164 54
General and administrative 1,242 790 2,966 1,630
Total operating expenses 2,544 2,089 5,561 4,109
Operating loss (2,533) (2,089) (5,539) (4,109)
Loss before income taxes (2,533) (2,089) (5,539) (4,109)
Income taxes 0 0 0 0
Net loss (2,533) (2,089) (5,539) (4,109)
Basic and diluted net loss per share (in dollars per share) $ (0.32) $ (0.27) $ (0.71) $ (0.53)
Weighted average common shares, basic and diluted (in shares) 7,816 7,740 7,788 7,740
Comprehensive loss:        
Net loss (2,533) (2,089) (5,539) (4,109)
Foreign currency translation adjustments 6 0 3 0
Total comprehensive loss $ (2,527) $ (2,089) $ (5,536) $ (4,109)
XML 29 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2014
Share-based Compensation [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
7.
Stock-Based Compensation
 
Harvard Bioscience maintains the Third Amended and Restated 2000 Stock Option and Incentive Plan, (as amended, the “Harvard Bioscience Plan”) for the benefit of certain of its officers, directors and employees. The disclosure of stock based compensation for the periods prior to the Separation represent the Company’s portion of such plan maintained by Harvard Bioscience in which the Company’s employees and directors participated. The securities underlying all options and awards granted under the Harvard Bioscience Plan consist of shares of Harvard Bioscience common stock.
 
HART maintains the 2013 Equity Incentive Plan (the “2013 Plan”) for the benefit of certain of its officers, directors and employees. The securities underlying all options and awards granted under the 2013 Plan consist of shares of HART common stock. Additionally, equity awards related to shares of the Company’s common stock were issued from the 2013 Plan at the time of the Distribution to the holders of Harvard Bioscience equity awards as part of an adjustment (the “Adjustment”) to those equity awards to prevent a loss of value to the holders due to the Distribution.
 
Prior to the Separation, HART stock-based compensation expense represented an allocation from Harvard Bioscience’s stock-based compensation expense for employees whose time had been allocated to HART. After the Separation, HART continues to record the expense on stock-based awards of Harvard Bioscience stock options and restricted stock units, issued by Harvard Bioscience, to former Harvard Bioscience employees now employed by HART.
 
As noted above relating to the Adjustment, Harvard Bioscience award holders were also issued stock-based compensation awards in HART stock options and restricted stock units. HART recognizes compensation expense on those awards to former Harvard Bioscience employees who now are employed by HART, and does not recognize expense on the Adjustment awards given to individuals not now employed by HART. Additionally, HART records expense on grants made under the 2013 Plan to HART officers, directors and employees granted subsequent to the Adjustment.
 
Harvard Bioscience Plan Award Information
 
During the six months ended June 30, 2013, all awards were granted to employees and directors at exercise prices equal to or greater than fair market value of the Harvard Bioscience’s common stock on the date of grant.
 
The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:
 
 
 
Stock Options
 
Restricted Stock Units
 
 
 
Stock Options
Outstanding
 
Weighted
Average Exercise
Price
 
Restricted Stock
Units Outstanding
 
Grant Date
Fair Value
 
Balance at December 31, 2013
 
 
2,500,339
 
$
3.20
 
 
326,185
 
$
5.46
 
Granted
 
 
-
 
 
-
 
 
-
 
 
-
 
Exercised
 
 
(23,057)
 
 
3.36
 
 
-
 
 
-
 
Vested (RSUs)
 
 
-
 
 
-
 
 
(154,628)
 
 
4.70
 
Cancelled/forfeited
 
 
(311,635)
 
 
5.58
 
 
-
 
 
-
 
Balance at June 30, 2014
 
 
2,165,647
 
$
2.85
 
 
171,557
 
$
6.14
 
 
Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
2014
 
2013
 
2014
 
2013
 
 
 
(in thousands)
 
(in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
$
11
 
$
21
 
$
31
 
$
37
 
Sales and marketing
 
 
4
 
 
-
 
 
7
 
 
-
 
General and administrative
 
 
165
 
 
137
 
 
324
 
 
257
 
Total stock-based compensation
 
$
180
 
$
158
 
$
362
 
$
294
 
 
The Company did not capitalize any stock-based compensation related to the Harvard Bioscience Plan.
 
 Harvard Apparatus Regenerative Technology, Inc. 2013 Equity Incentive Plan
 
The 2013 Plan was adopted by the Board of Directors on October 11, 2013. The aggregate number of shares authorized for issuance under the Plan is 3,000,000 shares of common stock.
 
The Company currently has 3,000,000 shares of its common stock reserved for the issuance, exercise or vesting of awards under the 2013 Plan. During the six months ended June 30, 2014, 150,000 options were granted under the 2013 Plan to HART employees at exercise prices equal to or greater than fair market value of the Company’s common stock on the date of grant.
 
The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:
 
 
 
Stock Options
 
Restricted Stock Units
 
 
 
Stock Options
Outstanding
 
Weighted
Average Exercise
Price
 
Restricted Stock
Units Outstanding
 
Grant Date
Fair Value
 
Balance at December 31, 2013
 
 
2,075,707
 
$
4.34
 
 
19,492
 
$
6.00
 
Granted
 
 
150,000
 
 
8.40
 
 
-
 
 
-
 
Exercised
 
 
(102,705)
 
 
4.94
 
 
-
 
 
-
 
Vested (RSUs)
 
 
-
 
 
-
 
 
(9,796)
 
 
6.00
 
Cancelled/forfeited
 
 
(147,301)
 
 
4.46
 
 
(1,716)
 
 
6.00
 
Balance at June 30, 2014
 
 
1,975,701
 
$
4.61
 
 
7,980
 
$
6.00
 
 
The following assumptions were used to estimate the fair value of stock options granted during the three and six months ended June 30, 2014:
 
 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
June 30, 2014
 
 
June 30, 2014
 
Volatility
 
 
74
%
 
 
74
%
Risk-free interest rate
 
 
1.68
%
 
 
1.66
%
Expected holding period
 
 
6.22 years
 
 
 
6.22 years
 
Dividend Yield
 
 
-
%
 
 
-
%
 
The weighted average fair values of the options granted under the 2013 Plan during the six months ended June 30, 2014 was $5.55, using the Black-Scholes option-pricing model.
 
Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
2014
 
2013
 
2014
 
2013
 
 
 
(in thousands)
 
(in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
$
26
 
$
-
 
$
313
 
$
-
 
Sales and marketing
 
 
-
 
 
-
 
 
65
 
 
-
 
General and administrative
 
 
89
 
 
-
 
 
731
 
 
-
 
Total stock-based compensation
 
$
115
 
$
-
 
$
1,109
 
$
-
 
 
The Company did not capitalize any stock-based compensation related to the 2013 Plan.
XML 30 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
Concentrations
 6 Months Ended
Jun. 30, 2014
Risks and Uncertainties [Abstract]  
Concentration Risk Disclosure [Text Block]
6.
Concentrations
 
At the time of the Separation, the Company entered into a 10-year product distribution agreement with Harvard Bioscience under which each company will become the exclusive distributor for the other party for products such other party develops for sale in the markets served by the other. In addition, Harvard Bioscience has agreed that except for certain existing activities of its German subsidiary, to the extent that any Harvard Bioscience businesses desire to resell or distribute any bioreactor that is then manufactured by HART, HART will be the exclusive manufacturer of such bioreactors and Harvard Bioscience will purchase such bioreactors from the Company. Sales to Harvard Bioscience accounted for 100% of the revenues and receivables as of and for the six months end June 30, 2014.
XML 31 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Details 2) (Equity Incentive Plan 2013 [Member])
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2014
Equity Incentive Plan 2013 [Member]
    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Volatility 74.00% 74.00%
Risk-free interest rate 1.68% 1.66%
Expected holding period 6 years 2 months 19 days 6 years 2 months 19 days
Dividend Yield 0.00% 0.00%
XML 32 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions (Details Textual) (Harvard Bioscience, Inc [Member], USD $)
In Millions, unless otherwise specified
 3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Harvard Bioscience, Inc [Member]
        
Related Party Transaction [Line Items]        
Costs and Expenses, Related Party $ 0.1 $ 0.7 $ 0.2 $ 1.2
XML 33 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
The following assumptions were used to estimate the fair value of stock options granted during the three and six months ended June 30, 2014:
 
 
 
Three Months Ended
 
 
Six Months Ended
 
 
 
June 30, 2014
 
 
June 30, 2014
 
Volatility
 
 
74
%
 
 
74
%
Risk-free interest rate
 
 
1.68
%
 
 
1.66
%
Expected holding period
 
 
6.22 years
 
 
 
6.22 years
 
Dividend Yield
 
 
-
%
 
 
-
%
Harvard Bioscience Plan [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Share-based Compensation, Activity [Table Text Block]
The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:
 
 
 
Stock Options
 
Restricted Stock Units
 
 
 
Stock Options
Outstanding
 
Weighted
Average Exercise
Price
 
Restricted Stock
Units Outstanding
 
Grant Date
Fair Value
 
Balance at December 31, 2013
 
 
2,500,339
 
$
3.20
 
 
326,185
 
$
5.46
 
Granted
 
 
-
 
 
-
 
 
-
 
 
-
 
Exercised
 
 
(23,057)
 
 
3.36
 
 
-
 
 
-
 
Vested (RSUs)
 
 
-
 
 
-
 
 
(154,628)
 
 
4.70
 
Cancelled/forfeited
 
 
(311,635)
 
 
5.58
 
 
-
 
 
-
 
Balance at June 30, 2014
 
 
2,165,647
 
$
2.85
 
 
171,557
 
$
6.14
 
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
2014
 
2013
 
2014
 
2013
 
 
 
(in thousands)
 
(in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
$
11
 
$
21
 
$
31
 
$
37
 
Sales and marketing
 
 
4
 
 
-
 
 
7
 
 
-
 
General and administrative
 
 
165
 
 
137
 
 
324
 
 
257
 
Total stock-based compensation
 
$
180
 
$
158
 
$
362
 
$
294
 
Equity Incentive Plan 2013 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Share-based Compensation, Activity [Table Text Block]
The following is a summary of stock option and restricted stock unit activity for the six months ended June 30, 2014:
 
 
 
Stock Options
 
Restricted Stock Units
 
 
 
Stock Options
Outstanding
 
Weighted
Average Exercise
Price
 
Restricted Stock
Units Outstanding
 
Grant Date
Fair Value
 
Balance at December 31, 2013
 
 
2,075,707
 
$
4.34
 
 
19,492
 
$
6.00
 
Granted
 
 
150,000
 
 
8.40
 
 
-
 
 
-
 
Exercised
 
 
(102,705)
 
 
4.94
 
 
-
 
 
-
 
Vested (RSUs)
 
 
-
 
 
-
 
 
(9,796)
 
 
6.00
 
Cancelled/forfeited
 
 
(147,301)
 
 
4.46
 
 
(1,716)
 
 
6.00
 
Balance at June 30, 2014
 
 
1,975,701
 
$
4.61
 
 
7,980
 
$
6.00
 
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Stock-based compensation expense for the three and six months ended June 30, 2014 and 2013, respectively, was allocated as follows:
 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
2014
 
2013
 
2014
 
2013
 
 
 
(in thousands)
 
(in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 
$
26
 
$
-
 
$
313
 
$
-
 
Sales and marketing
 
 
-
 
 
-
 
 
65
 
 
-
 
General and administrative
 
 
89
 
 
-
 
 
731
 
 
-
 
Total stock-based compensation
 
$
115
 
$
-
 
$
1,109
 
$
-
 
XML 34 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
8.
Commitments and Contingencies
 
From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. There are no such matters pending that we expect to be material in relation to our business, financial condition, results of operations or cash flows.
XML 35 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Inventories (Tables)
 6 Months Ended
Jun. 30, 2014
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block]
Inventories consisted of the following:
 
 
 
June
30, 2014
 
December
31, 2013
 
 
 
(in thousands)
 
Finished goods
 
$
16
 
$
7
 
Raw materials
 
 
130
 
 
31
 
Total
 
$
146
 
$
38
 
XML 36 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
Overview and Basis of Presentation (Details Textual) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended 18 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Oct. 31, 2013
Overview And Basis Of Presentation [Line Items]      
Proceeds from Contributions from Parent $ 0 $ 3,884 $ 15,000
XML 37 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stock-Based Compensation (Details) (USD $)
 6 Months Ended
Jun. 30, 2014
Harvard Bioscience Plan [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock Options Outstanding, Balance 2,500,339
Stock Options Outstanding, Granted 0
Stock Options Outstanding, Exercised (23,057)
Stock Options Outstanding, Cancelled / forfeited (311,635)
Stock Options Outstanding, Balance 2,165,647
Weighted Average Exercise Price, Balance $ 3.20
Weighted Average Exercise Price, Granted $ 0
Weighted Average Exercise Price, Exercised $ 3.36
Weighted Average Exercise Price, Cancelled / forfeited $ 5.58
Weighted Average Exercise Price, Balance $ 2.85
Equity Incentive Plan 2013 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock Options Outstanding, Balance 2,075,707
Stock Options Outstanding, Granted 150,000
Stock Options Outstanding, Exercised (102,705)
Stock Options Outstanding, Cancelled / forfeited (147,301)
Stock Options Outstanding, Balance 1,975,701
Weighted Average Exercise Price, Balance $ 4.34
Weighted Average Exercise Price, Granted $ 8.40
Weighted Average Exercise Price, Exercised $ 4.94
Weighted Average Exercise Price, Cancelled / forfeited $ 4.46
Weighted Average Exercise Price, Balance $ 4.61
Restricted Stock Units (RSUs) [Member] | Harvard Bioscience Plan [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Restricted Stock Units Outstanding, Balance 326,185
Restricted Stock Units Outstanding, Granted 0
Restricted Stock Units Outstanding, Vested (RSUs) (154,628)
Restricted Stock Units Outstanding, Cancelled / forfeited 0
Restricted Stock Units Outstanding, Balance 171,557
GrantDate Fair Value, Balance $ 5.46
GrantDate Fair Value, Granted $ 0
GrantDate Fair Value, Vested (RSUs) $ 4.70
GrantDate Fair Value, Cancelled / forfeited $ 0
GrantDate Fair Value, Balance $ 6.14
Restricted Stock Units (RSUs) [Member] | Equity Incentive Plan 2013 [Member]
  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Restricted Stock Units Outstanding, Balance 19,492
Restricted Stock Units Outstanding, Granted 0
Restricted Stock Units Outstanding, Vested (RSUs) (9,796)
Restricted Stock Units Outstanding, Cancelled / forfeited (1,716)
Restricted Stock Units Outstanding, Balance 7,980
GrantDate Fair Value, Balance $ 6.00
GrantDate Fair Value, Granted $ 0
GrantDate Fair Value, Vested (RSUs) $ 6.00
GrantDate Fair Value, Cancelled / forfeited $ 6.00
GrantDate Fair Value, Balance $ 6.00
XML 38 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Cash flows used in operating activities:    
Net loss: $ (5,539) $ (4,109)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 1,471 294
Depreciation 151 83
Changes in operating assets and liabilities:    
(Increase) in related party receivables (60) 0
(Increase) in inventories (108) 0
Decrease in prepaid expenses 65 0
Increase (decrease) in accounts payable 71 (35)
(Decrease) in related party payable (49) 0
Increase (decrease) in accrued and other current liabilities 189 (66)
Net cash used in operating activities (3,809) (3,833)
Cash flows used in investing activities:    
Additions to property, plant and equipment (495) (51)
Net cash used in investing activities (495) (51)
Cash flows from financing activities:    
Proceeds from funding provided by Harvard Bioscience, Inc. 0 3,884
Proceeds from issuance of common stock 358 0
Net cash provided by financing activities 358 3,884
Effect of exchange rate changes on cash 3 0
Net decrease in cash (3,943) 0
Cash at the beginning of the period 14,008 0
Cash at the end of the period $ 10,065 $ 0
XML 39 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions
 6 Months Ended
Jun. 30, 2014
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]
5.
Related Party Transactions
 
Harvard Bioscience is considered to be a related party to the Company because David Green, the Company’s Chairman and CEO, is also a director of Harvard Bioscience.
 
Cost Allocations
 
For periods presented prior to the Separation, HART’s operations were fully integrated with Harvard Bioscience, including executive services, finance, treasury, corporate income tax, human resources, legal services and investor relations. The accompanying financial statements for periods prior to the Separation reflect the application of certain estimates and allocations of operating expenses and the Company believes the methods used to allocate these operating expenses were reasonable. The allocation methods included time devoted to HART activities, headcount, percentage of operating expenses or other relevant measures. Allocations of expenses for these services were $0.7 million for the three month period ended June 30, 2013 and $1.2 million for the six month period ended June 30, 2013. These allocated expenses are reflected in the total operating expenses in the consolidated statements of operations, in addition to direct expenses.
 
Agreements with Harvard Bioscience
 
In connection with the Separation of the Company from Harvard Bioscience, on October 31, 2013 the Company entered into a series of agreements with Harvard Bioscience, including a separation and distribution agreement, a transition services agreement, a tax sharing agreement, a sublicense agreement, a product distribution agreement, an intellectual property matters agreement and a sublease agreement. Some of these agreements require us to pay fees to Harvard Bioscience for services provided subsequent to the Separation, and will remain in place through at least October 31, 2014. Expenses recorded under these agreements were $0.1 million and $0.2 million for the three and six months ended June 30, 2014, respectively.
XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 57 116 1 false 8 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.harvardapparatusregen.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.harvardapparatusregen.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS false false R3.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.harvardapparatusregen.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.harvardapparatusregen.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS false false R5.htm 105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.harvardapparatusregen.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 106 - Disclosure - Overview and Basis of Presentation Sheet http://www.harvardapparatusregen.com/role/OverviewAndBasisOfPresentation Overview and Basis of Presentation false false R7.htm 107 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements Sheet http://www.harvardapparatusregen.com/role/SummaryOfSignificantAccountingPoliciesAndRecentlyIssuedAccountingPronouncements Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements false false R8.htm 108 - Disclosure - Liquidity Sheet http://www.harvardapparatusregen.com/role/Liquidity Liquidity false false R9.htm 109 - Disclosure - Inventories Sheet http://www.harvardapparatusregen.com/role/Inventories Inventories false false R10.htm 110 - Disclosure - Related Party Transactions Sheet http://www.harvardapparatusregen.com/role/RelatedPartyTransactions Related Party Transactions false false R11.htm 111 - Disclosure - Concentrations Sheet http://www.harvardapparatusregen.com/role/Concentrations Concentrations false false R12.htm 112 - Disclosure - Stock-Based Compensation Sheet http://www.harvardapparatusregen.com/role/StockbasedCompensation Stock-Based Compensation false false R13.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.harvardapparatusregen.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R14.htm 114 - Disclosure - Inventories (Tables) Sheet http://www.harvardapparatusregen.com/role/InventoriesTables Inventories (Tables) false false R15.htm 115 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.harvardapparatusregen.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) false false R16.htm 116 - Disclosure - Overview and Basis of Presentation (Details Textual) Sheet http://www.harvardapparatusregen.com/role/OverviewAndBasisOfPresentationDetailsTextual Overview and Basis of Presentation (Details Textual) false false R17.htm 117 - Disclosure - Liquidity (Details Textual) Sheet http://www.harvardapparatusregen.com/role/LiquidityDetailsTextual Liquidity (Details Textual) false false R18.htm 118 - Disclosure - Inventories (Details) Sheet http://www.harvardapparatusregen.com/role/InventoriesDetails Inventories (Details) false false R19.htm 119 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.harvardapparatusregen.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) false false R20.htm 120 - Disclosure - Concentrations (Details Textual) Sheet http://www.harvardapparatusregen.com/role/ConcentrationsDetailsTextual Concentrations (Details Textual) false false R21.htm 121 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.harvardapparatusregen.com/role/StockbasedCompensationDetails Stock-Based Compensation (Details) false false R22.htm 122 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://www.harvardapparatusregen.com/role/StockbasedCompensationDetails1 Stock-Based Compensation (Details 1) false false R23.htm 123 - Disclosure - Stock-Based Compensation (Details 2) Sheet http://www.harvardapparatusregen.com/role/StockbasedCompensationDetails2 Stock-Based Compensation (Details 2) false false R24.htm 124 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://www.harvardapparatusregen.com/role/StockbasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false All Reports Book All Reports Element us-gaap_ProceedsFromContributionsFromParent had a mix of decimals attribute values: -6 -3. 'Monetary' elements on report '117 - Disclosure - Liquidity (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 104 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Process Flow-Through: Removing column '18 Months Ended Oct. 31, 2013' hart-20140630.xml hart-20140630.xsd hart-20140630_cal.xml hart-20140630_def.xml hart-20140630_lab.xml hart-20140630_pre.xml true true XML 41 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Concentrations (Details Textual)
 6 Months Ended
Jun. 30, 2014
Concentration Risk [Line Items]  
Product Distribution Agreement Term 10 years
Accounts Receivable [Member]
  
Concentration Risk [Line Items]  
Concentration Risk, Percentage 100.00%